id sid tid token lemma pos dti-2622 1 1 dti dti PROPN dti-2622 1 2 drug drug PROPN dti-2622 1 3 target target NOUN dti-2622 1 4 insights insight NOUN dti-2622 1 5 2023 2023 NUM dti-2622 1 6 ; ; PUNCT dti-2622 1 7 17 17 NUM dti-2622 1 8 : : SYM dti-2622 1 9 120 120 NUM dti-2622 1 10 - - SYM dti-2622 1 11 125 125 NUM dti-2622 1 12 issn issn PROPN dti-2622 1 13 1177 1177 NUM dti-2622 1 14 - - SYM dti-2622 1 15 3928 3928 NUM dti-2622 1 16 | | ADV dti-2622 1 17 doi doi NOUN dti-2622 1 18 : : PUNCT dti-2622 1 19 10.33393 10.33393 NUM dti-2622 1 20 / / SYM dti-2622 1 21 dti.2023.2622 dti.2023.2622 NUM dti-2622 1 22 original original ADJ dti-2622 1 23 research research NOUN dti-2622 1 24 article article NOUN dti-2622 1 25 drug drug NOUN dti-2622 1 26 target target NOUN dti-2622 1 27 insights insight NOUN dti-2622 1 28 issn issn VERB dti-2622 1 29 1177 1177 NUM dti-2622 1 30 - - SYM dti-2622 1 31 3928 3928 NUM dti-2622 1 32 www.aboutscience.eu/dti www.aboutscience.eu/dti NOUN dti-2622 1 33 © © PROPN dti-2622 1 34 2023 2023 NUM dti-2622 1 35 the the DET dti-2622 1 36 authors author NOUN dti-2622 1 37 . . PUNCT dti-2622 2 1 this this DET dti-2622 2 2 article article NOUN dti-2622 2 3 is be AUX dti-2622 2 4 published publish VERB dti-2622 2 5 by by ADP dti-2622 2 6 aboutscience aboutscience NOUN dti-2622 2 7 and and CCONJ dti-2622 2 8 licensed license VERB dti-2622 2 9 under under ADP dti-2622 2 10 creative creative ADJ dti-2622 2 11 commons common NOUN dti-2622 2 12 attribution attribution NOUN dti-2622 2 13 - - PUNCT dti-2622 2 14 noncommercial noncommercial ADJ dti-2622 2 15 4.0 4.0 NUM dti-2622 2 16 international international NOUN dti-2622 2 17 ( ( PUNCT dti-2622 2 18 cc cc NOUN dti-2622 2 19 by by ADP dti-2622 2 20 - - PUNCT dti-2622 2 21 nc nc PROPN dti-2622 2 22 4.0 4.0 NUM dti-2622 2 23 ) ) PUNCT dti-2622 2 24 . . PUNCT dti-2622 3 1 commercial commercial ADJ dti-2622 3 2 use use NOUN dti-2622 3 3 is be AUX dti-2622 3 4 not not PART dti-2622 3 5 permitted permit VERB dti-2622 3 6 and and CCONJ dti-2622 3 7 is be AUX dti-2622 3 8 subject subject ADJ dti-2622 3 9 to to ADP dti-2622 3 10 publisher publisher NOUN dti-2622 3 11 ’s ’s PART dti-2622 3 12 permissions permission NOUN dti-2622 3 13 . . PUNCT dti-2622 4 1 full full ADJ dti-2622 4 2 information information NOUN dti-2622 4 3 is be AUX dti-2622 4 4 available available ADJ dti-2622 4 5 at at ADP dti-2622 4 6 www.aboutscience.eu www.aboutscience.eu NOUN dti-2622 4 7 mortality mortality NOUN dti-2622 4 8 rate rate NOUN dti-2622 4 9 and and CCONJ dti-2622 4 10 factors factor NOUN dti-2622 4 11 associated associate VERB dti-2622 4 12 with with ADP dti-2622 4 13 mortality mortality NOUN dti-2622 4 14 of of ADP dti-2622 4 15 carbapenem carbapenem NOUN dti-2622 4 16 - - PUNCT dti-2622 4 17 resistant resistant ADJ dti-2622 4 18 enterobacteriaceae enterobacteriaceae PROPN dti-2622 4 19 infection infection NOUN dti-2622 4 20 apichart apichart NOUN dti-2622 4 21 so so ADV dti-2622 4 22 - - PUNCT dti-2622 4 23 ngern1 ngern1 NOUN dti-2622 4 24 , , PUNCT dti-2622 4 25 naphol naphol ADJ dti-2622 4 26 osaithai2 osaithai2 PROPN dti-2622 4 27 , , PUNCT dti-2622 4 28 atibordee atibordee PROPN dti-2622 4 29 meesing3,4 meesing3,4 PROPN dti-2622 4 30 , , PUNCT dti-2622 4 31 worawat worawat VERB dti-2622 4 32 chumpangern5 chumpangern5 PROPN dti-2622 4 33 1division 1division NUM dti-2622 4 34 of of ADP dti-2622 4 35 sleep sleep NOUN dti-2622 4 36 medicine medicine NOUN dti-2622 4 37 , , PUNCT dti-2622 4 38 department department NOUN dti-2622 4 39 of of ADP dti-2622 4 40 medicine medicine NOUN dti-2622 4 41 , , PUNCT dti-2622 4 42 faculty faculty NOUN dti-2622 4 43 of of ADP dti-2622 4 44 medicine medicine NOUN dti-2622 4 45 , , PUNCT dti-2622 4 46 khon khon PROPN dti-2622 4 47 kaen kaen PROPN dti-2622 4 48 university university PROPN dti-2622 4 49 , , PUNCT dti-2622 5 1 khon khon PROPN dti-2622 5 2 kaen kaen PROPN dti-2622 5 3 thailand thailand PROPN dti-2622 6 1 2department 2department NUM dti-2622 6 2 of of ADP dti-2622 6 3 medicine medicine NOUN dti-2622 6 4 , , PUNCT dti-2622 6 5 faculty faculty NOUN dti-2622 6 6 of of ADP dti-2622 6 7 medicine medicine NOUN dti-2622 6 8 , , PUNCT dti-2622 6 9 khon khon PROPN dti-2622 6 10 kaen kaen PROPN dti-2622 6 11 university university PROPN dti-2622 6 12 , , PUNCT dti-2622 6 13 khon khon PROPN dti-2622 6 14 kaen kaen PROPN dti-2622 6 15 thailand thailand PROPN dti-2622 6 16 3 3 NUM dti-2622 6 17 division division NOUN dti-2622 6 18 of of ADP dti-2622 6 19 infectious infectious ADJ dti-2622 6 20 diseases disease NOUN dti-2622 6 21 and and CCONJ dti-2622 6 22 tropical tropical ADJ dti-2622 6 23 medicines medicine NOUN dti-2622 6 24 , , PUNCT dti-2622 6 25 department department NOUN dti-2622 6 26 of of ADP dti-2622 6 27 medicine medicine NOUN dti-2622 6 28 , , PUNCT dti-2622 6 29 faculty faculty NOUN dti-2622 6 30 of of ADP dti-2622 6 31 medicine medicine NOUN dti-2622 6 32 , , PUNCT dti-2622 6 33 khon khon PROPN dti-2622 6 34 kaen kaen PROPN dti-2622 6 35 university university PROPN dti-2622 6 36 , , PUNCT dti-2622 6 37 khon khon PROPN dti-2622 6 38 kaen kaen PROPN dti-2622 6 39 thailand thailand PROPN dti-2622 6 40 4research 4research PROPN dti-2622 6 41 and and CCONJ dti-2622 6 42 diagnostic diagnostic ADJ dti-2622 6 43 center center NOUN dti-2622 6 44 for for ADP dti-2622 6 45 emerging emerge VERB dti-2622 6 46 infectious infectious ADJ dti-2622 6 47 diseases disease NOUN dti-2622 6 48 ( ( PUNCT dti-2622 6 49 rceid rceid NOUN dti-2622 6 50 ) ) PUNCT dti-2622 6 51 , , PUNCT dti-2622 6 52 khon khon PROPN dti-2622 6 53 kaen kaen PROPN dti-2622 6 54 university university PROPN dti-2622 6 55 , , PUNCT dti-2622 6 56 khon khon PROPN dti-2622 6 57 kaen kaen PROPN dti-2622 6 58 thailand thailand PROPN dti-2622 6 59 5 5 NUM dti-2622 6 60 division division NOUN dti-2622 6 61 of of ADP dti-2622 6 62 pulmonary pulmonary ADJ dti-2622 6 63 medicine medicine NOUN dti-2622 6 64 and and CCONJ dti-2622 6 65 pulmonary pulmonary ADJ dti-2622 6 66 critical critical ADJ dti-2622 6 67 care care NOUN dti-2622 6 68 medicine medicine NOUN dti-2622 6 69 , , PUNCT dti-2622 6 70 department department NOUN dti-2622 6 71 of of ADP dti-2622 6 72 medicine medicine NOUN dti-2622 6 73 , , PUNCT dti-2622 6 74 faculty faculty NOUN dti-2622 6 75 of of ADP dti-2622 6 76 medicine medicine NOUN dti-2622 6 77 , , PUNCT dti-2622 6 78 khon khon PROPN dti-2622 6 79 kaen kaen PROPN dti-2622 6 80 university university PROPN dti-2622 6 81 , , PUNCT dti-2622 6 82 khon khon PROPN dti-2622 6 83 kaen kaen PROPN dti-2622 6 84 thailand thailand PROPN dti-2622 6 85 abstract abstract PROPN dti-2622 6 86 background background NOUN dti-2622 6 87 : : PUNCT dti-2622 6 88 carbapenem carbapenem NOUN dti-2622 6 89 - - PUNCT dti-2622 6 90 resistant resistant ADJ dti-2622 6 91 enterobacteriaceae enterobacteriaceae PROPN dti-2622 6 92 ( ( PUNCT dti-2622 6 93 cre cre PROPN dti-2622 6 94 ) ) PUNCT dti-2622 6 95 is be AUX dti-2622 6 96 a a DET dti-2622 6 97 serious serious ADJ dti-2622 6 98 pathogen pathogen NOUN dti-2622 6 99 with with ADP dti-2622 6 100 high high ADJ dti-2622 6 101 mortality mortality NOUN dti-2622 6 102 . . PUNCT dti-2622 7 1 recognition recognition NOUN dti-2622 7 2 of of ADP dti-2622 7 3 factors factor NOUN dti-2622 7 4 associated associate VERB dti-2622 7 5 with with ADP dti-2622 7 6 mortality mortality NOUN dti-2622 7 7 and and CCONJ dti-2622 7 8 treating treat VERB dti-2622 7 9 these these DET dti-2622 7 10 modifiable modifiable ADJ dti-2622 7 11 factors factor NOUN dti-2622 7 12 are be AUX dti-2622 7 13 crucial crucial ADJ dti-2622 7 14 to to ADP dti-2622 7 15 reducing reduce VERB dti-2622 7 16 mortality mortality NOUN dti-2622 7 17 . . PUNCT dti-2622 8 1 objective objective NOUN dti-2622 8 2 : : PUNCT dti-2622 8 3 to to PART dti-2622 8 4 determine determine VERB dti-2622 8 5 the the DET dti-2622 8 6 30 30 NUM dti-2622 8 7 - - PUNCT dti-2622 8 8 day day NOUN dti-2622 8 9 mortality mortality NOUN dti-2622 8 10 and and CCONJ dti-2622 8 11 factors factor NOUN dti-2622 8 12 associated associate VERB dti-2622 8 13 with with ADP dti-2622 8 14 a a DET dti-2622 8 15 30 30 NUM dti-2622 8 16 - - PUNCT dti-2622 8 17 day day NOUN dti-2622 8 18 mortality mortality NOUN dti-2622 8 19 of of ADP dti-2622 8 20 cre cre PROPN dti-2622 8 21 infection infection NOUN dti-2622 8 22 . . PUNCT dti-2622 9 1 methods method NOUN dti-2622 9 2 : : PUNCT dti-2622 9 3 a a DET dti-2622 9 4 retrospective retrospective ADJ dti-2622 9 5 cohort cohort NOUN dti-2622 9 6 study study NOUN dti-2622 9 7 was be AUX dti-2622 9 8 conducted conduct VERB dti-2622 9 9 between between ADP dti-2622 9 10 january january PROPN dti-2622 9 11 1 1 NUM dti-2622 9 12 , , PUNCT dti-2622 9 13 2015 2015 NUM dti-2622 9 14 , , PUNCT dti-2622 9 15 and and CCONJ dti-2622 9 16 december december PROPN dti-2622 9 17 31 31 NUM dti-2622 9 18 , , PUNCT dti-2622 9 19 2019 2019 NUM dti-2622 9 20 . . PUNCT dti-2622 10 1 all all DET dti-2622 10 2 patients patient NOUN dti-2622 10 3 diagnosed diagnose VERB dti-2622 10 4 with with ADP dti-2622 10 5 cre cre PROPN dti-2622 10 6 infection infection NOUN dti-2622 10 7 aged age VERB dti-2622 10 8 ≥18 ≥18 NUM dti-2622 10 9 years year NOUN dti-2622 10 10 were be AUX dti-2622 10 11 included include VERB dti-2622 10 12 . . PUNCT dti-2622 11 1 multivariate multivariate NOUN dti-2622 11 2 logistic logistic ADJ dti-2622 11 3 regression regression NOUN dti-2622 11 4 was be AUX dti-2622 11 5 used use VERB dti-2622 11 6 for for ADP dti-2622 11 7 evaluating evaluate VERB dti-2622 11 8 the the DET dti-2622 11 9 factors factor NOUN dti-2622 11 10 associated associate VERB dti-2622 11 11 with with ADP dti-2622 11 12 30 30 NUM dti-2622 11 13 - - PUNCT dti-2622 11 14 day day NOUN dti-2622 11 15 mortality mortality NOUN dti-2622 11 16 and and CCONJ dti-2622 11 17 presented present VERB dti-2622 11 18 as as ADP dti-2622 11 19 adjusted adjust VERB dti-2622 11 20 odds odd NOUN dti-2622 11 21 ratio ratio NOUN dti-2622 11 22 ( ( PUNCT dti-2622 11 23 aor aor NOUN dti-2622 11 24 ) ) PUNCT dti-2622 11 25 with with ADP dti-2622 11 26 95 95 NUM dti-2622 11 27 % % NOUN dti-2622 11 28 confidence confidence NOUN dti-2622 11 29 interval interval NOUN dti-2622 11 30 ( ( PUNCT dti-2622 11 31 ci ci NOUN dti-2622 11 32 ) ) PUNCT dti-2622 11 33 . . PUNCT dti-2622 12 1 result result NOUN dti-2622 12 2 : : PUNCT dti-2622 12 3 one one NUM dti-2622 12 4 hundred hundred NUM dti-2622 12 5 and and CCONJ dti-2622 12 6 ninety ninety NUM dti-2622 12 7 - - PUNCT dti-2622 12 8 four four NUM dti-2622 12 9 patients patient NOUN dti-2622 12 10 were be AUX dti-2622 12 11 enrolled enrol VERB dti-2622 12 12 . . PUNCT dti-2622 13 1 the the DET dti-2622 13 2 30 30 NUM dti-2622 13 3 - - PUNCT dti-2622 13 4 day day NOUN dti-2622 13 5 mortality mortality NOUN dti-2622 13 6 occurred occur VERB dti-2622 13 7 in in ADP dti-2622 13 8 75 75 NUM dti-2622 13 9 patients patient NOUN dti-2622 13 10 ( ( PUNCT dti-2622 13 11 38.7 38.7 NUM dti-2622 13 12 % % NOUN dti-2622 13 13 ) ) PUNCT dti-2622 13 14 . . PUNCT dti-2622 14 1 the the DET dti-2622 14 2 common common ADJ dti-2622 14 3 antibiotic antibiotic ADJ dti-2622 14 4 regimen regiman NOUN dti-2622 14 5 was be AUX dti-2622 14 6 monotherapy monotherapy NOUN dti-2622 14 7 and and CCONJ dti-2622 14 8 combination combination NOUN dti-2622 14 9 of of ADP dti-2622 14 10 carbapenem carbapenem PROPN dti-2622 14 11 , , PUNCT dti-2622 14 12 colistin colistin NOUN dti-2622 14 13 , , PUNCT dti-2622 14 14 amikacin amikacin PROPN dti-2622 14 15 , , PUNCT dti-2622 14 16 tigecycline tigecycline INTJ dti-2622 14 17 , , PUNCT dti-2622 14 18 and and CCONJ dti-2622 14 19 fosfomycin fosfomycin PROPN dti-2622 14 20 . . PUNCT dti-2622 15 1 cre cre PROPN dti-2622 15 2 isolates isolate NOUN dti-2622 15 3 were be AUX dti-2622 15 4 susceptible susceptible ADJ dti-2622 15 5 to to ADP dti-2622 15 6 tigecycline tigecycline NOUN dti-2622 15 7 ( ( PUNCT dti-2622 15 8 93.8 93.8 NUM dti-2622 15 9 % % NOUN dti-2622 15 10 ) ) PUNCT dti-2622 15 11 , , PUNCT dti-2622 15 12 colistin colistin NOUN dti-2622 15 13 ( ( PUNCT dti-2622 15 14 91.8 91.8 NUM dti-2622 15 15 % % NOUN dti-2622 15 16 ) ) PUNCT dti-2622 15 17 , , PUNCT dti-2622 15 18 fosfomycin fosfomycin PROPN dti-2622 15 19 ( ( PUNCT dti-2622 15 20 89.2 89.2 NUM dti-2622 15 21 % % NOUN dti-2622 15 22 ) ) PUNCT dti-2622 15 23 , , PUNCT dti-2622 15 24 and and CCONJ dti-2622 15 25 amikacin amikacin PROPN dti-2622 15 26 ( ( PUNCT dti-2622 15 27 89.2 89.2 NUM dti-2622 15 28 % % NOUN dti-2622 15 29 ) ) PUNCT dti-2622 15 30 . . PUNCT dti-2622 16 1 the the DET dti-2622 16 2 independent independent ADJ dti-2622 16 3 factors factor NOUN dti-2622 16 4 associated associate VERB dti-2622 16 5 with with ADP dti-2622 16 6 30 30 NUM dti-2622 16 7 - - PUNCT dti-2622 16 8 day day NOUN dti-2622 16 9 mortality mortality NOUN dti-2622 16 10 were be AUX dti-2622 16 11 an an DET dti-2622 16 12 increasing increase VERB dti-2622 16 13 simplified simplified ADJ dti-2622 16 14 acute acute NOUN dti-2622 16 15 physiology physiology NOUN dti-2622 16 16 ( ( PUNCT dti-2622 16 17 sap sap PROPN dti-2622 16 18 ) ) PUNCT dti-2622 16 19 ii ii PROPN dti-2622 16 20 score score NOUN dti-2622 16 21 ( ( PUNCT dti-2622 16 22 aor aor NOUN dti-2622 16 23 1.11 1.11 NUM dti-2622 16 24 , , PUNCT dti-2622 16 25 95 95 NUM dti-2622 16 26 % % NOUN dti-2622 16 27 ci ci NOUN dti-2622 16 28 1.05 1.05 NUM dti-2622 16 29 - - SYM dti-2622 16 30 1.16 1.16 NUM dti-2622 16 31 , , PUNCT dti-2622 16 32 p p X dti-2622 16 33 < < X dti-2622 16 34 0.001 0.001 NUM dti-2622 16 35 ) ) PUNCT dti-2622 16 36 , , PUNCT dti-2622 16 37 sepsis sepsis NOUN dti-2622 16 38 at at ADP dti-2622 16 39 time time NOUN dti-2622 16 40 of of ADP dti-2622 16 41 cre cre PROPN dti-2622 16 42 infection infection NOUN dti-2622 16 43 diagnosis diagnosis NOUN dti-2622 16 44 ( ( PUNCT dti-2622 16 45 aor aor NOUN dti-2622 16 46 7.93 7.93 NUM dti-2622 16 47 , , PUNCT dti-2622 16 48 95 95 NUM dti-2622 16 49 % % NOUN dti-2622 16 50 ci ci NOUN dti-2622 16 51 2.21 2.21 NUM dti-2622 16 52 - - SYM dti-2622 16 53 28.51 28.51 NUM dti-2622 16 54 , , PUNCT dti-2622 16 55 p p X dti-2622 16 56 = = NOUN dti-2622 16 57 0.002 0.002 NUM dti-2622 16 58 ) ) PUNCT dti-2622 16 59 , , PUNCT dti-2622 16 60 pneumonia pneumonia NOUN dti-2622 16 61 ( ( PUNCT dti-2622 16 62 aor aor PROPN dti-2622 16 63 4.48 4.48 NUM dti-2622 16 64 , , PUNCT dti-2622 16 65 95 95 NUM dti-2622 16 66 % % NOUN dti-2622 16 67 ci ci NOUN dti-2622 16 68 1.61 1.61 NUM dti-2622 16 69 - - SYM dti-2622 16 70 12.44 12.44 NUM dti-2622 16 71 , , PUNCT dti-2622 16 72 p p X dti-2622 16 73 = = NOUN dti-2622 16 74 0.004 0.004 NUM dti-2622 16 75 ) ) PUNCT dti-2622 16 76 , , PUNCT dti-2622 16 77 monotherapy monotherapy NOUN dti-2622 16 78 ( ( PUNCT dti-2622 16 79 aor aor PROPN dti-2622 16 80 4.69 4.69 NUM dti-2622 16 81 , , PUNCT dti-2622 16 82 95 95 NUM dti-2622 16 83 % % NOUN dti-2622 16 84 ci ci NOUN dti-2622 16 85 1.71 1.71 NUM dti-2622 16 86 - - SYM dti-2622 16 87 12.85 12.85 NUM dti-2622 16 88 , , PUNCT dti-2622 16 89 p p X dti-2622 16 90 = = NOUN dti-2622 16 91 0.003 0.003 NUM dti-2622 16 92 ) ) PUNCT dti-2622 16 93 , , PUNCT dti-2622 16 94 and and CCONJ dti-2622 16 95 improper improper ADJ dti-2622 16 96 empiric empiric ADJ dti-2622 16 97 antibiotic antibiotic NOUN dti-2622 16 98 ( ( PUNCT dti-2622 16 99 aor aor PROPN dti-2622 16 100 5.13 5.13 NUM dti-2622 16 101 , , PUNCT dti-2622 16 102 95 95 NUM dti-2622 16 103 % % NOUN dti-2622 16 104 ci ci NOUN dti-2622 16 105 1.83 1.83 NUM dti-2622 16 106 - - SYM dti-2622 16 107 14.40 14.40 NUM dti-2622 16 108 , , PUNCT dti-2622 16 109 p p X dti-2622 16 110 = = NOUN dti-2622 16 111 0.002 0.002 NUM dti-2622 16 112 ) ) PUNCT dti-2622 16 113 . . PUNCT dti-2622 17 1 conclusion conclusion NOUN dti-2622 17 2 : : PUNCT dti-2622 17 3 the the DET dti-2622 17 4 overall overall ADJ dti-2622 17 5 30 30 NUM dti-2622 17 6 - - PUNCT dti-2622 17 7 day day NOUN dti-2622 17 8 mortality mortality NOUN dti-2622 17 9 of of ADP dti-2622 17 10 cre cre PROPN dti-2622 17 11 infection infection NOUN dti-2622 17 12 was be AUX dti-2622 17 13 high high ADJ dti-2622 17 14 . . PUNCT dti-2622 18 1 the the DET dti-2622 18 2 factors factor NOUN dti-2622 18 3 associated associate VERB dti-2622 18 4 with with ADP dti-2622 18 5 mortality mortality NOUN dti-2622 18 6 were be AUX dti-2622 18 7 an an DET dti-2622 18 8 increasing increase VERB dti-2622 18 9 sap sap PROPN dti-2622 18 10 ii ii PROPN dti-2622 18 11 score score NOUN dti-2622 18 12 , , PUNCT dti-2622 18 13 sepsis sepsis NOUN dti-2622 18 14 at at ADP dti-2622 18 15 time time NOUN dti-2622 18 16 of of ADP dti-2622 18 17 cre cre PROPN dti-2622 18 18 infection infection NOUN dti-2622 18 19 diagnosis diagnosis NOUN dti-2622 18 20 , , PUNCT dti-2622 18 21 pneumonia pneumonia NOUN dti-2622 18 22 , , PUNCT dti-2622 18 23 monotherapy monotherapy NOUN dti-2622 18 24 , , PUNCT dti-2622 18 25 and and CCONJ dti-2622 18 26 improper improper ADJ dti-2622 18 27 empiric empiric ADJ dti-2622 18 28 antibiotic antibiotic NOUN dti-2622 18 29 . . PUNCT dti-2622 19 1 the the DET dti-2622 19 2 study study NOUN dti-2622 19 3 suggested suggest VERB dti-2622 19 4 that that SCONJ dti-2622 19 5 proper proper ADJ dti-2622 19 6 empiric empiric ADJ dti-2622 19 7 antibiotic antibiotic ADJ dti-2622 19 8 and and CCONJ dti-2622 19 9 combination combination NOUN dti-2622 19 10 antibiotics antibiotic NOUN dti-2622 19 11 might might AUX dti-2622 19 12 reduce reduce VERB dti-2622 19 13 mortality mortality NOUN dti-2622 19 14 from from ADP dti-2622 19 15 cre cre PROPN dti-2622 19 16 infection infection NOUN dti-2622 19 17 . . PUNCT dti-2622 20 1 keywords keyword NOUN dti-2622 20 2 : : PUNCT dti-2622 20 3 30 30 NUM dti-2622 20 4 - - PUNCT dti-2622 20 5 day day NOUN dti-2622 20 6 mortality mortality NOUN dti-2622 20 7 , , PUNCT dti-2622 20 8 carbapenem carbapenem NOUN dti-2622 20 9 - - PUNCT dti-2622 20 10 resistant resistant ADJ dti-2622 20 11 enterobacteriaceae enterobacteriaceae NOUN dti-2622 20 12 , , PUNCT dti-2622 20 13 factors factor NOUN dti-2622 20 14 received receive VERB dti-2622 20 15 : : PUNCT dti-2622 20 16 june june PROPN dti-2622 20 17 23 23 NUM dti-2622 20 18 , , PUNCT dti-2622 20 19 2023 2023 NUM dti-2622 20 20 accepted accept VERB dti-2622 20 21 : : PUNCT dti-2622 20 22 october october PROPN dti-2622 20 23 11 11 NUM dti-2622 20 24 , , PUNCT dti-2622 20 25 2023 2023 NUM dti-2622 20 26 published publish VERB dti-2622 20 27 online online ADV dti-2622 20 28 : : PUNCT dti-2622 20 29 october october PROPN dti-2622 20 30 27 27 NUM dti-2622 20 31 , , PUNCT dti-2622 20 32 2023 2023 NUM dti-2622 20 33 corresponding correspond VERB dti-2622 20 34 author author NOUN dti-2622 20 35 : : PUNCT dti-2622 20 36 atibordee atibordee PROPN dti-2622 20 37 meesing meesing PROPN dti-2622 20 38 department department PROPN dti-2622 20 39 of of ADP dti-2622 20 40 medicine medicine NOUN dti-2622 20 41 faculty faculty NOUN dti-2622 20 42 of of ADP dti-2622 20 43 medicine medicine PROPN dti-2622 20 44 khon khon PROPN dti-2622 20 45 kaen kaen PROPN dti-2622 20 46 university university PROPN dti-2622 20 47 nai nai PROPN dti-2622 20 48 mueang mueang PROPN dti-2622 20 49 subdistrict subdistrict PROPN dti-2622 20 50 , , PUNCT dti-2622 20 51 mueang mueang NOUN dti-2622 20 52 district district PROPN dti-2622 20 53 khon khon PROPN dti-2622 20 54 kaen kaen PROPN dti-2622 20 55 thailand thailand PROPN dti-2622 21 1 40002 40002 NUM dti-2622 22 1 atibordee@kku.ac.th atibordee@kku.ac.th PRON dti-2622 22 2 introduction introduction NOUN dti-2622 22 3 carbapenems carbapenem NOUN dti-2622 22 4 are be AUX dti-2622 22 5 broad broad ADJ dti-2622 22 6 - - PUNCT dti-2622 22 7 spectrum spectrum NOUN dti-2622 22 8 antibiotics antibiotic NOUN dti-2622 22 9 and and CCONJ dti-2622 22 10 have have VERB dti-2622 22 11 a a DET dti-2622 22 12 good good ADJ dti-2622 22 13 potency potency NOUN dti-2622 22 14 against against ADP dti-2622 22 15 gram gram NOUN dti-2622 22 16 - - PUNCT dti-2622 22 17 positive positive ADJ dti-2622 22 18 and and CCONJ dti-2622 22 19 gram gram NOUN dti-2622 22 20 - - PUNCT dti-2622 22 21 negative negative ADJ dti-2622 22 22 bacteria bacteria NOUN dti-2622 22 23 by by ADP dti-2622 22 24 penetrating penetrate VERB dti-2622 22 25 the the DET dti-2622 22 26 cell cell NOUN dti-2622 22 27 walls wall NOUN dti-2622 22 28 of of ADP dti-2622 22 29 bacteria bacteria NOUN dti-2622 22 30 , , PUNCT dti-2622 22 31 binding bind VERB dti-2622 22 32 with with ADP dti-2622 22 33 penicillin penicillin NOUN dti-2622 22 34 - - PUNCT dti-2622 22 35 binding bind VERB dti-2622 22 36 proteins protein NOUN dti-2622 22 37 ( ( PUNCT dti-2622 22 38 pbps pbps NOUN dti-2622 22 39 ) ) PUNCT dti-2622 22 40 , , PUNCT dti-2622 22 41 and and CCONJ dti-2622 22 42 resulting result VERB dti-2622 22 43 in in ADP dti-2622 22 44 inhibiting inhibit VERB dti-2622 22 45 cell cell NOUN dti-2622 22 46 wall wall NOUN dti-2622 22 47 synthesis synthesis NOUN dti-2622 22 48 , , PUNCT dti-2622 22 49 ultimately ultimately ADV dti-2622 22 50 killing kill VERB dti-2622 22 51 the the DET dti-2622 22 52 bacteria bacteria NOUN dti-2622 22 53 . . PUNCT dti-2622 23 1 they they PRON dti-2622 23 2 are be AUX dti-2622 23 3 used use VERB dti-2622 23 4 as as ADP dti-2622 23 5 antibiotics antibiotic NOUN dti-2622 23 6 of of ADP dti-2622 23 7 mostly mostly ADV dti-2622 23 8 last last ADJ dti-2622 23 9 resort resort NOUN dti-2622 23 10 for for ADP dti-2622 23 11 fighting fight VERB dti-2622 23 12 drug drug NOUN dti-2622 23 13 - - PUNCT dti-2622 23 14 resistant resistant ADJ dti-2622 23 15 gram gram NOUN dti-2622 23 16 - - PUNCT dti-2622 23 17 negative negative ADJ dti-2622 23 18 pathogens pathogen NOUN dti-2622 23 19 ( ( PUNCT dti-2622 23 20 1,2 1,2 NUM dti-2622 23 21 ) ) PUNCT dti-2622 23 22 . . PUNCT dti-2622 24 1 carbapenemresistant carbapenemresistant PROPN dti-2622 24 2 enterobacteriaceae enterobacteriaceae PROPN dti-2622 24 3 ( ( PUNCT dti-2622 24 4 cre cre PROPN dti-2622 24 5 ) ) PUNCT dti-2622 24 6 have have AUX dti-2622 24 7 emerged emerge VERB dti-2622 24 8 and and CCONJ dti-2622 24 9 become become VERB dti-2622 24 10 a a DET dti-2622 24 11 major major ADJ dti-2622 24 12 problem problem NOUN dti-2622 24 13 of of ADP dti-2622 24 14 nosocomial nosocomial ADJ dti-2622 24 15 infection infection NOUN dti-2622 24 16 after after ADP dti-2622 24 17 extensive extensive ADJ dti-2622 24 18 use use NOUN dti-2622 24 19 of of ADP dti-2622 24 20 carbapenems carbapenem NOUN dti-2622 24 21 and and CCONJ dti-2622 24 22 its its PRON dti-2622 24 23 spread spread NOUN dti-2622 24 24 , , PUNCT dti-2622 24 25 with with ADP dti-2622 24 26 the the DET dti-2622 24 27 consequent consequent ADJ dti-2622 24 28 change change NOUN dti-2622 24 29 in in ADP dti-2622 24 30 local local ADJ dti-2622 24 31 epidemiology epidemiology NOUN dti-2622 24 32 continuing continue VERB dti-2622 24 33 to to PART dti-2622 24 34 evolve evolve VERB dti-2622 24 35 rapidly rapidly ADV dti-2622 24 36 worldwide worldwide ADV dti-2622 24 37 ( ( PUNCT dti-2622 24 38 3 3 NUM dti-2622 24 39 - - SYM dti-2622 24 40 6 6 NUM dti-2622 24 41 ) ) PUNCT dti-2622 24 42 . . PUNCT dti-2622 25 1 among among ADP dti-2622 25 2 hospitalized hospitalize VERB dti-2622 25 3 patients patient NOUN dti-2622 25 4 , , PUNCT dti-2622 25 5 asymptomatic asymptomatic ADJ dti-2622 25 6 gastrointestinal gastrointestinal ADJ dti-2622 25 7 colonization colonization NOUN dti-2622 25 8 of of ADP dti-2622 25 9 cre cre PROPN dti-2622 25 10 is be AUX dti-2622 25 11 challenging challenging ADJ dti-2622 25 12 , , PUNCT dti-2622 25 13 which which DET dti-2622 25 14 oversteps overstep NOUN dti-2622 25 15 and and CCONJ dti-2622 25 16 significantly significantly ADV dti-2622 25 17 increases increase VERB dti-2622 25 18 the the DET dti-2622 25 19 risk risk NOUN dti-2622 25 20 of of ADP dti-2622 25 21 subsequent subsequent ADJ dti-2622 25 22 infections infection NOUN dti-2622 25 23 caused cause VERB dti-2622 25 24 by by ADP dti-2622 25 25 these these DET dti-2622 25 26 pathogens pathogen NOUN dti-2622 25 27 . . PUNCT dti-2622 26 1 the the DET dti-2622 26 2 prevalence prevalence NOUN dti-2622 26 3 of of ADP dti-2622 26 4 cre cre PROPN dti-2622 26 5 infection infection NOUN dti-2622 26 6 was be AUX dti-2622 26 7 shown show VERB dti-2622 26 8 to to PART dti-2622 26 9 be be AUX dti-2622 26 10 1.3 1.3 NUM dti-2622 26 11 per per ADP dti-2622 26 12 10,000 10,000 NUM dti-2622 26 13 hospital hospital NOUN dti-2622 26 14 admissions admission NOUN dti-2622 26 15 ( ( PUNCT dti-2622 26 16 1 1 NUM dti-2622 26 17 ) ) PUNCT dti-2622 26 18 . . PUNCT dti-2622 27 1 the the DET dti-2622 27 2 mechanisms mechanism NOUN dti-2622 27 3 of of ADP dti-2622 27 4 resistance resistance NOUN dti-2622 27 5 to to ADP dti-2622 27 6 carbapenems carbapenem NOUN dti-2622 27 7 include include VERB dti-2622 27 8 β β NOUN dti-2622 27 9 - - PUNCT dti-2622 27 10 lactamase lactamase ADJ dti-2622 27 11 production production NOUN dti-2622 27 12 , , PUNCT dti-2622 27 13 efflux efflux NOUN dti-2622 27 14 pumps pump NOUN dti-2622 27 15 , , PUNCT dti-2622 27 16 and and CCONJ dti-2622 27 17 mutations mutation NOUN dti-2622 27 18 that that PRON dti-2622 27 19 alter alter VERB dti-2622 27 20 the the DET dti-2622 27 21 expression expression NOUN dti-2622 27 22 and/or and/or CCONJ dti-2622 27 23 function function NOUN dti-2622 27 24 of of ADP dti-2622 27 25 porins porin NOUN dti-2622 27 26 and and CCONJ dti-2622 27 27 pbps pbps NOUN dti-2622 27 28 . . PUNCT dti-2622 28 1 https://doi.org/10.33393/dti.2023.2622 https://doi.org/10.33393/dti.2023.2622 X dti-2622 28 2 https://creativecommons.org/licenses/by-nc/4.0/legalcode https://creativecommons.org/licenses/by-nc/4.0/legalcode NUM dti-2622 28 3 mailto:atibordee@kku.ac.th mailto:atibordee@kku.ac.th PRON dti-2622 28 4 so so ADV dti-2622 28 5 - - PUNCT dti-2622 28 6 ngern ngern ADJ dti-2622 28 7 et et PROPN dti-2622 28 8 al al PROPN dti-2622 28 9 drug drug PROPN dti-2622 28 10 target target NOUN dti-2622 28 11 insights insight NOUN dti-2622 28 12 2023 2023 NUM dti-2622 28 13 ; ; PUNCT dti-2622 28 14 17 17 NUM dti-2622 28 15 : : SYM dti-2622 28 16 121 121 NUM dti-2622 28 17 © © PROPN dti-2622 28 18 2023 2023 NUM dti-2622 29 1 the the DET dti-2622 29 2 authors author NOUN dti-2622 29 3 . . PUNCT dti-2622 29 4 published publish VERB dti-2622 29 5 by by ADP dti-2622 29 6 aboutscience aboutscience NOUN dti-2622 29 7 www.aboutscience.eu www.aboutscience.eu VERB dti-2622 29 8 certain certain ADJ dti-2622 29 9 bacteria bacteria NOUN dti-2622 29 10 have have VERB dti-2622 29 11 combinations combination NOUN dti-2622 29 12 of of ADP dti-2622 29 13 these these DET dti-2622 29 14 mechanisms mechanism NOUN dti-2622 29 15 that that PRON dti-2622 29 16 cause cause VERB dti-2622 29 17 high high ADJ dti-2622 29 18 levels level NOUN dti-2622 29 19 of of ADP dti-2622 29 20 resistance resistance NOUN dti-2622 29 21 to to ADP dti-2622 29 22 carbapenems carbapenem NOUN dti-2622 29 23 ( ( PUNCT dti-2622 29 24 1,2 1,2 NUM dti-2622 29 25 ) ) PUNCT dti-2622 29 26 . . PUNCT dti-2622 30 1 cefiderocol cefiderocol VERB dti-2622 30 2 and and CCONJ dti-2622 30 3 new new ADJ dti-2622 30 4 beta beta NOUN dti-2622 30 5 - - PUNCT dti-2622 30 6 lactam lactam NOUN dti-2622 30 7 - - PUNCT dti-2622 30 8 beta beta NOUN dti-2622 30 9 - - PUNCT dti-2622 30 10 lactamase lactamase ADJ dti-2622 30 11 inhibitors inhibitor NOUN dti-2622 30 12 ( ( PUNCT dti-2622 30 13 blbis blbis NOUN dti-2622 30 14 ) ) PUNCT dti-2622 30 15 , , PUNCT dti-2622 30 16 that that ADV dti-2622 30 17 is is ADV dti-2622 30 18 , , PUNCT dti-2622 30 19 ceftazidime ceftazidime NOUN dti-2622 30 20 - - PUNCT dti-2622 30 21 avibactam avibactam NOUN dti-2622 30 22 , , PUNCT dti-2622 30 23 meropenem meropenem NOUN dti-2622 30 24 - - PUNCT dti-2622 30 25 vaborbactam vaborbactam NOUN dti-2622 30 26 , , PUNCT dti-2622 30 27 and and CCONJ dti-2622 30 28 imipenem imipenem PROPN dti-2622 30 29 - - PUNCT dti-2622 30 30 cilastatin cilastatin NOUN dti-2622 30 31 - - PUNCT dti-2622 30 32 relebactam relebactam NOUN dti-2622 30 33 , , PUNCT dti-2622 30 34 have have AUX dti-2622 30 35 been be AUX dti-2622 30 36 developed develop VERB dti-2622 30 37 to to PART dti-2622 30 38 fight fight VERB dti-2622 30 39 with with ADP dti-2622 30 40 cre cre PROPN dti-2622 30 41 infection infection NOUN dti-2622 30 42 ( ( PUNCT dti-2622 30 43 7 7 NUM dti-2622 30 44 ) ) PUNCT dti-2622 30 45 . . PUNCT dti-2622 31 1 the the DET dti-2622 31 2 infectious infectious ADJ dti-2622 31 3 diseases disease NOUN dti-2622 31 4 society society NOUN dti-2622 31 5 of of ADP dti-2622 31 6 america america PROPN dti-2622 31 7 ( ( PUNCT dti-2622 31 8 idsa idsa PROPN dti-2622 31 9 ) ) PUNCT dti-2622 31 10 and and CCONJ dti-2622 31 11 the the DET dti-2622 31 12 european european ADJ dti-2622 31 13 society society NOUN dti-2622 31 14 of of ADP dti-2622 31 15 clinical clinical ADJ dti-2622 31 16 microbiology microbiology NOUN dti-2622 31 17 and and CCONJ dti-2622 31 18 infectious infectious ADJ dti-2622 31 19 diseases disease NOUN dti-2622 31 20 ( ( PUNCT dti-2622 31 21 esmid esmid NOUN dti-2622 31 22 ) ) PUNCT dti-2622 31 23 have have AUX dti-2622 31 24 published publish VERB dti-2622 31 25 updated update VERB dti-2622 31 26 guidance guidance NOUN dti-2622 31 27 on on ADP dti-2622 31 28 the the DET dti-2622 31 29 treatment treatment NOUN dti-2622 31 30 of of ADP dti-2622 31 31 antimicrobial antimicrobial ADJ dti-2622 31 32 - - PUNCT dti-2622 31 33 resistant resistant ADJ dti-2622 31 34 gram gram NOUN dti-2622 31 35 - - PUNCT dti-2622 31 36 negative negative ADJ dti-2622 31 37 infections infection NOUN dti-2622 31 38 ( ( PUNCT dti-2622 31 39 2,8 2,8 NUM dti-2622 31 40 ) ) PUNCT dti-2622 31 41 . . PUNCT dti-2622 32 1 the the DET dti-2622 32 2 new new ADJ dti-2622 32 3 blbis blbis NOUN dti-2622 32 4 and and CCONJ dti-2622 32 5 cefiderocol cefiderocol NOUN dti-2622 32 6 are be AUX dti-2622 32 7 preferred preferred ADJ dti-2622 32 8 treatment treatment NOUN dti-2622 32 9 options option NOUN dti-2622 32 10 for for ADP dti-2622 32 11 cre cre PROPN dti-2622 32 12 infection infection NOUN dti-2622 32 13 . . PUNCT dti-2622 33 1 new new ADJ dti-2622 33 2 blbis blbis NOUN dti-2622 33 3 and and CCONJ dti-2622 33 4 cefiderocol cefiderocol VERB dti-2622 33 5 , , PUNCT dti-2622 33 6 however however ADV dti-2622 33 7 , , PUNCT dti-2622 33 8 are be AUX dti-2622 33 9 not not PART dti-2622 33 10 widely widely ADV dti-2622 33 11 available available ADJ dti-2622 33 12 including include VERB dti-2622 33 13 in in ADP dti-2622 33 14 our our PRON dti-2622 33 15 center center NOUN dti-2622 33 16 ; ; PUNCT dti-2622 33 17 therefore therefore ADV dti-2622 33 18 , , PUNCT dti-2622 33 19 monotherapy monotherapy NOUN dti-2622 33 20 or or CCONJ dti-2622 33 21 combination combination NOUN dti-2622 33 22 of of ADP dti-2622 33 23 colistin colistin NOUN dti-2622 33 24 , , PUNCT dti-2622 33 25 fosfomycin fosfomycin PROPN dti-2622 33 26 , , PUNCT dti-2622 33 27 tigecycline tigecycline NOUN dti-2622 33 28 , , PUNCT dti-2622 33 29 amikacin amikacin PROPN dti-2622 33 30 , , PUNCT dti-2622 33 31 gentamicin gentamicin NOUN dti-2622 33 32 , , PUNCT dti-2622 33 33 and and CCONJ dti-2622 33 34 carbapenem carbapenem PROPN dti-2622 33 35 is be AUX dti-2622 33 36 usually usually ADV dti-2622 33 37 used use VERB dti-2622 33 38 to to PART dti-2622 33 39 combat combat VERB dti-2622 33 40 cre cre PROPN dti-2622 33 41 infection infection NOUN dti-2622 33 42 ( ( PUNCT dti-2622 33 43 9,10 9,10 NUM dti-2622 33 44 ) ) PUNCT dti-2622 33 45 . . PUNCT dti-2622 34 1 the the DET dti-2622 34 2 mortality mortality NOUN dti-2622 34 3 rate rate NOUN dti-2622 34 4 of of ADP dti-2622 34 5 cre cre PROPN dti-2622 34 6 infection infection NOUN dti-2622 34 7 is be AUX dti-2622 34 8 high high ADJ dti-2622 34 9 as as SCONJ dti-2622 34 10 shown show VERB dti-2622 34 11 in in ADP dti-2622 34 12 many many ADJ dti-2622 34 13 studies study NOUN dti-2622 34 14 , , PUNCT dti-2622 34 15 varying vary VERB dti-2622 34 16 from from ADP dti-2622 34 17 31 31 NUM dti-2622 34 18 % % NOUN dti-2622 34 19 to to ADP dti-2622 34 20 53 53 NUM dti-2622 34 21 % % NOUN dti-2622 34 22 ( ( PUNCT dti-2622 34 23 11 11 NUM dti-2622 34 24 - - SYM dti-2622 34 25 14 14 NUM dti-2622 34 26 ) ) PUNCT dti-2622 34 27 . . PUNCT dti-2622 35 1 recognition recognition NOUN dti-2622 35 2 and and CCONJ dti-2622 35 3 identification identification NOUN dti-2622 35 4 of of ADP dti-2622 35 5 factors factor NOUN dti-2622 35 6 associated associate VERB dti-2622 35 7 with with ADP dti-2622 35 8 mortality mortality NOUN dti-2622 35 9 of of ADP dti-2622 35 10 cre cre PROPN dti-2622 35 11 infection infection NOUN dti-2622 35 12 are be AUX dti-2622 35 13 important important ADJ dti-2622 35 14 in in ADP dti-2622 35 15 clinical clinical ADJ dti-2622 35 16 practice practice NOUN dti-2622 35 17 . . PUNCT dti-2622 36 1 treatment treatment NOUN dti-2622 36 2 of of ADP dti-2622 36 3 modifiable modifiable ADJ dti-2622 36 4 risk risk NOUN dti-2622 36 5 factors factor NOUN dti-2622 36 6 is be AUX dti-2622 36 7 useful useful ADJ dti-2622 36 8 for for ADP dti-2622 36 9 reducing reduce VERB dti-2622 36 10 the the DET dti-2622 36 11 mortality mortality NOUN dti-2622 36 12 of of ADP dti-2622 36 13 cre cre PROPN dti-2622 36 14 infection infection NOUN dti-2622 36 15 . . PUNCT dti-2622 37 1 previous previous ADJ dti-2622 37 2 reports report NOUN dti-2622 37 3 demonstrated demonstrate VERB dti-2622 37 4 age age NOUN dti-2622 37 5 , , PUNCT dti-2622 37 6 sepsis sepsis NOUN dti-2622 37 7 , , PUNCT dti-2622 37 8 shock shock NOUN dti-2622 37 9 , , PUNCT dti-2622 37 10 chronic chronic ADJ dti-2622 37 11 renal renal ADJ dti-2622 37 12 failure failure NOUN dti-2622 37 13 , , PUNCT dti-2622 37 14 dialysis dialysis NOUN dti-2622 37 15 , , PUNCT dti-2622 37 16 neutropenia neutropenia NOUN dti-2622 37 17 , , PUNCT dti-2622 37 18 high high ADJ dti-2622 37 19 acute acute NOUN dti-2622 37 20 physiology physiology NOUN dti-2622 37 21 and and CCONJ dti-2622 37 22 chronic chronic ADJ dti-2622 37 23 health health NOUN dti-2622 37 24 evaluation evaluation NOUN dti-2622 37 25 ( ( PUNCT dti-2622 37 26 apache apache NOUN dti-2622 37 27 ) ) PUNCT dti-2622 37 28 scores score NOUN dti-2622 37 29 , , PUNCT dti-2622 37 30 monotherapy monotherapy NOUN dti-2622 37 31 , , PUNCT dti-2622 37 32 and and CCONJ dti-2622 37 33 inadequate inadequate ADJ dti-2622 37 34 empiric empiric ADJ dti-2622 37 35 antibiotic antibiotic NOUN dti-2622 37 36 were be AUX dti-2622 37 37 the the DET dti-2622 37 38 factors factor NOUN dti-2622 37 39 associated associate VERB dti-2622 37 40 with with ADP dti-2622 37 41 mortality mortality NOUN dti-2622 37 42 ( ( PUNCT dti-2622 37 43 12,13,15 12,13,15 NUM dti-2622 37 44 - - SYM dti-2622 37 45 17 17 NUM dti-2622 37 46 ) ) PUNCT dti-2622 37 47 . . PUNCT dti-2622 38 1 the the DET dti-2622 38 2 study study NOUN dti-2622 38 3 of of ADP dti-2622 38 4 the the DET dti-2622 38 5 mortality mortality NOUN dti-2622 38 6 rate rate NOUN dti-2622 38 7 and and CCONJ dti-2622 38 8 factors factor NOUN dti-2622 38 9 associated associate VERB dti-2622 38 10 with with ADP dti-2622 38 11 mortality mortality NOUN dti-2622 38 12 in in ADP dti-2622 38 13 cre cre PROPN dti-2622 38 14 infection infection NOUN dti-2622 38 15 are be AUX dti-2622 38 16 still still ADV dti-2622 38 17 limited limit VERB dti-2622 38 18 in in ADP dti-2622 38 19 thailand thailand PROPN dti-2622 38 20 . . PUNCT dti-2622 39 1 hence hence ADV dti-2622 39 2 , , PUNCT dti-2622 39 3 the the DET dti-2622 39 4 study study NOUN dti-2622 39 5 was be AUX dti-2622 39 6 conducted conduct VERB dti-2622 39 7 for for ADP dti-2622 39 8 evaluating evaluate VERB dti-2622 39 9 the the DET dti-2622 39 10 mortality mortality NOUN dti-2622 39 11 rate rate NOUN dti-2622 39 12 and and CCONJ dti-2622 39 13 factors factor NOUN dti-2622 39 14 associated associate VERB dti-2622 39 15 with with ADP dti-2622 39 16 cre cre PROPN dti-2622 39 17 infection infection NOUN dti-2622 39 18 . . PUNCT dti-2622 40 1 methods method NOUN dti-2622 40 2 this this PRON dti-2622 40 3 was be AUX dti-2622 40 4 a a DET dti-2622 40 5 retrospective retrospective ADJ dti-2622 40 6 cohort cohort NOUN dti-2622 40 7 study study NOUN dti-2622 40 8 that that PRON dti-2622 40 9 was be AUX dti-2622 40 10 conducted conduct VERB dti-2622 40 11 between between ADP dti-2622 40 12 january january PROPN dti-2622 40 13 1 1 NUM dti-2622 40 14 , , PUNCT dti-2622 40 15 2015 2015 NUM dti-2622 40 16 , , PUNCT dti-2622 40 17 and and CCONJ dti-2622 40 18 december december PROPN dti-2622 40 19 31 31 NUM dti-2622 40 20 , , PUNCT dti-2622 40 21 2019 2019 NUM dti-2622 40 22 , , PUNCT dti-2622 40 23 at at ADP dti-2622 40 24 srinagarind srinagarind ADJ dti-2622 40 25 hospital hospital NOUN dti-2622 40 26 , , PUNCT dti-2622 40 27 faculty faculty NOUN dti-2622 40 28 of of ADP dti-2622 40 29 medicine medicine NOUN dti-2622 40 30 , , PUNCT dti-2622 40 31 khon khon PROPN dti-2622 40 32 kaen kaen PROPN dti-2622 40 33 university university PROPN dti-2622 40 34 , , PUNCT dti-2622 40 35 which which PRON dti-2622 40 36 is be AUX dti-2622 40 37 a a DET dti-2622 40 38 1,466 1,466 NUM dti-2622 40 39 - - PUNCT dti-2622 40 40 bed bed NOUN dti-2622 40 41 tertiary tertiary ADJ dti-2622 40 42 center center NOUN dti-2622 40 43 in in ADP dti-2622 40 44 northeast northeast PROPN dti-2622 40 45 thailand thailand PROPN dti-2622 40 46 . . PUNCT dti-2622 41 1 the the DET dti-2622 41 2 study study NOUN dti-2622 41 3 was be AUX dti-2622 41 4 approved approve VERB dti-2622 41 5 by by ADP dti-2622 41 6 the the DET dti-2622 41 7 local local ADJ dti-2622 41 8 human human PROPN dti-2622 41 9 research research PROPN dti-2622 41 10 ethics ethic NOUN dti-2622 41 11 committee committee PROPN dti-2622 41 12 ( ( PUNCT dti-2622 41 13 approval approval NOUN dti-2622 41 14 number number NOUN dti-2622 41 15 he631252 he631252 PROPN dti-2622 41 16 ) ) PUNCT dti-2622 41 17 . . PUNCT dti-2622 42 1 patients patient NOUN dti-2622 42 2 and and CCONJ dti-2622 42 3 data datum NOUN dti-2622 42 4 collection collection NOUN dti-2622 42 5 the the DET dti-2622 42 6 study study NOUN dti-2622 42 7 included include VERB dti-2622 42 8 patients patient NOUN dti-2622 42 9 aged age VERB dti-2622 42 10 ≥18 ≥18 NUM dti-2622 42 11 years year NOUN dti-2622 42 12 who who PRON dti-2622 42 13 had have AUX dti-2622 42 14 been be AUX dti-2622 42 15 diagnosed diagnose VERB dti-2622 42 16 with with ADP dti-2622 42 17 cre cre PROPN dti-2622 42 18 infection infection NOUN dti-2622 42 19 by by ADP dti-2622 42 20 criteria criterion NOUN dti-2622 42 21 from from ADP dti-2622 42 22 the the DET dti-2622 42 23 clinical clinical ADJ dti-2622 42 24 and and CCONJ dti-2622 42 25 laboratory laboratory NOUN dti-2622 42 26 standards standard NOUN dti-2622 42 27 institute institute PROPN dti-2622 42 28 ( ( PUNCT dti-2622 42 29 clsi clsi PROPN dti-2622 42 30 ) ) PUNCT dti-2622 42 31 2015 2015 NUM dti-2622 42 32 . . PUNCT dti-2622 43 1 in in ADP dti-2622 43 2 brief brief ADJ dti-2622 43 3 , , PUNCT dti-2622 43 4 cre cre PROPN dti-2622 43 5 is be AUX dti-2622 43 6 defined define VERB dti-2622 43 7 as as ADP dti-2622 43 8 resistant resistant ADJ dti-2622 43 9 to to ADP dti-2622 43 10 at at ADV dti-2622 43 11 least least ADV dti-2622 43 12 one one NUM dti-2622 43 13 carbapenem carbapenem NOUN dti-2622 43 14 or or CCONJ dti-2622 43 15 producing produce VERB dti-2622 43 16 a a DET dti-2622 43 17 carbapenemase carbapenemase NOUN dti-2622 43 18 enzyme enzyme NOUN dti-2622 43 19 ( ( PUNCT dti-2622 43 20 18 18 NUM dti-2622 43 21 ) ) PUNCT dti-2622 43 22 . . PUNCT dti-2622 44 1 the the DET dti-2622 44 2 exclusion exclusion NOUN dti-2622 44 3 criteria criterion NOUN dti-2622 44 4 were be AUX dti-2622 44 5 the the DET dti-2622 44 6 patients patient NOUN dti-2622 44 7 who who PRON dti-2622 44 8 were be AUX dti-2622 44 9 colonized colonize VERB dti-2622 44 10 with with ADP dti-2622 44 11 cre cre PROPN dti-2622 44 12 organisms organism NOUN dti-2622 44 13 without without ADP dti-2622 44 14 clinical clinical ADJ dti-2622 44 15 signs sign NOUN dti-2622 44 16 and and CCONJ dti-2622 44 17 symptoms symptom NOUN dti-2622 44 18 of of ADP dti-2622 44 19 infection infection NOUN dti-2622 44 20 . . PUNCT dti-2622 45 1 the the DET dti-2622 45 2 medical medical ADJ dti-2622 45 3 records record NOUN dti-2622 45 4 of of ADP dti-2622 45 5 demographic demographic ADJ dti-2622 45 6 data datum NOUN dti-2622 45 7 , , PUNCT dti-2622 45 8 laboratory laboratory NOUN dti-2622 45 9 results result NOUN dti-2622 45 10 , , PUNCT dti-2622 45 11 microbiological microbiological ADJ dti-2622 45 12 and and CCONJ dti-2622 45 13 sensitivity sensitivity NOUN dti-2622 45 14 profiles profile NOUN dti-2622 45 15 , , PUNCT dti-2622 45 16 treatment treatment NOUN dti-2622 45 17 regimen regiman NOUN dti-2622 45 18 , , PUNCT dti-2622 45 19 and and CCONJ dti-2622 45 20 30 30 NUM dti-2622 45 21 - - PUNCT dti-2622 45 22 day day NOUN dti-2622 45 23 mortality mortality NOUN dti-2622 45 24 were be AUX dti-2622 45 25 reviewed review VERB dti-2622 45 26 . . PUNCT dti-2622 46 1 the the DET dti-2622 46 2 simplified simplified ADJ dti-2622 46 3 acute acute NOUN dti-2622 46 4 physiology physiology NOUN dti-2622 46 5 ( ( PUNCT dti-2622 46 6 sap sap PROPN dti-2622 46 7 ) ) PUNCT dti-2622 46 8 ii ii PROPN dti-2622 46 9 score score NOUN dti-2622 46 10 and and CCONJ dti-2622 46 11 sepsis sepsis NOUN dti-2622 46 12 at at ADP dti-2622 46 13 time time NOUN dti-2622 46 14 of of ADP dti-2622 46 15 cre cre PROPN dti-2622 46 16 infection infection NOUN dti-2622 46 17 diagnosis diagnosis NOUN dti-2622 46 18 were be AUX dti-2622 46 19 obtained obtain VERB dti-2622 46 20 . . PUNCT dti-2622 47 1 definition definition NOUN dti-2622 47 2 and and CCONJ dti-2622 47 3 outcomes outcome NOUN dti-2622 47 4 the the DET dti-2622 47 5 outcome outcome NOUN dti-2622 47 6 was be AUX dti-2622 47 7 the the DET dti-2622 47 8 30 30 NUM dti-2622 47 9 - - PUNCT dti-2622 47 10 day day NOUN dti-2622 47 11 mortality mortality NOUN dti-2622 47 12 and and CCONJ dti-2622 47 13 factors factor NOUN dti-2622 47 14 associated associate VERB dti-2622 47 15 with with ADP dti-2622 47 16 30 30 NUM dti-2622 47 17 - - PUNCT dti-2622 47 18 day day NOUN dti-2622 47 19 mortality mortality NOUN dti-2622 47 20 . . PUNCT dti-2622 48 1 the the DET dti-2622 48 2 30 30 NUM dti-2622 48 3 - - PUNCT dti-2622 48 4 day day NOUN dti-2622 48 5 mortality mortality NOUN dti-2622 48 6 was be AUX dti-2622 48 7 death death NOUN dti-2622 48 8 for for ADP dti-2622 48 9 any any DET dti-2622 48 10 reason reason NOUN dti-2622 48 11 after after ADP dti-2622 48 12 cre cre PROPN dti-2622 48 13 infection infection NOUN dti-2622 48 14 diagnosis diagnosis NOUN dti-2622 48 15 within within ADP dti-2622 48 16 30 30 NUM dti-2622 48 17 calendar calendar NOUN dti-2622 48 18 days day NOUN dti-2622 48 19 . . PUNCT dti-2622 49 1 the the DET dti-2622 49 2 empiric empiric ADJ dti-2622 49 3 antibiotic antibiotic ADJ dti-2622 49 4 regimen regiman NOUN dti-2622 49 5 was be AUX dti-2622 49 6 selected select VERB dti-2622 49 7 depending depend VERB dti-2622 49 8 on on ADP dti-2622 49 9 the the DET dti-2622 49 10 gram gram NOUN dti-2622 49 11 stain stain NOUN dti-2622 49 12 of of ADP dti-2622 49 13 the the DET dti-2622 49 14 specimen speciman NOUN dti-2622 49 15 from from ADP dti-2622 49 16 source source NOUN dti-2622 49 17 of of ADP dti-2622 49 18 infection infection NOUN dti-2622 49 19 , , PUNCT dti-2622 49 20 local local ADJ dti-2622 49 21 data datum NOUN dti-2622 49 22 , , PUNCT dti-2622 49 23 and and CCONJ dti-2622 49 24 antibiogram antibiogram NUM dti-2622 49 25 of of ADP dti-2622 49 26 pathogens pathogen NOUN dti-2622 49 27 . . PUNCT dti-2622 50 1 the the DET dti-2622 50 2 improper improper ADJ dti-2622 50 3 empiric empiric ADJ dti-2622 50 4 antibiotic antibiotic NOUN dti-2622 50 5 was be AUX dti-2622 50 6 defined define VERB dti-2622 50 7 as as ADP dti-2622 50 8 any any DET dti-2622 50 9 antibiotic antibiotic NOUN dti-2622 50 10 in in ADP dti-2622 50 11 the the DET dti-2622 50 12 empiric empiric ADJ dti-2622 50 13 treatment treatment NOUN dti-2622 50 14 regimen regiman NOUN dti-2622 50 15 for for ADP dti-2622 50 16 the the DET dti-2622 50 17 pathogens pathogen NOUN dti-2622 50 18 that that PRON dti-2622 50 19 were be AUX dti-2622 50 20 not not PART dti-2622 50 21 susceptible susceptible ADJ dti-2622 50 22 to to ADP dti-2622 50 23 antibiotic antibiotic NOUN dti-2622 50 24 in in ADP dti-2622 50 25 the the DET dti-2622 50 26 empiric empiric ADJ dti-2622 50 27 regimen regiman NOUN dti-2622 50 28 . . PUNCT dti-2622 51 1 the the DET dti-2622 51 2 result result NOUN dti-2622 51 3 of of ADP dti-2622 51 4 culture culture NOUN dti-2622 51 5 and and CCONJ dti-2622 51 6 drug drug NOUN dti-2622 51 7 susceptibility susceptibility NOUN dti-2622 51 8 test test NOUN dti-2622 51 9 was be AUX dti-2622 51 10 reported report VERB dti-2622 51 11 72 72 NUM dti-2622 51 12 - - SYM dti-2622 51 13 96 96 NUM dti-2622 51 14 hours hour NOUN dti-2622 51 15 after after SCONJ dti-2622 51 16 specimens specimen NOUN dti-2622 51 17 were be AUX dti-2622 51 18 collected collect VERB dti-2622 51 19 . . PUNCT dti-2622 52 1 the the DET dti-2622 52 2 drug drug NOUN dti-2622 52 3 susceptibility susceptibility NOUN dti-2622 52 4 test test NOUN dti-2622 52 5 of of ADP dti-2622 52 6 microbiology microbiology NOUN dti-2622 52 7 was be AUX dti-2622 52 8 interpreted interpret VERB dti-2622 52 9 by by ADP dti-2622 52 10 clsi clsi NOUN dti-2622 52 11 2015 2015 NUM dti-2622 52 12 ( ( PUNCT dti-2622 52 13 18 18 NUM dti-2622 52 14 ) ) PUNCT dti-2622 52 15 . . PUNCT dti-2622 53 1 the the DET dti-2622 53 2 treatment treatment NOUN dti-2622 53 3 regimen regiman NOUN dti-2622 53 4 was be AUX dti-2622 53 5 adjusted adjust VERB dti-2622 53 6 by by ADP dti-2622 53 7 the the DET dti-2622 53 8 drug drug NOUN dti-2622 53 9 susceptibility susceptibility NOUN dti-2622 53 10 test test NOUN dti-2622 53 11 . . PUNCT dti-2622 54 1 the the DET dti-2622 54 2 common common ADJ dti-2622 54 3 antibiotic antibiotic ADJ dti-2622 54 4 treatment treatment NOUN dti-2622 54 5 is be AUX dti-2622 54 6 monotherapy monotherapy NOUN dti-2622 54 7 or or CCONJ dti-2622 54 8 a a DET dti-2622 54 9 combination combination NOUN dti-2622 54 10 of of ADP dti-2622 54 11 carbapenem carbapenem PROPN dti-2622 54 12 , , PUNCT dti-2622 54 13 colistin colistin NOUN dti-2622 54 14 , , PUNCT dti-2622 54 15 amikacin amikacin PROPN dti-2622 54 16 , , PUNCT dti-2622 54 17 tigecycline tigecycline INTJ dti-2622 54 18 , , PUNCT dti-2622 54 19 and and CCONJ dti-2622 54 20 fosfomycin fosfomycin PROPN dti-2622 54 21 . . PUNCT dti-2622 55 1 the the DET dti-2622 55 2 administration administration NOUN dti-2622 55 3 dose dose NOUN dti-2622 55 4 of of ADP dti-2622 55 5 these these DET dti-2622 55 6 antibiotics antibiotic NOUN dti-2622 55 7 was be AUX dti-2622 55 8 as as SCONJ dti-2622 55 9 follows follow VERB dti-2622 55 10 : : PUNCT dti-2622 55 11 meropenem meropenem PROPN dti-2622 55 12 1000 1000 NUM dti-2622 55 13 mg mg NOUN dti-2622 55 14 intravenous intravenous ADJ dti-2622 55 15 every every DET dti-2622 55 16 8 8 NUM dti-2622 55 17 hours hour NOUN dti-2622 55 18 , , PUNCT dti-2622 55 19 imipenem imipenem PROPN dti-2622 55 20 - - PUNCT dti-2622 55 21 cilastatin cilastatin PROPN dti-2622 55 22 1000 1000 NUM dti-2622 55 23 mg mg NOUN dti-2622 55 24 intravenous intravenous ADJ dti-2622 55 25 every every DET dti-2622 55 26 8 8 NUM dti-2622 55 27 hours hour NOUN dti-2622 55 28 , , PUNCT dti-2622 55 29 colistin colistin VERB dti-2622 55 30 300 300 NUM dti-2622 55 31 mg mg NOUN dti-2622 55 32 intravenous intravenous ADJ dti-2622 55 33 loading loading NOUN dti-2622 55 34 then then ADV dti-2622 55 35 150 150 NUM dti-2622 55 36 mg mg NOUN dti-2622 55 37 intravenous intravenous ADJ dti-2622 55 38 every every DET dti-2622 55 39 12 12 NUM dti-2622 55 40 hours hour NOUN dti-2622 55 41 , , PUNCT dti-2622 55 42 fosfomycin fosfomycin VERB dti-2622 55 43 4 4 NUM dti-2622 55 44 g g NOUN dti-2622 55 45 intravenous intravenous ADJ dti-2622 55 46 every every DET dti-2622 55 47 8 8 NUM dti-2622 55 48 hours hour NOUN dti-2622 55 49 , , PUNCT dti-2622 55 50 amikacin amikacin PROPN dti-2622 55 51 750 750 NUM dti-2622 55 52 mg mg ADV dti-2622 55 53 intravenous intravenous ADJ dti-2622 55 54 every every DET dti-2622 55 55 24 24 NUM dti-2622 55 56 hours hour NOUN dti-2622 55 57 , , PUNCT dti-2622 55 58 tigecycline tigecycline VERB dti-2622 55 59 200 200 NUM dti-2622 55 60 mg mg NOUN dti-2622 55 61 intravenous intravenous ADJ dti-2622 55 62 loading loading NOUN dti-2622 55 63 then then ADV dti-2622 55 64 100 100 NUM dti-2622 55 65 mg mg NOUN dti-2622 55 66 intravenous intravenous ADJ dti-2622 55 67 every every DET dti-2622 55 68 12 12 NUM dti-2622 55 69 hours hour NOUN dti-2622 55 70 , , PUNCT dti-2622 55 71 sitafloxacin sitafloxacin PROPN dti-2622 55 72 100 100 NUM dti-2622 55 73 mg mg NOUN dti-2622 55 74 oral oral ADJ dti-2622 55 75 every every DET dti-2622 55 76 12 12 NUM dti-2622 55 77 hours hour NOUN dti-2622 55 78 , , PUNCT dti-2622 55 79 cotrimoxazole cotrimoxazole NOUN dti-2622 55 80 15 15 NUM dti-2622 55 81 - - SYM dti-2622 55 82 20 20 NUM dti-2622 55 83 mg mg NOUN dti-2622 55 84 of of ADP dti-2622 55 85 trimethoprim/ trimethoprim/ NUM dti-2622 55 86 kg kg NOUN dti-2622 55 87 / / SYM dti-2622 55 88 day day NOUN dti-2622 55 89 intravenous intravenous ADV dti-2622 55 90 divided divide VERB dti-2622 55 91 every every DET dti-2622 55 92 8 8 NUM dti-2622 55 93 hours hour NOUN dti-2622 55 94 . . PUNCT dti-2622 56 1 the the DET dti-2622 56 2 renal renal ADJ dti-2622 56 3 dosage dosage NOUN dti-2622 56 4 was be AUX dti-2622 56 5 adjusted adjust VERB dti-2622 56 6 where where SCONJ dti-2622 56 7 appropriate appropriate ADJ dti-2622 56 8 . . PUNCT dti-2622 57 1 statistical statistical ADJ dti-2622 57 2 analyses analysis NOUN dti-2622 57 3 the the DET dti-2622 57 4 categorical categorical ADJ dti-2622 57 5 data datum NOUN dti-2622 57 6 were be AUX dti-2622 57 7 presented present VERB dti-2622 57 8 with with ADP dti-2622 57 9 numbers number NOUN dti-2622 57 10 and and CCONJ dti-2622 57 11 percentages percentage NOUN dti-2622 57 12 . . PUNCT dti-2622 58 1 the the DET dti-2622 58 2 normal normal ADJ dti-2622 58 3 distributed distribute VERB dti-2622 58 4 continuous continuous ADJ dti-2622 58 5 data datum NOUN dti-2622 58 6 are be AUX dti-2622 58 7 presented present VERB dti-2622 58 8 as as ADP dti-2622 58 9 mean mean ADJ dti-2622 58 10 and and CCONJ dti-2622 58 11 standard standard ADJ dti-2622 58 12 deviation deviation NOUN dti-2622 58 13 ( ( PUNCT dti-2622 58 14 sd sd NOUN dti-2622 58 15 ) ) PUNCT dti-2622 58 16 while while SCONJ dti-2622 58 17 the the DET dti-2622 58 18 non non ADJ dti-2622 58 19 - - ADJ dti-2622 58 20 normal normal ADJ dti-2622 58 21 distributed distribute VERB dti-2622 58 22 data datum NOUN dti-2622 58 23 were be AUX dti-2622 58 24 presented present VERB dti-2622 58 25 with with ADP dti-2622 58 26 median median ADJ dti-2622 58 27 and and CCONJ dti-2622 58 28 interquartile interquartile ADJ dti-2622 58 29 range range NOUN dti-2622 58 30 ( ( PUNCT dti-2622 58 31 iqr iqr NOUN dti-2622 58 32 ) ) PUNCT dti-2622 58 33 . . PUNCT dti-2622 59 1 a a DET dti-2622 59 2 comparison comparison NOUN dti-2622 59 3 of of ADP dti-2622 59 4 category category NOUN dti-2622 59 5 data datum NOUN dti-2622 59 6 used use VERB dti-2622 59 7 the the DET dti-2622 59 8 chi chi ADJ dti-2622 59 9 - - PUNCT dti-2622 59 10 square square NOUN dti-2622 59 11 test test NOUN dti-2622 59 12 and and CCONJ dti-2622 59 13 fisher fisher PROPN dti-2622 59 14 ’s ’s PART dti-2622 59 15 exact exact ADJ dti-2622 59 16 test test NOUN dti-2622 59 17 depending depend VERB dti-2622 59 18 on on ADP dti-2622 59 19 data datum NOUN dti-2622 59 20 . . PUNCT dti-2622 60 1 the the DET dti-2622 60 2 nonparametric nonparametric NOUN dti-2622 60 3 data datum NOUN dti-2622 60 4 used use VERB dti-2622 60 5 the the DET dti-2622 60 6 mann mann PROPN dti-2622 60 7 - - PUNCT dti-2622 60 8 whitney whitney PROPN dti-2622 60 9 u u NOUN dti-2622 60 10 - - NOUN dti-2622 60 11 test test NOUN dti-2622 60 12 for for ADP dti-2622 60 13 comparison comparison NOUN dti-2622 60 14 . . PUNCT dti-2622 61 1 the the DET dti-2622 61 2 factors factor NOUN dti-2622 61 3 associated associate VERB dti-2622 61 4 with with ADP dti-2622 61 5 30 30 NUM dti-2622 61 6 - - PUNCT dti-2622 61 7 day day NOUN dti-2622 61 8 mortality mortality NOUN dti-2622 61 9 were be AUX dti-2622 61 10 evaluated evaluate VERB dti-2622 61 11 by by ADP dti-2622 61 12 univariate univariate ADJ dti-2622 61 13 logistic logistic ADJ dti-2622 61 14 regression regression NOUN dti-2622 61 15 analysis analysis NOUN dti-2622 61 16 . . PUNCT dti-2622 62 1 the the DET dti-2622 62 2 stepwise stepwise PROPN dti-2622 62 3 backward backward ADJ dti-2622 62 4 multiple multiple ADJ dti-2622 62 5 logistic logistic ADJ dti-2622 62 6 regression regression NOUN dti-2622 62 7 analysis analysis NOUN dti-2622 62 8 including include VERB dti-2622 62 9 factors factor NOUN dti-2622 62 10 with with ADP dti-2622 62 11 a a DET dti-2622 62 12 p p NOUN dti-2622 62 13 - - PUNCT dti-2622 62 14 value value NOUN dti-2622 62 15 < < NOUN dti-2622 62 16 0.2 0.2 NUM dti-2622 62 17 on on ADP dti-2622 62 18 univariate univariate ADJ dti-2622 62 19 analysis analysis NOUN dti-2622 62 20 or or CCONJ dti-2622 62 21 factors factor NOUN dti-2622 62 22 with with ADP dti-2622 62 23 previous previous ADJ dti-2622 62 24 reports report NOUN dti-2622 62 25 of of ADP dti-2622 62 26 clinical clinical ADJ dti-2622 62 27 significance significance NOUN dti-2622 62 28 was be AUX dti-2622 62 29 performed perform VERB dti-2622 62 30 . . PUNCT dti-2622 63 1 crude crude ADJ dti-2622 63 2 odds odd NOUN dti-2622 63 3 ratio ratio NOUN dti-2622 63 4 ( ( PUNCT dti-2622 63 5 cor cor NOUN dti-2622 63 6 ) ) PUNCT dti-2622 63 7 and and CCONJ dti-2622 63 8 adjusted adjust VERB dti-2622 63 9 odds odd NOUN dti-2622 63 10 ratio ratio NOUN dti-2622 63 11 ( ( PUNCT dti-2622 63 12 aor aor NOUN dti-2622 63 13 ) ) PUNCT dti-2622 63 14 with with ADP dti-2622 63 15 their their PRON dti-2622 63 16 95 95 NUM dti-2622 63 17 % % NOUN dti-2622 63 18 confidence confidence NOUN dti-2622 63 19 intervals interval NOUN dti-2622 63 20 ( ( PUNCT dti-2622 63 21 95 95 NUM dti-2622 63 22 % % NOUN dti-2622 63 23 ci ci NOUN dti-2622 63 24 ) ) PUNCT dti-2622 63 25 were be AUX dti-2622 63 26 demonstrated demonstrate VERB dti-2622 63 27 . . PUNCT dti-2622 64 1 a a PRON dti-2622 64 2 p p NOUN dti-2622 64 3 - - PUNCT dti-2622 64 4 value value NOUN dti-2622 64 5 < < NOUN dti-2622 64 6 0.05 0.05 NUM dti-2622 64 7 was be AUX dti-2622 64 8 considered consider VERB dti-2622 64 9 statistically statistically ADV dti-2622 64 10 significant significant ADJ dti-2622 64 11 . . PUNCT dti-2622 65 1 the the DET dti-2622 65 2 statistical statistical ADJ dti-2622 65 3 analysis analysis NOUN dti-2622 65 4 was be AUX dti-2622 65 5 performed perform VERB dti-2622 65 6 by by ADP dti-2622 65 7 stata stata NOUN dti-2622 65 8 version version NOUN dti-2622 65 9 10.1 10.1 NUM dti-2622 65 10 ( ( PUNCT dti-2622 65 11 statacorp statacorp PROPN dti-2622 65 12 , , PUNCT dti-2622 65 13 texas texas PROPN dti-2622 65 14 , , PUNCT dti-2622 65 15 usa usa PROPN dti-2622 65 16 ) ) PUNCT dti-2622 65 17 . . PUNCT dti-2622 66 1 results result VERB dti-2622 66 2 a a DET dti-2622 66 3 total total NOUN dti-2622 66 4 of of ADP dti-2622 66 5 194 194 NUM dti-2622 66 6 patients patient NOUN dti-2622 66 7 were be AUX dti-2622 66 8 included include VERB dti-2622 66 9 in in ADP dti-2622 66 10 the the DET dti-2622 66 11 study study NOUN dti-2622 66 12 . . PUNCT dti-2622 67 1 of of ADP dti-2622 67 2 these these PRON dti-2622 67 3 , , PUNCT dti-2622 67 4 110 110 NUM dti-2622 67 5 patients patient NOUN dti-2622 67 6 ( ( PUNCT dti-2622 67 7 56.7 56.7 NUM dti-2622 67 8 % % NOUN dti-2622 67 9 ) ) PUNCT dti-2622 67 10 were be AUX dti-2622 67 11 male male ADJ dti-2622 67 12 . . PUNCT dti-2622 68 1 the the DET dti-2622 68 2 mean mean ADJ dti-2622 68 3 age age NOUN dti-2622 68 4 ( ( PUNCT dti-2622 68 5 sd sd NOUN dti-2622 68 6 ) ) PUNCT dti-2622 68 7 was be AUX dti-2622 68 8 61.6 61.6 NUM dti-2622 68 9 ( ( PUNCT dti-2622 68 10 16.7 16.7 NUM dti-2622 68 11 ) ) PUNCT dti-2622 68 12 years year NOUN dti-2622 68 13 . . PUNCT dti-2622 69 1 the the DET dti-2622 69 2 overall overall ADJ dti-2622 69 3 30 30 NUM dti-2622 69 4 - - PUNCT dti-2622 69 5 day day NOUN dti-2622 69 6 mortality mortality NOUN dti-2622 69 7 occurred occur VERB dti-2622 69 8 in in ADP dti-2622 69 9 75 75 NUM dti-2622 69 10 patients patient NOUN dti-2622 69 11 ( ( PUNCT dti-2622 69 12 38.7 38.7 NUM dti-2622 69 13 % % NOUN dti-2622 69 14 ) ) PUNCT dti-2622 69 15 . . PUNCT dti-2622 70 1 the the DET dti-2622 70 2 most most ADV dti-2622 70 3 common common ADJ dti-2622 70 4 source source NOUN dti-2622 70 5 of of ADP dti-2622 70 6 infection infection NOUN dti-2622 70 7 was be AUX dti-2622 70 8 pneumonia pneumonia NOUN dti-2622 70 9 ( ( PUNCT dti-2622 70 10 90 90 NUM dti-2622 70 11 cases case NOUN dti-2622 70 12 , , PUNCT dti-2622 70 13 46.4 46.4 NUM dti-2622 70 14 % % NOUN dti-2622 70 15 ) ) PUNCT dti-2622 70 16 , , PUNCT dti-2622 70 17 intra intra ADJ dti-2622 70 18 - - ADJ dti-2622 70 19 abdominal abdominal ADJ dti-2622 70 20 infection infection NOUN dti-2622 70 21 ( ( PUNCT dti-2622 70 22 43 43 NUM dti-2622 70 23 cases case NOUN dti-2622 70 24 , , PUNCT dti-2622 70 25 22.2 22.2 NUM dti-2622 70 26 % % NOUN dti-2622 70 27 ) ) PUNCT dti-2622 70 28 , , PUNCT dti-2622 70 29 and and CCONJ dti-2622 70 30 urinary urinary ADJ dti-2622 70 31 tract tract NOUN dti-2622 70 32 infection infection NOUN dti-2622 70 33 ( ( PUNCT dti-2622 70 34 41 41 NUM dti-2622 70 35 cases case NOUN dti-2622 70 36 , , PUNCT dti-2622 70 37 21.1 21.1 NUM dti-2622 70 38 % % NOUN dti-2622 70 39 ) ) PUNCT dti-2622 70 40 . . PUNCT dti-2622 71 1 the the DET dti-2622 71 2 nonsurviving nonsurvive VERB dti-2622 71 3 patients patient NOUN dti-2622 71 4 had have VERB dti-2622 71 5 a a DET dti-2622 71 6 significantly significantly ADV dti-2622 71 7 greater great ADJ dti-2622 71 8 proportion proportion NOUN dti-2622 71 9 of of ADP dti-2622 71 10 lung lung NOUN dti-2622 71 11 disease disease NOUN dti-2622 71 12 , , PUNCT dti-2622 71 13 sepsis sepsis NOUN dti-2622 71 14 at at ADP dti-2622 71 15 time time NOUN dti-2622 71 16 of of ADP dti-2622 71 17 cre cre PROPN dti-2622 71 18 infection infection NOUN dti-2622 71 19 diagnosis diagnosis NOUN dti-2622 71 20 , , PUNCT dti-2622 71 21 and and CCONJ dti-2622 71 22 a a DET dti-2622 71 23 higher high ADJ dti-2622 71 24 sap sap PROPN dti-2622 71 25 ii ii PROPN dti-2622 71 26 score score NOUN dti-2622 71 27 ( ( PUNCT dti-2622 71 28 p p X dti-2622 71 29 < < X dti-2622 71 30 0.05 0.05 NUM dti-2622 71 31 ) ) PUNCT dti-2622 71 32 . . PUNCT dti-2622 72 1 the the DET dti-2622 72 2 nonsurviving nonsurvive VERB dti-2622 72 3 patients patient NOUN dti-2622 72 4 had have VERB dti-2622 72 5 a a DET dti-2622 72 6 significantly significantly ADV dti-2622 72 7 lower low ADJ dti-2622 72 8 proportion proportion NOUN dti-2622 72 9 of of ADP dti-2622 72 10 urinary urinary ADJ dti-2622 72 11 tract tract NOUN dti-2622 72 12 infection infection NOUN dti-2622 72 13 and and CCONJ dti-2622 72 14 intra intra ADJ dti-2622 72 15 - - ADJ dti-2622 72 16 abdominal abdominal ADJ dti-2622 72 17 infection infection NOUN dti-2622 72 18 ( ( PUNCT dti-2622 72 19 p p X dti-2622 72 20 < < X dti-2622 72 21 0.05 0.05 NUM dti-2622 72 22 ) ) PUNCT dti-2622 72 23 . . PUNCT dti-2622 73 1 the the DET dti-2622 73 2 demographic demographic ADJ dti-2622 73 3 data datum NOUN dti-2622 73 4 of of ADP dti-2622 73 5 patients patient NOUN dti-2622 73 6 are be AUX dti-2622 73 7 shown show VERB dti-2622 73 8 in in ADP dti-2622 73 9 table table NOUN dti-2622 73 10 i. i. PROPN dti-2622 73 11 table table PROPN dti-2622 73 12 ii ii PROPN dti-2622 73 13 shows show VERB dti-2622 73 14 the the DET dti-2622 73 15 cre cre PROPN dti-2622 73 16 pathogens pathogen NOUN dti-2622 73 17 and and CCONJ dti-2622 73 18 in in ADP dti-2622 73 19 vitro vitro X dti-2622 73 20 susceptibility susceptibility NOUN dti-2622 73 21 . . PUNCT dti-2622 74 1 the the DET dti-2622 74 2 most most ADV dti-2622 74 3 common common ADJ dti-2622 74 4 pathogens pathogen NOUN dti-2622 74 5 were be AUX dti-2622 74 6 klebsiella klebsiella NOUN dti-2622 74 7 pneumoniae pneumoniae ADJ dti-2622 74 8 mortality mortality NOUN dti-2622 74 9 and and CCONJ dti-2622 74 10 factors factor NOUN dti-2622 74 11 associated associate VERB dti-2622 74 12 with with ADP dti-2622 74 13 mortality mortality NOUN dti-2622 74 14 of of ADP dti-2622 74 15 cre cre PROPN dti-2622 74 16 infection122 infection122 PROPN dti-2622 75 1 © © PROPN dti-2622 75 2 2023 2023 NUM dti-2622 75 3 the the DET dti-2622 75 4 authors author NOUN dti-2622 75 5 . . PUNCT dti-2622 76 1 drug drug NOUN dti-2622 76 2 target target NOUN dti-2622 76 3 insights insight NOUN dti-2622 76 4 issn issn VERB dti-2622 76 5 1177 1177 NUM dti-2622 76 6 - - SYM dti-2622 76 7 3928 3928 NUM dti-2622 76 8 www.aboutscience.eu/dti www.aboutscience.eu/dti NOUN dti-2622 76 9 ( ( PUNCT dti-2622 76 10 153 153 NUM dti-2622 76 11 patients patient NOUN dti-2622 76 12 , , PUNCT dti-2622 76 13 78.9 78.9 NUM dti-2622 76 14 % % NOUN dti-2622 76 15 ) ) PUNCT dti-2622 76 16 , , PUNCT dti-2622 76 17 escherichia escherichia NOUN dti-2622 76 18 coli coli NOUN dti-2622 76 19 ( ( PUNCT dti-2622 76 20 25 25 NUM dti-2622 76 21 patients patient NOUN dti-2622 76 22 , , PUNCT dti-2622 76 23 12.9 12.9 NUM dti-2622 76 24 % % NOUN dti-2622 76 25 ) ) PUNCT dti-2622 76 26 , , PUNCT dti-2622 76 27 and and CCONJ dti-2622 76 28 enterobacter enterobacter ADJ dti-2622 76 29 spp spp NOUN dti-2622 76 30 . . PUNCT dti-2622 77 1 ( ( PUNCT dti-2622 77 2 12 12 NUM dti-2622 77 3 patients patient NOUN dti-2622 77 4 , , PUNCT dti-2622 77 5 6.2 6.2 NUM dti-2622 77 6 % % NOUN dti-2622 77 7 ) ) PUNCT dti-2622 77 8 . . PUNCT dti-2622 78 1 the the DET dti-2622 78 2 cre cre PROPN dti-2622 78 3 isolates isolate NOUN dti-2622 78 4 were be AUX dti-2622 78 5 susceptible susceptible ADJ dti-2622 78 6 to to ADP dti-2622 78 7 24.7 24.7 NUM dti-2622 78 8 % % NOUN dti-2622 78 9 of of ADP dti-2622 78 10 meropenem meropenem PROPN dti-2622 78 11 , , PUNCT dti-2622 78 12 20.1 20.1 NUM dti-2622 78 13 % % NOUN dti-2622 78 14 of of ADP dti-2622 78 15 imipenem imipenem PROPN dti-2622 78 16 , , PUNCT dti-2622 78 17 89.2 89.2 NUM dti-2622 78 18 % % NOUN dti-2622 78 19 of of ADP dti-2622 78 20 amikacin amikacin PROPN dti-2622 78 21 , , PUNCT dti-2622 78 22 91.8 91.8 NUM dti-2622 78 23 % % NOUN dti-2622 78 24 of of ADP dti-2622 78 25 colistin colistin NOUN dti-2622 78 26 , , PUNCT dti-2622 78 27 89.2 89.2 NUM dti-2622 78 28 % % NOUN dti-2622 78 29 of of ADP dti-2622 78 30 fosfomycin fosfomycin PROPN dti-2622 78 31 , , PUNCT dti-2622 78 32 and and CCONJ dti-2622 78 33 93.8 93.8 NUM dti-2622 78 34 % % NOUN dti-2622 78 35 of of ADP dti-2622 78 36 tigecycline tigecycline NOUN dti-2622 78 37 . . PUNCT dti-2622 79 1 table table NOUN dti-2622 79 2 iii iii PROPN dti-2622 79 3 shows show VERB dti-2622 79 4 treatment treatment NOUN dti-2622 79 5 regimen regiman NOUN dti-2622 79 6 of of ADP dti-2622 79 7 cre cre PROPN dti-2622 79 8 infection infection NOUN dti-2622 79 9 . . PUNCT dti-2622 80 1 one one NUM dti-2622 80 2 hundred hundred NUM dti-2622 80 3 and and CCONJ dti-2622 80 4 eighteen eighteen NUM dti-2622 80 5 patients patient NOUN dti-2622 80 6 ( ( PUNCT dti-2622 80 7 60.8 60.8 NUM dti-2622 80 8 % % NOUN dti-2622 80 9 ) ) PUNCT dti-2622 80 10 were be AUX dti-2622 80 11 treated treat VERB dti-2622 80 12 with with ADP dti-2622 80 13 monotherapy monotherapy NOUN dti-2622 80 14 and and CCONJ dti-2622 80 15 76 76 NUM dti-2622 80 16 patients patient NOUN dti-2622 80 17 ( ( PUNCT dti-2622 80 18 39.2 39.2 NUM dti-2622 80 19 % % NOUN dti-2622 80 20 ) ) PUNCT dti-2622 80 21 were be AUX dti-2622 80 22 treated treat VERB dti-2622 80 23 with with ADP dti-2622 80 24 combination combination NOUN dti-2622 80 25 therapy therapy NOUN dti-2622 80 26 . . PUNCT dti-2622 81 1 the the DET dti-2622 81 2 surviving survive VERB dti-2622 81 3 patients patient NOUN dti-2622 81 4 had have VERB dti-2622 81 5 a a DET dti-2622 81 6 significantly significantly ADV dti-2622 81 7 greater great ADJ dti-2622 81 8 proportion proportion NOUN dti-2622 81 9 that that PRON dti-2622 81 10 was be AUX dti-2622 81 11 treated treat VERB dti-2622 81 12 with with ADP dti-2622 81 13 combination combination NOUN dti-2622 81 14 antibiotics antibiotic NOUN dti-2622 81 15 than than ADP dti-2622 81 16 nonsurviving nonsurvive VERB dti-2622 81 17 patients patient NOUN dti-2622 81 18 ( ( PUNCT dti-2622 81 19 p p X dti-2622 81 20 = = NOUN dti-2622 81 21 0.001 0.001 NUM dti-2622 81 22 ) ) PUNCT dti-2622 81 23 . . PUNCT dti-2622 82 1 an an DET dti-2622 82 2 improper improper ADJ dti-2622 82 3 empiric empiric ADJ dti-2622 82 4 antibiotic antibiotic NOUN dti-2622 82 5 was be AUX dti-2622 82 6 used use VERB dti-2622 82 7 in in ADP dti-2622 82 8 107 107 NUM dti-2622 82 9 patients patient NOUN dti-2622 82 10 ( ( PUNCT dti-2622 82 11 55.2 55.2 NUM dti-2622 82 12 % % NOUN dti-2622 82 13 ) ) PUNCT dti-2622 82 14 , , PUNCT dti-2622 82 15 60 60 NUM dti-2622 82 16 patients patient NOUN dti-2622 82 17 ( ( PUNCT dti-2622 82 18 50.4 50.4 NUM dti-2622 82 19 % % NOUN dti-2622 82 20 ) ) PUNCT dti-2622 82 21 in in ADP dti-2622 82 22 the the DET dti-2622 82 23 surviving survive VERB dti-2622 82 24 group group NOUN dti-2622 82 25 and and CCONJ dti-2622 82 26 47 47 NUM dti-2622 82 27 patients patient NOUN dti-2622 82 28 ( ( PUNCT dti-2622 82 29 62.7 62.7 NUM dti-2622 82 30 % % NOUN dti-2622 82 31 ) ) PUNCT dti-2622 82 32 in in ADP dti-2622 82 33 the the DET dti-2622 82 34 nonsurviving nonsurvive VERB dti-2622 82 35 group group NOUN dti-2622 82 36 ( ( PUNCT dti-2622 82 37 p p NOUN dti-2622 82 38 = = NOUN dti-2622 82 39 0.09 0.09 NUM dti-2622 82 40 ) ) PUNCT dti-2622 82 41 . . PUNCT dti-2622 83 1 table table NOUN dti-2622 83 2 iv iv NUM dti-2622 83 3 shows show VERB dti-2622 83 4 the the DET dti-2622 83 5 factors factor NOUN dti-2622 83 6 associated associate VERB dti-2622 83 7 with with ADP dti-2622 83 8 30 30 NUM dti-2622 83 9 - - PUNCT dti-2622 83 10 day day NOUN dti-2622 83 11 mortality mortality NOUN dti-2622 83 12 that that PRON dti-2622 83 13 were be AUX dti-2622 83 14 analyzed analyze VERB dti-2622 83 15 by by ADP dti-2622 83 16 univariate univariate ADJ dti-2622 83 17 and and CCONJ dti-2622 83 18 multivariate multivariate VERB dti-2622 83 19 analysis analysis NOUN dti-2622 83 20 . . PUNCT dti-2622 84 1 with with ADP dti-2622 84 2 univariate univariate ADJ dti-2622 84 3 analysis analysis NOUN dti-2622 84 4 , , PUNCT dti-2622 84 5 sepsis sepsis NOUN dti-2622 84 6 at at ADP dti-2622 84 7 time time NOUN dti-2622 84 8 of of ADP dti-2622 84 9 cre cre PROPN dti-2622 84 10 infection infection NOUN dti-2622 84 11 diagnosis diagnosis NOUN dti-2622 84 12 ( ( PUNCT dti-2622 84 13 cor cor NOUN dti-2622 84 14 24.51 24.51 NUM dti-2622 84 15 ; ; PUNCT dti-2622 84 16 95 95 NUM dti-2622 84 17 % % NOUN dti-2622 84 18 ci ci NOUN dti-2622 84 19 9.78 9.78 NUM dti-2622 84 20 - - SYM dti-2622 84 21 61.44 61.44 NUM dti-2622 84 22 ; ; PUNCT dti-2622 84 23 p p X dti-2622 84 24 < < X dti-2622 84 25 0.001 0.001 NUM dti-2622 84 26 ) ) PUNCT dti-2622 84 27 , , PUNCT dti-2622 84 28 increasing increase VERB dti-2622 84 29 sap sap PROPN dti-2622 84 30 ii ii PROPN dti-2622 84 31 score score NOUN dti-2622 84 32 ( ( PUNCT dti-2622 84 33 cor cor NOUN dti-2622 84 34 1.13 1.13 NUM dti-2622 84 35 ; ; PUNCT dti-2622 84 36 95 95 NUM dti-2622 84 37 % % NOUN dti-2622 84 38 ci ci NOUN dti-2622 84 39 1.09 1.09 NUM dti-2622 84 40 - - SYM dti-2622 84 41 1.17 1.17 NUM dti-2622 84 42 ; ; PUNCT dti-2622 84 43 p p X dti-2622 84 44 < < X dti-2622 84 45 0.001 0.001 NUM dti-2622 84 46 ) ) PUNCT dti-2622 84 47 , , PUNCT dti-2622 84 48 pneumonia pneumonia NOUN dti-2622 84 49 ( ( PUNCT dti-2622 84 50 cor cor PROPN dti-2622 84 51 9.28 9.28 NUM dti-2622 84 52 ; ; PUNCT dti-2622 84 53 95 95 NUM dti-2622 84 54 % % NOUN dti-2622 84 55 ci ci NOUN dti-2622 84 56 4.72 4.72 NUM dti-2622 84 57 - - SYM dti-2622 84 58 18.22 18.22 NUM dti-2622 84 59 ; ; PUNCT dti-2622 84 60 p p X dti-2622 84 61 < < X dti-2622 84 62 0.001 0.001 NUM dti-2622 84 63 ) ) PUNCT dti-2622 84 64 , , PUNCT dti-2622 84 65 and and CCONJ dti-2622 84 66 monotherapy monotherapy NOUN dti-2622 84 67 ( ( PUNCT dti-2622 84 68 cor cor NOUN dti-2622 84 69 3.01 3.01 NUM dti-2622 84 70 ; ; PUNCT dti-2622 84 71 95 95 NUM dti-2622 84 72 % % NOUN dti-2622 84 73 ci ci NOUN dti-2622 84 74 1.59 1.59 NUM dti-2622 84 75 - - SYM dti-2622 84 76 5.71 5.71 NUM dti-2622 84 77 ; ; PUNCT dti-2622 84 78 p p PROPN dti-2622 84 79 = = NOUN dti-2622 84 80 0.001 0.001 NUM dti-2622 84 81 ) ) PUNCT dti-2622 84 82 were be AUX dti-2622 84 83 significantly significantly ADV dti-2622 84 84 associated associate VERB dti-2622 84 85 with with ADP dti-2622 84 86 30 30 NUM dti-2622 84 87 - - PUNCT dti-2622 84 88 day day NOUN dti-2622 84 89 mortality mortality NOUN dti-2622 84 90 . . PUNCT dti-2622 85 1 with with ADP dti-2622 85 2 backward backward ADJ dti-2622 85 3 stepwise stepwise PROPN dti-2622 85 4 logistic logistic ADJ dti-2622 85 5 regression regression NOUN dti-2622 85 6 analysis analysis NOUN dti-2622 85 7 , , PUNCT dti-2622 85 8 sepsis sepsis NOUN dti-2622 85 9 at at ADP dti-2622 85 10 time time NOUN dti-2622 85 11 of of ADP dti-2622 85 12 cre cre PROPN dti-2622 85 13 infection infection NOUN dti-2622 85 14 diagnosis diagnosis NOUN dti-2622 85 15 ( ( PUNCT dti-2622 85 16 aor aor NOUN dti-2622 85 17 7.93 7.93 NUM dti-2622 85 18 ; ; PUNCT dti-2622 85 19 95 95 NUM dti-2622 85 20 % % NOUN dti-2622 85 21 ci ci NOUN dti-2622 85 22 2.21 2.21 NUM dti-2622 85 23 - - SYM dti-2622 85 24 28.51 28.51 NUM dti-2622 85 25 ; ; PUNCT dti-2622 85 26 p p X dti-2622 85 27 = = NOUN dti-2622 85 28 0.002 0.002 NUM dti-2622 85 29 ) ) PUNCT dti-2622 85 30 , , PUNCT dti-2622 85 31 increasing increase VERB dti-2622 85 32 sap sap PROPN dti-2622 85 33 ii ii PROPN dti-2622 85 34 score score NOUN dti-2622 85 35 ( ( PUNCT dti-2622 85 36 aor aor NOUN dti-2622 85 37 1.11 1.11 NUM dti-2622 85 38 ; ; PUNCT dti-2622 85 39 95 95 NUM dti-2622 85 40 % % NOUN dti-2622 85 41 ci ci NOUN dti-2622 85 42 1.05 1.05 NUM dti-2622 85 43 - - SYM dti-2622 85 44 1.16 1.16 NUM dti-2622 85 45 ; ; PUNCT dti-2622 85 46 p p X dti-2622 85 47 < < X dti-2622 85 48 0.001 0.001 NUM dti-2622 85 49 ) ) PUNCT dti-2622 85 50 , , PUNCT dti-2622 85 51 pneumonia pneumonia NOUN dti-2622 85 52 ( ( PUNCT dti-2622 85 53 aor aor PROPN dti-2622 85 54 4.48 4.48 NUM dti-2622 85 55 ; ; PUNCT dti-2622 85 56 95 95 NUM dti-2622 85 57 % % NOUN dti-2622 85 58 ci ci NOUN dti-2622 85 59 1.61 1.61 NUM dti-2622 85 60 - - SYM dti-2622 85 61 12.44 12.44 NUM dti-2622 85 62 ; ; PUNCT dti-2622 85 63 p p X dti-2622 85 64 = = NOUN dti-2622 85 65 0.004 0.004 NUM dti-2622 85 66 ) ) PUNCT dti-2622 85 67 , , PUNCT dti-2622 85 68 monotherapy monotherapy NOUN dti-2622 85 69 ( ( PUNCT dti-2622 85 70 aor aor PROPN dti-2622 85 71 4.69 4.69 NUM dti-2622 85 72 ; ; PUNCT dti-2622 85 73 95 95 NUM dti-2622 85 74 % % NOUN dti-2622 85 75 ci ci NOUN dti-2622 85 76 1.71 1.71 NUM dti-2622 85 77 - - SYM dti-2622 85 78 12.85 12.85 NUM dti-2622 85 79 ; ; PUNCT dti-2622 85 80 p p X dti-2622 85 81 = = NOUN dti-2622 85 82 0.003 0.003 NUM dti-2622 85 83 ) ) PUNCT dti-2622 85 84 , , PUNCT dti-2622 85 85 and and CCONJ dti-2622 85 86 improper improper ADJ dti-2622 85 87 empiric empiric ADJ dti-2622 85 88 antibiotic antibiotic NOUN dti-2622 85 89 ( ( PUNCT dti-2622 85 90 aor aor PROPN dti-2622 85 91 5.13 5.13 NUM dti-2622 85 92 ; ; PUNCT dti-2622 85 93 95 95 NUM dti-2622 85 94 % % NOUN dti-2622 85 95 ci ci NOUN dti-2622 85 96 1.83 1.83 NUM dti-2622 85 97 - - SYM dti-2622 85 98 14.40 14.40 NUM dti-2622 85 99 ; ; PUNCT dti-2622 85 100 p p X dti-2622 85 101 = = NOUN dti-2622 85 102 0.002 0.002 NUM dti-2622 85 103 ) ) PUNCT dti-2622 85 104 were be AUX dti-2622 85 105 independent independent ADJ dti-2622 85 106 factors factor NOUN dti-2622 85 107 associated associate VERB dti-2622 85 108 with with ADP dti-2622 85 109 30 30 NUM dti-2622 85 110 - - PUNCT dti-2622 85 111 day day NOUN dti-2622 85 112 mortality mortality NOUN dti-2622 85 113 . . PUNCT dti-2622 86 1 table table NOUN dti-2622 86 2 i i PRON dti-2622 86 3 demographic demographic ADJ dti-2622 86 4 data datum NOUN dti-2622 86 5 of of ADP dti-2622 86 6 patients patient NOUN dti-2622 86 7 parameters parameter NOUN dti-2622 86 8 surviving survive VERB dti-2622 86 9 group group NOUN dti-2622 86 10 n n ADP dti-2622 86 11 = = SYM dti-2622 86 12 119 119 NUM dti-2622 86 13 nonsurviving nonsurviving NOUN dti-2622 86 14 group group NOUN dti-2622 86 15 n n NOUN dti-2622 86 16 = = SYM dti-2622 86 17 75 75 NUM dti-2622 86 18 pvalue pvalue NOUN dti-2622 86 19 mean mean VERB dti-2622 86 20 age age NOUN dti-2622 86 21 in in ADP dti-2622 86 22 years year NOUN dti-2622 86 23 ( ( PUNCT dti-2622 86 24 sd sd NOUN dti-2622 86 25 ) ) PUNCT dti-2622 86 26 61.6 61.6 NUM dti-2622 86 27 ( ( PUNCT dti-2622 86 28 16.0 16.0 NUM dti-2622 86 29 ) ) PUNCT dti-2622 86 30 61.6 61.6 NUM dti-2622 86 31 ( ( PUNCT dti-2622 86 32 17.8 17.8 NUM dti-2622 86 33 ) ) PUNCT dti-2622 86 34 0.98 0.98 NUM dti-2622 86 35 male male NOUN dti-2622 86 36 , , PUNCT dti-2622 86 37 n n CCONJ dti-2622 86 38 ( ( PUNCT dti-2622 86 39 % % INTJ dti-2622 86 40 ) ) PUNCT dti-2622 86 41 62 62 NUM dti-2622 86 42 ( ( PUNCT dti-2622 86 43 52.1 52.1 NUM dti-2622 86 44 ) ) PUNCT dti-2622 86 45 48 48 NUM dti-2622 86 46 ( ( PUNCT dti-2622 86 47 64.0 64.0 NUM dti-2622 86 48 ) ) PUNCT dti-2622 86 49 0.10 0.10 NUM dti-2622 86 50 bmi bmi NOUN dti-2622 86 51 ( ( PUNCT dti-2622 86 52 kg kg NOUN dti-2622 86 53 / / SYM dti-2622 86 54 m2 m2 PROPN dti-2622 86 55 ) ) PUNCT dti-2622 86 56 , , PUNCT dti-2622 86 57 mean mean INTJ dti-2622 86 58 ( ( PUNCT dti-2622 86 59 sd sd NOUN dti-2622 86 60 ) ) PUNCT dti-2622 86 61 21.1 21.1 NUM dti-2622 86 62 ( ( PUNCT dti-2622 86 63 4.0 4.0 NUM dti-2622 86 64 ) ) PUNCT dti-2622 86 65 20.8 20.8 NUM dti-2622 86 66 ( ( PUNCT dti-2622 86 67 3.5 3.5 NUM dti-2622 86 68 ) ) PUNCT dti-2622 86 69 0.57 0.57 NUM dti-2622 86 70 comorbidity comorbidity NOUN dti-2622 86 71 , , PUNCT dti-2622 86 72 n n CCONJ dti-2622 86 73 ( ( PUNCT dti-2622 86 74 % % INTJ dti-2622 86 75 ) ) PUNCT dti-2622 86 76 111 111 NUM dti-2622 86 77 ( ( PUNCT dti-2622 86 78 93.3 93.3 NUM dti-2622 86 79 ) ) PUNCT dti-2622 86 80 72 72 NUM dti-2622 86 81 ( ( PUNCT dti-2622 86 82 96.0 96.0 NUM dti-2622 86 83 ) ) PUNCT dti-2622 86 84 0.43 0.43 NUM dti-2622 86 85     SPACE dti-2622 86 86 diabetes diabetes NOUN dti-2622 86 87 mellitus mellitus NOUN dti-2622 86 88 , , PUNCT dti-2622 86 89 n n PROPN dti-2622 86 90 ( ( PUNCT dti-2622 86 91 % % INTJ dti-2622 86 92 ) ) PUNCT dti-2622 86 93 36 36 NUM dti-2622 86 94 ( ( PUNCT dti-2622 86 95 30.3 30.3 NUM dti-2622 86 96 ) ) PUNCT dti-2622 86 97 21 21 NUM dti-2622 86 98 ( ( PUNCT dti-2622 86 99 28.0 28.0 NUM dti-2622 86 100 ) ) PUNCT dti-2622 86 101 0.74 0.74 NUM dti-2622 86 102     SPACE dti-2622 86 103 hypertension hypertension NOUN dti-2622 86 104 , , PUNCT dti-2622 86 105 n n CCONJ dti-2622 86 106 ( ( PUNCT dti-2622 86 107 % % INTJ dti-2622 86 108 ) ) PUNCT dti-2622 86 109 47 47 NUM dti-2622 86 110 ( ( PUNCT dti-2622 86 111 39.5 39.5 NUM dti-2622 86 112 ) ) PUNCT dti-2622 86 113 30 30 NUM dti-2622 86 114 ( ( PUNCT dti-2622 86 115 40.0 40.0 NUM dti-2622 86 116 ) ) PUNCT dti-2622 86 117 0.94 0.94 NUM dti-2622 86 118     SPACE dti-2622 86 119 dyslipidemia dyslipidemia NOUN dti-2622 86 120 , , PUNCT dti-2622 86 121 n n PROPN dti-2622 86 122 ( ( PUNCT dti-2622 86 123 % % INTJ dti-2622 86 124 ) ) PUNCT dti-2622 86 125 15 15 NUM dti-2622 86 126 ( ( PUNCT dti-2622 86 127 12.6 12.6 NUM dti-2622 86 128 ) ) PUNCT dti-2622 86 129 6 6 NUM dti-2622 86 130 ( ( PUNCT dti-2622 86 131 8.0 8.0 NUM dti-2622 86 132 ) ) PUNCT dti-2622 86 133 0.32 0.32 NUM dti-2622 86 134     SPACE dti-2622 86 135 neurological neurological ADJ dti-2622 86 136 disease disease NOUN dti-2622 86 137 , , PUNCT dti-2622 86 138 n n CCONJ dti-2622 86 139 ( ( PUNCT dti-2622 86 140 % % INTJ dti-2622 86 141 ) ) PUNCT dti-2622 86 142 24 24 NUM dti-2622 86 143 ( ( PUNCT dti-2622 86 144 20.2 20.2 NUM dti-2622 86 145 ) ) PUNCT dti-2622 86 146 11 11 NUM dti-2622 86 147 ( ( PUNCT dti-2622 86 148 14.7 14.7 NUM dti-2622 86 149 ) ) PUNCT dti-2622 86 150 0.33 0.33 NUM dti-2622 86 151     SPACE dti-2622 86 152 cardiovascular cardiovascular ADJ dti-2622 86 153 disease disease NOUN dti-2622 86 154 , , PUNCT dti-2622 86 155 n n CCONJ dti-2622 86 156 ( ( PUNCT dti-2622 86 157 % % INTJ dti-2622 86 158 ) ) PUNCT dti-2622 86 159 18 18 NUM dti-2622 86 160 ( ( PUNCT dti-2622 86 161 15.1 15.1 NUM dti-2622 86 162 ) ) PUNCT dti-2622 86 163 18 18 NUM dti-2622 86 164 ( ( PUNCT dti-2622 86 165 24.0 24.0 NUM dti-2622 86 166 ) ) PUNCT dti-2622 86 167 0.12 0.12 NUM dti-2622 86 168     SPACE dti-2622 86 169 lung lung NOUN dti-2622 86 170 disease disease NOUN dti-2622 86 171 , , PUNCT dti-2622 86 172 n n PROPN dti-2622 86 173 ( ( PUNCT dti-2622 86 174 % % INTJ dti-2622 86 175 ) ) PUNCT dti-2622 86 176 3 3 NUM dti-2622 86 177 ( ( PUNCT dti-2622 86 178 2.5 2.5 NUM dti-2622 86 179 ) ) SYM dti-2622 86 180 8 8 NUM dti-2622 86 181 ( ( PUNCT dti-2622 86 182 10.7 10.7 NUM dti-2622 86 183 ) ) PUNCT dti-2622 86 184 0.02 0.02 NUM dti-2622 86 185     SPACE dti-2622 86 186 liver liver NOUN dti-2622 86 187 disease disease NOUN dti-2622 86 188 , , PUNCT dti-2622 86 189 n n CCONJ dti-2622 86 190 ( ( PUNCT dti-2622 86 191 % % INTJ dti-2622 86 192 ) ) PUNCT dti-2622 86 193 11 11 NUM dti-2622 86 194 ( ( PUNCT dti-2622 86 195 9.2 9.2 NUM dti-2622 86 196 ) ) PUNCT dti-2622 86 197 12 12 NUM dti-2622 86 198 ( ( PUNCT dti-2622 86 199 16.0 16.0 NUM dti-2622 86 200 ) ) PUNCT dti-2622 86 201 0.16 0.16 NUM dti-2622 86 202     SPACE dti-2622 86 203 renal renal ADJ dti-2622 86 204 disease disease NOUN dti-2622 86 205 , , PUNCT dti-2622 86 206 n n CCONJ dti-2622 86 207 ( ( PUNCT dti-2622 86 208 % % INTJ dti-2622 86 209 ) ) PUNCT dti-2622 86 210 15 15 NUM dti-2622 86 211 ( ( PUNCT dti-2622 86 212 12.6 12.6 NUM dti-2622 86 213 ) ) PUNCT dti-2622 86 214 16 16 NUM dti-2622 86 215 ( ( PUNCT dti-2622 86 216 21.3 21.3 NUM dti-2622 86 217 ) ) PUNCT dti-2622 86 218 0.11 0.11 NUM dti-2622 86 219         SPACE dti-2622 86 220 malignancy malignancy NOUN dti-2622 86 221 , , PUNCT dti-2622 86 222 n n CCONJ dti-2622 86 223 ( ( PUNCT dti-2622 86 224 % % INTJ dti-2622 86 225 ) ) PUNCT dti-2622 86 226 45 45 NUM dti-2622 86 227 ( ( PUNCT dti-2622 86 228 37.8 37.8 NUM dti-2622 86 229 ) ) SYM dti-2622 86 230 18 18 NUM dti-2622 86 231 ( ( PUNCT dti-2622 86 232 24.0 24.0 NUM dti-2622 86 233 ) ) PUNCT dti-2622 86 234 0.05 0.05 NUM dti-2622 86 235 sepsis sepsis NOUN dti-2622 86 236 * * PUNCT dti-2622 86 237 , , PUNCT dti-2622 86 238 n n PROPN dti-2622 86 239 ( ( PUNCT dti-2622 86 240 % % INTJ dti-2622 86 241 ) ) PUNCT dti-2622 86 242 38 38 NUM dti-2622 86 243 ( ( PUNCT dti-2622 86 244 31.9 31.9 NUM dti-2622 86 245 ) ) SYM dti-2622 86 246 69 69 NUM dti-2622 86 247 ( ( PUNCT dti-2622 86 248 92.0 92.0 NUM dti-2622 86 249 ) ) PUNCT dti-2622 87 1 < < X dti-2622 87 2 0.001 0.001 NUM dti-2622 87 3 sap sap PROPN dti-2622 87 4 ii ii PROPN dti-2622 87 5 score score NOUN dti-2622 87 6 * * PUNCT dti-2622 87 7 , , PUNCT dti-2622 87 8 mean mean INTJ dti-2622 87 9 ( ( PUNCT dti-2622 87 10 sd sd NOUN dti-2622 87 11 ) ) PUNCT dti-2622 87 12 29.5 29.5 NUM dti-2622 87 13 ( ( PUNCT dti-2622 87 14 11.6 11.6 NUM dti-2622 87 15 ) ) PUNCT dti-2622 87 16 47.9 47.9 NUM dti-2622 87 17 ( ( PUNCT dti-2622 87 18 13.4 13.4 NUM dti-2622 87 19 ) ) PUNCT dti-2622 87 20 < < NOUN dti-2622 87 21 0.001 0.001 NUM dti-2622 87 22 source source NOUN dti-2622 87 23 of of ADP dti-2622 87 24 infection infection NOUN dti-2622 87 25     SPACE dti-2622 87 26 pneumonia pneumonia NOUN dti-2622 87 27 , , PUNCT dti-2622 87 28 n n PROPN dti-2622 87 29 ( ( PUNCT dti-2622 87 30 % % INTJ dti-2622 87 31 ) ) PUNCT dti-2622 87 32 32 32 NUM dti-2622 87 33 ( ( PUNCT dti-2622 87 34 26.9 26.9 NUM dti-2622 87 35 ) ) PUNCT dti-2622 87 36 58 58 NUM dti-2622 87 37 ( ( PUNCT dti-2622 87 38 77.3 77.3 NUM dti-2622 87 39 ) ) PUNCT dti-2622 87 40 < < X dti-2622 87 41 0.001 0.001 NUM dti-2622 87 42     SPACE dti-2622 87 43 urinary urinary ADJ dti-2622 87 44 tract tract NOUN dti-2622 87 45 infection infection NOUN dti-2622 87 46 , , PUNCT dti-2622 87 47 n n CCONJ dti-2622 87 48 ( ( PUNCT dti-2622 87 49 % % INTJ dti-2622 87 50 ) ) PUNCT dti-2622 87 51 36 36 NUM dti-2622 87 52 ( ( PUNCT dti-2622 87 53 30.3 30.3 NUM dti-2622 87 54 ) ) PUNCT dti-2622 87 55 5 5 NUM dti-2622 87 56 ( ( PUNCT dti-2622 87 57 6.7 6.7 NUM dti-2622 87 58 ) ) PUNCT dti-2622 87 59 < < X dti-2622 87 60 0.001 0.001 NUM dti-2622 87 61     SPACE dti-2622 87 62 intra intra ADJ dti-2622 87 63 - - ADJ dti-2622 87 64 abdominal abdominal ADJ dti-2622 87 65 infection infection NOUN dti-2622 87 66 , , PUNCT dti-2622 87 67 n n CCONJ dti-2622 87 68 ( ( PUNCT dti-2622 87 69 % % INTJ dti-2622 87 70 ) ) PUNCT dti-2622 87 71 35 35 NUM dti-2622 87 72 ( ( PUNCT dti-2622 87 73 29.4 29.4 NUM dti-2622 87 74 ) ) SYM dti-2622 87 75 8 8 NUM dti-2622 87 76 ( ( PUNCT dti-2622 87 77 10.7 10.7 NUM dti-2622 87 78 ) ) PUNCT dti-2622 87 79 0.002 0.002 NUM dti-2622 87 80     SPACE dti-2622 87 81 ssi ssi PROPN dti-2622 87 82 , , PUNCT dti-2622 87 83 n n PROPN dti-2622 87 84 ( ( PUNCT dti-2622 87 85 % % INTJ dti-2622 87 86 ) ) PUNCT dti-2622 87 87 8 8 NUM dti-2622 87 88 ( ( PUNCT dti-2622 87 89 6.7 6.7 NUM dti-2622 87 90 ) ) PUNCT dti-2622 87 91 3 3 NUM dti-2622 87 92 ( ( PUNCT dti-2622 87 93 4.0 4.0 NUM dti-2622 87 94 ) ) PUNCT dti-2622 87 95 0.43 0.43 NUM dti-2622 87 96 bmi bmi NOUN dti-2622 87 97 = = PUNCT dti-2622 87 98 body body NOUN dti-2622 87 99 mass mass PROPN dti-2622 87 100 index index NOUN dti-2622 87 101 ; ; PUNCT dti-2622 87 102 sap sap PROPN dti-2622 87 103 = = SYM dti-2622 87 104 simplified simplify VERB dti-2622 87 105 acute acute NOUN dti-2622 87 106 physiology physiology NOUN dti-2622 87 107 ; ; PUNCT dti-2622 87 108 sd sd NOUN dti-2622 87 109 = = SYM dti-2622 87 110 standard standard ADJ dti-2622 87 111 deviation deviation NOUN dti-2622 87 112 ; ; PUNCT dti-2622 87 113 ssi ssi PROPN dti-2622 87 114 = = PROPN dti-2622 87 115 skin skin NOUN dti-2622 87 116 and and CCONJ dti-2622 87 117 soft soft ADJ dti-2622 87 118 tissue tissue NOUN dti-2622 87 119 infection infection NOUN dti-2622 87 120 . . PUNCT dti-2622 88 1 * * PUNCT dti-2622 88 2 status status NOUN dti-2622 88 3 at at ADP dti-2622 88 4 time time NOUN dti-2622 88 5 of of ADP dti-2622 88 6 cre cre PROPN dti-2622 88 7 infection infection NOUN dti-2622 88 8 diagnosis diagnosis NOUN dti-2622 88 9 . . PUNCT dti-2622 89 1 table table NOUN dti-2622 89 2 ii ii NOUN dti-2622 89 3 pathogens pathogen NOUN dti-2622 89 4 and and CCONJ dti-2622 89 5 in in ADP dti-2622 89 6 vitro vitro X dti-2622 89 7 sensitivity sensitivity NOUN dti-2622 89 8 parameters parameter NOUN dti-2622 89 9 surviving survive VERB dti-2622 89 10 group group NOUN dti-2622 89 11 ( ( PUNCT dti-2622 89 12 n n NOUN dti-2622 89 13 = = SYM dti-2622 89 14 119 119 NUM dti-2622 89 15 ) ) PUNCT dti-2622 89 16 nonsurviving nonsurvive VERB dti-2622 89 17 group group NOUN dti-2622 89 18 ( ( PUNCT dti-2622 89 19 n n NOUN dti-2622 89 20 = = SYM dti-2622 89 21 75 75 NUM dti-2622 89 22 ) ) PUNCT dti-2622 89 23 pvalue pvalue NOUN dti-2622 89 24 pathogens pathogen NOUN dti-2622 89 25     SPACE dti-2622 89 26 klebsiella klebsiella NOUN dti-2622 89 27 pneumoniae pneumoniae VERB dti-2622 89 28 90 90 NUM dti-2622 89 29 ( ( PUNCT dti-2622 89 30 75.6 75.6 NUM dti-2622 89 31 ) ) PUNCT dti-2622 89 32 63 63 NUM dti-2622 89 33 ( ( PUNCT dti-2622 89 34 84.0 84.0 NUM dti-2622 89 35 ) ) PUNCT dti-2622 89 36 0.16 0.16 NUM dti-2622 89 37     SPACE dti-2622 89 38 escherichia escherichia NOUN dti-2622 89 39 coli coli NOUN dti-2622 89 40 18 18 NUM dti-2622 89 41 ( ( PUNCT dti-2622 89 42 15.1 15.1 NUM dti-2622 89 43 ) ) PUNCT dti-2622 89 44 7 7 NUM dti-2622 89 45 ( ( PUNCT dti-2622 89 46 9.3 9.3 NUM dti-2622 89 47 ) ) PUNCT dti-2622 89 48 0.24 0.24 NUM dti-2622 89 49     SPACE dti-2622 89 50 enterobacter enterobacter NOUN dti-2622 89 51 spp spp NOUN dti-2622 89 52 . . PROPN dti-2622 89 53 8 8 NUM dti-2622 89 54 ( ( PUNCT dti-2622 89 55 6.7 6.7 NUM dti-2622 89 56 ) ) PUNCT dti-2622 89 57 4 4 NUM dti-2622 89 58 ( ( PUNCT dti-2622 89 59 5.3 5.3 NUM dti-2622 89 60 ) ) PUNCT dti-2622 89 61 0.70 0.70 NUM dti-2622 89 62     SPACE dti-2622 89 63 others other NOUN dti-2622 89 64 * * SYM dti-2622 89 65 3 3 NUM dti-2622 89 66 ( ( PUNCT dti-2622 89 67 2.5 2.5 NUM dti-2622 89 68 ) ) SYM dti-2622 89 69 1 1 NUM dti-2622 89 70 ( ( PUNCT dti-2622 89 71 1.3 1.3 NUM dti-2622 89 72 ) ) PUNCT dti-2622 89 73 0.57 0.57 NUM dti-2622 89 74 in in ADP dti-2622 89 75 vitro vitro X dti-2622 89 76 sensitivity sensitivity NOUN dti-2622 89 77 , , PUNCT dti-2622 89 78 n n CCONJ dti-2622 89 79 ( ( PUNCT dti-2622 89 80 % % NOUN dti-2622 89 81 sensitive sensitive ADJ dti-2622 89 82 ) ) PUNCT dti-2622 89 83     SPACE dti-2622 89 84 meropenem meropenem PROPN dti-2622 89 85 32 32 NUM dti-2622 89 86 ( ( PUNCT dti-2622 89 87 26.9 26.9 NUM dti-2622 89 88 ) ) PUNCT dti-2622 89 89 16 16 NUM dti-2622 89 90 ( ( PUNCT dti-2622 89 91 21.3 21.3 NUM dti-2622 89 92 ) ) PUNCT dti-2622 89 93 0.38 0.38 NUM dti-2622 89 94     SPACE dti-2622 89 95 imipenem imipenem PROPN dti-2622 89 96 24 24 NUM dti-2622 89 97 ( ( PUNCT dti-2622 89 98 20.2 20.2 NUM dti-2622 89 99 ) ) PUNCT dti-2622 89 100 15 15 NUM dti-2622 89 101 ( ( PUNCT dti-2622 89 102 20.0 20.0 NUM dti-2622 89 103 ) ) PUNCT dti-2622 89 104 0.98 0.98 NUM dti-2622 89 105     SPACE dti-2622 89 106 amikacin amikacin PROPN dti-2622 89 107 105 105 NUM dti-2622 89 108 ( ( PUNCT dti-2622 89 109 88.2 88.2 NUM dti-2622 89 110 ) ) PUNCT dti-2622 89 111 68 68 NUM dti-2622 89 112 ( ( PUNCT dti-2622 89 113 90.7 90.7 NUM dti-2622 89 114 ) ) PUNCT dti-2622 89 115 0.60 0.60 NUM dti-2622 89 116     SPACE dti-2622 89 117 fosfomycin fosfomycin VERB dti-2622 89 118 110 110 NUM dti-2622 89 119 ( ( PUNCT dti-2622 89 120 92.4 92.4 NUM dti-2622 89 121 ) ) PUNCT dti-2622 89 122 63 63 NUM dti-2622 89 123 ( ( PUNCT dti-2622 89 124 84.0 84.0 NUM dti-2622 89 125 ) ) PUNCT dti-2622 89 126 0.07 0.07 NUM dti-2622 89 127     SPACE dti-2622 89 128 colistin colistin NOUN dti-2622 89 129 111 111 NUM dti-2622 89 130 ( ( PUNCT dti-2622 89 131 93.3 93.3 NUM dti-2622 89 132 ) ) PUNCT dti-2622 89 133 67 67 NUM dti-2622 89 134 ( ( PUNCT dti-2622 89 135 89.3 89.3 NUM dti-2622 89 136 ) ) PUNCT dti-2622 89 137 0.33 0.33 NUM dti-2622 89 138     SPACE dti-2622 89 139 tigecycline tigecycline NOUN dti-2622 89 140 114 114 NUM dti-2622 89 141 ( ( PUNCT dti-2622 89 142 95.8 95.8 NUM dti-2622 89 143 ) ) PUNCT dti-2622 89 144 68 68 NUM dti-2622 89 145 ( ( PUNCT dti-2622 89 146 90.7 90.7 NUM dti-2622 89 147 ) ) PUNCT dti-2622 89 148 0.15 0.15 NUM dti-2622 89 149 data datum NOUN dti-2622 89 150 were be AUX dti-2622 89 151 presented present VERB dti-2622 89 152 as as ADP dti-2622 89 153 n n PROPN dti-2622 89 154 ( ( PUNCT dti-2622 89 155 % % NOUN dti-2622 89 156 ) ) PUNCT dti-2622 89 157 . . PUNCT dti-2622 90 1 * * PUNCT dti-2622 90 2 others other NOUN dti-2622 90 3 : : PUNCT dti-2622 90 4 proteus proteus NOUN dti-2622 90 5 mirabilis mirabilis PROPN dti-2622 90 6 ( ( PUNCT dti-2622 90 7 n n NOUN dti-2622 90 8 = = SYM dti-2622 90 9 1 1 NUM dti-2622 90 10 ) ) PUNCT dti-2622 90 11 , , PUNCT dti-2622 90 12 citrobacter citrobacter PROPN dti-2622 90 13 spp spp NOUN dti-2622 90 14 . . PUNCT dti-2622 91 1 ( ( PUNCT dti-2622 91 2 n n NOUN dti-2622 91 3 = = SYM dti-2622 91 4 2 2 NUM dti-2622 91 5 ) ) PUNCT dti-2622 91 6 in in ADP dti-2622 91 7 surviving survive VERB dti-2622 91 8 group group NOUN dti-2622 91 9 , , PUNCT dti-2622 91 10 p. p. NOUN dti-2622 91 11 mirabilis mirabilis PROPN dti-2622 91 12 ( ( PUNCT dti-2622 91 13 n n NOUN dti-2622 91 14 = = SYM dti-2622 91 15 1 1 NUM dti-2622 91 16 ) ) PUNCT dti-2622 91 17 in in ADP dti-2622 91 18 the the DET dti-2622 91 19 nonsurviving nonsurvive VERB dti-2622 91 20 group group NOUN dti-2622 91 21 . . PUNCT dti-2622 92 1 table table NOUN dti-2622 92 2 iii iii NUM dti-2622 92 3 treatment treatment NOUN dti-2622 92 4 regimen regiman NOUN dti-2622 92 5 of of ADP dti-2622 92 6 cre cre PROPN dti-2622 92 7 infection infection NOUN dti-2622 92 8 regimen regiman NOUN dti-2622 92 9 surviving survive VERB dti-2622 92 10 group group NOUN dti-2622 92 11 ( ( PUNCT dti-2622 92 12 n n NOUN dti-2622 92 13 = = SYM dti-2622 92 14 119 119 NUM dti-2622 92 15 ) ) PUNCT dti-2622 92 16 nonsurviving nonsurvive VERB dti-2622 92 17 group group NOUN dti-2622 92 18 ( ( PUNCT dti-2622 92 19 n n NOUN dti-2622 92 20 = = SYM dti-2622 92 21 75 75 NUM dti-2622 92 22 ) ) PUNCT dti-2622 92 23 pvalue pvalue NOUN dti-2622 92 24 monotherapy monotherapy NOUN dti-2622 92 25 61 61 NUM dti-2622 92 26 ( ( PUNCT dti-2622 92 27 51.3 51.3 NUM dti-2622 92 28 ) ) PUNCT dti-2622 92 29 57 57 NUM dti-2622 92 30 ( ( PUNCT dti-2622 92 31 76.0 76.0 NUM dti-2622 92 32 ) ) PUNCT dti-2622 92 33 0.001 0.001 NUM dti-2622 92 34     SPACE dti-2622 92 35 meropenem/ meropenem/ NUM dti-2622 92 36 imipenem imipenem PROPN dti-2622 92 37 - - PUNCT dti-2622 92 38 cilastatin cilastatin NOUN dti-2622 92 39 22 22 NUM dti-2622 92 40 ( ( PUNCT dti-2622 92 41 18.5 18.5 NUM dti-2622 92 42 ) ) PUNCT dti-2622 92 43 13 13 NUM dti-2622 92 44 ( ( PUNCT dti-2622 92 45 17.3 17.3 NUM dti-2622 92 46 ) ) PUNCT dti-2622 92 47 0.84 0.84 NUM dti-2622 92 48     SPACE dti-2622 92 49 colistin colistin VERB dti-2622 92 50 19 19 NUM dti-2622 92 51 ( ( PUNCT dti-2622 92 52 16.0 16.0 NUM dti-2622 92 53 ) ) PUNCT dti-2622 92 54 40 40 NUM dti-2622 92 55 ( ( PUNCT dti-2622 92 56 53.3 53.3 NUM dti-2622 92 57 ) ) PUNCT dti-2622 92 58 < < X dti-2622 92 59 0.001 0.001 NUM dti-2622 92 60     SPACE dti-2622 92 61 fosfomycin fosfomycin PROPN dti-2622 92 62 3 3 NUM dti-2622 92 63 ( ( PUNCT dti-2622 92 64 2.5 2.5 NUM dti-2622 92 65 ) ) PUNCT dti-2622 92 66 3 3 NUM dti-2622 92 67 ( ( PUNCT dti-2622 92 68 4.0 4.0 NUM dti-2622 92 69 ) ) PUNCT dti-2622 92 70 0.68 0.68 NUM dti-2622 92 71     SPACE dti-2622 92 72 amikacin amikacin PROPN dti-2622 92 73 15 15 NUM dti-2622 92 74 ( ( PUNCT dti-2622 92 75 12.6 12.6 NUM dti-2622 92 76 ) ) PUNCT dti-2622 92 77 1 1 NUM dti-2622 92 78 ( ( PUNCT dti-2622 92 79 1.3 1.3 NUM dti-2622 92 80 ) ) PUNCT dti-2622 92 81 0.005 0.005 NUM dti-2622 92 82     SPACE dti-2622 92 83 tigecycline tigecycline NOUN dti-2622 92 84 0 0 PUNCT dti-2622 92 85 ( ( PUNCT dti-2622 92 86 0.0 0.0 NUM dti-2622 92 87 ) ) PUNCT dti-2622 92 88 2 2 NUM dti-2622 92 89 ( ( PUNCT dti-2622 92 90 2.7 2.7 NUM dti-2622 92 91 ) ) PUNCT dti-2622 92 92 0.15 0.15 NUM dti-2622 92 93 combination combination NOUN dti-2622 92 94 therapy therapy NOUN dti-2622 92 95 58 58 NUM dti-2622 92 96 ( ( PUNCT dti-2622 92 97 48.7 48.7 NUM dti-2622 92 98 ) ) SYM dti-2622 92 99 18 18 NUM dti-2622 92 100 ( ( PUNCT dti-2622 92 101 24.0 24.0 NUM dti-2622 92 102 ) ) PUNCT dti-2622 92 103 0.001 0.001 NUM dti-2622 92 104     SPACE dti-2622 92 105 fosfomycin fosfomycin PROPN dti-2622 92 106 / / SYM dti-2622 92 107 colistin colistin NOUN dti-2622 92 108 29 29 NUM dti-2622 92 109 ( ( PUNCT dti-2622 92 110 24.4 24.4 NUM dti-2622 92 111 ) ) PUNCT dti-2622 92 112 7 7 NUM dti-2622 92 113 ( ( PUNCT dti-2622 92 114 9.3 9.3 NUM dti-2622 92 115 ) ) PUNCT dti-2622 92 116 0.009 0.009 NUM dti-2622 92 117     SPACE dti-2622 92 118 fosfomycin fosfomycin PROPN dti-2622 92 119 / / SYM dti-2622 92 120 amikacin amikacin PROPN dti-2622 92 121 7 7 NUM dti-2622 92 122 ( ( PUNCT dti-2622 92 123 5.9 5.9 NUM dti-2622 92 124 ) ) PUNCT dti-2622 92 125 1 1 NUM dti-2622 92 126 ( ( PUNCT dti-2622 92 127 1.3 1.3 NUM dti-2622 92 128 ) ) PUNCT dti-2622 92 129 0.16 0.16 NUM dti-2622 92 130     SPACE dti-2622 92 131 meropenem meropenem PROPN dti-2622 92 132 / / SYM dti-2622 92 133 colistin colistin NOUN dti-2622 92 134 14 14 NUM dti-2622 92 135 ( ( PUNCT dti-2622 92 136 11.8 11.8 NUM dti-2622 92 137 ) ) PUNCT dti-2622 92 138 3 3 NUM dti-2622 92 139 ( ( PUNCT dti-2622 92 140 4.0 4.0 NUM dti-2622 92 141 ) ) PUNCT dti-2622 92 142 0.06 0.06 NUM dti-2622 92 143     SPACE dti-2622 92 144 fosfomycin fosfomycin PROPN dti-2622 92 145 / / SYM dti-2622 92 146 tigecycline tigecycline NOUN dti-2622 92 147 1 1 NUM dti-2622 92 148 ( ( PUNCT dti-2622 92 149 0.8 0.8 NUM dti-2622 92 150 ) ) PUNCT dti-2622 92 151 1 1 NUM dti-2622 92 152 ( ( PUNCT dti-2622 92 153 1.3 1.3 NUM dti-2622 92 154 ) ) PUNCT dti-2622 92 155 1.00 1.00 NUM dti-2622 92 156     SPACE dti-2622 92 157 fosfomycin fosfomycin PROPN dti-2622 92 158 / / SYM dti-2622 92 159 meropenem meropenem PROPN dti-2622 92 160 4 4 NUM dti-2622 92 161 ( ( PUNCT dti-2622 92 162 3.4 3.4 NUM dti-2622 92 163 ) ) PUNCT dti-2622 92 164 0 0 NUM dti-2622 93 1 ( ( PUNCT dti-2622 93 2 0.0 0.0 NUM dti-2622 93 3 ) ) PUNCT dti-2622 93 4 0.16 0.16 NUM dti-2622 93 5     SPACE dti-2622 93 6 fosfomycin fosfomycin PROPN dti-2622 93 7 / / SYM dti-2622 93 8 others other NOUN dti-2622 93 9 * * SYM dti-2622 93 10 2 2 NUM dti-2622 93 11 ( ( PUNCT dti-2622 93 12 1.7 1.7 NUM dti-2622 93 13 ) ) PUNCT dti-2622 93 14 0 0 NUM dti-2622 93 15 ( ( PUNCT dti-2622 93 16 0.0 0.0 NUM dti-2622 93 17 ) ) PUNCT dti-2622 93 18 0.52 0.52 NUM dti-2622 93 19     SPACE dti-2622 93 20 tigecycline tigecycline ADV dti-2622 93 21 / / SYM dti-2622 93 22 colistin colistin NOUN dti-2622 93 23 0 0 NUM dti-2622 94 1 ( ( PUNCT dti-2622 94 2 0.0 0.0 NUM dti-2622 94 3 ) ) PUNCT dti-2622 94 4 2 2 NUM dti-2622 94 5 ( ( PUNCT dti-2622 94 6 2.7 2.7 NUM dti-2622 94 7 ) ) PUNCT dti-2622 94 8 0.15 0.15 NUM dti-2622 94 9     SPACE dti-2622 94 10 tigecycline tigecycline ADJ dti-2622 94 11 / / SYM dti-2622 94 12 meropenem meropenem PROPN dti-2622 94 13 0 0 PUNCT dti-2622 94 14 ( ( PUNCT dti-2622 94 15 0.0 0.0 NUM dti-2622 94 16 ) ) PUNCT dti-2622 94 17 2 2 NUM dti-2622 94 18 ( ( PUNCT dti-2622 94 19 2.7 2.7 NUM dti-2622 94 20 ) ) PUNCT dti-2622 94 21 0.15 0.15 NUM dti-2622 94 22 data datum NOUN dti-2622 94 23 were be AUX dti-2622 94 24 presented present VERB dti-2622 94 25 as as ADP dti-2622 94 26 n n PROPN dti-2622 94 27 ( ( PUNCT dti-2622 94 28 % % INTJ dti-2622 94 29 ) ) PUNCT dti-2622 94 30 cre cre PROPN dti-2622 94 31 = = SYM dti-2622 94 32 carbapenem carbapenem PROPN dti-2622 94 33 - - PUNCT dti-2622 94 34 resistant resistant ADJ dti-2622 94 35 enterobacteriaceae enterobacteriaceae NOUN dti-2622 94 36 ; ; PUNCT dti-2622 94 37 fosfomycin fosfomycin PROPN dti-2622 94 38 / / SYM dti-2622 94 39 others other NOUN dti-2622 94 40 = = PUNCT dti-2622 94 41 fosfomycin fosfomycin PROPN dti-2622 94 42 / / SYM dti-2622 94 43 sitafloxacin sitafloxacin PROPN dti-2622 94 44 ( ( PUNCT dti-2622 94 45 n n NOUN dti-2622 94 46 = = SYM dti-2622 94 47 1 1 NUM dti-2622 94 48 ) ) PUNCT dti-2622 94 49 , , PUNCT dti-2622 94 50 fosfomycin fosfomycin PROPN dti-2622 94 51 / / SYM dti-2622 94 52 cotrimoxazole cotrimoxazole NOUN dti-2622 94 53 ( ( PUNCT dti-2622 94 54 n n NOUN dti-2622 94 55 = = SYM dti-2622 94 56 1 1 NUM dti-2622 94 57 ) ) PUNCT dti-2622 94 58 in in ADP dti-2622 94 59 the the DET dti-2622 94 60 surviving surviving NOUN dti-2622 94 61 group group NOUN dti-2622 94 62 . . PUNCT dti-2622 95 1 so so ADV dti-2622 95 2 - - PUNCT dti-2622 95 3 ngern ngern ADJ dti-2622 95 4 et et PROPN dti-2622 95 5 al al PROPN dti-2622 95 6 drug drug PROPN dti-2622 95 7 target target NOUN dti-2622 95 8 insights insight NOUN dti-2622 95 9 2023 2023 NUM dti-2622 95 10 ; ; PUNCT dti-2622 95 11 17 17 NUM dti-2622 95 12 : : SYM dti-2622 95 13 123 123 NUM dti-2622 95 14 © © PROPN dti-2622 95 15 2023 2023 NUM dti-2622 95 16 the the DET dti-2622 95 17 authors author NOUN dti-2622 95 18 . . PUNCT dti-2622 96 1 published publish VERB dti-2622 96 2 by by ADP dti-2622 96 3 aboutscience aboutscience NOUN dti-2622 96 4 www.aboutscience.eu www.aboutscience.eu NOUN dti-2622 96 5 discussion discussion NOUN dti-2622 96 6 cre cre PROPN dti-2622 96 7 infection infection NOUN dti-2622 96 8 has have AUX dti-2622 96 9 been be AUX dti-2622 96 10 an an DET dti-2622 96 11 important important ADJ dti-2622 96 12 health health NOUN dti-2622 96 13 problem problem NOUN dti-2622 96 14 in in ADP dti-2622 96 15 recent recent ADJ dti-2622 96 16 decades decade NOUN dti-2622 96 17 ( ( PUNCT dti-2622 96 18 19 19 NUM dti-2622 96 19 ) ) PUNCT dti-2622 96 20 . . PUNCT dti-2622 97 1 this this DET dti-2622 97 2 study study NOUN dti-2622 97 3 revealed reveal VERB dti-2622 97 4 that that SCONJ dti-2622 97 5 the the DET dti-2622 97 6 most most ADV dti-2622 97 7 common common ADJ dti-2622 97 8 cre cre PROPN dti-2622 97 9 pathogens pathogen NOUN dti-2622 97 10 were be AUX dti-2622 97 11 k. k. NOUN dti-2622 97 12 pneumoniae pneumoniae ADJ dti-2622 97 13 ( ( PUNCT dti-2622 97 14 78.9 78.9 NUM dti-2622 97 15 % % NOUN dti-2622 97 16 ) ) PUNCT dti-2622 97 17 , , PUNCT dti-2622 97 18 e. e. PROPN dti-2622 97 19 coli coli PROPN dti-2622 97 20 ( ( PUNCT dti-2622 97 21 12.9 12.9 NUM dti-2622 97 22 % % NOUN dti-2622 97 23 ) ) PUNCT dti-2622 97 24 , , PUNCT dti-2622 97 25 and and CCONJ dti-2622 97 26 enterobacter enterobacter ADJ dti-2622 97 27 spp spp NOUN dti-2622 97 28 . . PUNCT dti-2622 98 1 ( ( PUNCT dti-2622 98 2 6.2 6.2 NUM dti-2622 98 3 % % NOUN dti-2622 98 4 ) ) PUNCT dti-2622 98 5 , , PUNCT dti-2622 98 6 which which PRON dti-2622 98 7 are be AUX dti-2622 98 8 similar similar ADJ dti-2622 98 9 to to ADP dti-2622 98 10 previous previous ADJ dti-2622 98 11 reports report NOUN dti-2622 98 12 ( ( PUNCT dti-2622 98 13 12,13,16,20 12,13,16,20 NUM dti-2622 98 14 - - SYM dti-2622 98 15 22 22 NUM dti-2622 98 16 ) ) PUNCT dti-2622 98 17 . . PUNCT dti-2622 99 1 the the DET dti-2622 99 2 mortality mortality NOUN dti-2622 99 3 rate rate NOUN dti-2622 99 4 of of ADP dti-2622 99 5 cre cre PROPN dti-2622 99 6 infection infection NOUN dti-2622 99 7 from from ADP dti-2622 99 8 several several ADJ dti-2622 99 9 studies study NOUN dti-2622 99 10 is be AUX dti-2622 99 11 high high ADJ dti-2622 99 12 , , PUNCT dti-2622 99 13 from from ADP dti-2622 99 14 31 31 NUM dti-2622 99 15 % % NOUN dti-2622 99 16 to to ADP dti-2622 99 17 53 53 NUM dti-2622 99 18 % % NOUN dti-2622 99 19 ( ( PUNCT dti-2622 99 20 1114 1114 NUM dti-2622 99 21 ) ) PUNCT dti-2622 99 22 . . PUNCT dti-2622 100 1 similar similar ADJ dti-2622 100 2 to to ADP dti-2622 100 3 this this DET dti-2622 100 4 current current ADJ dti-2622 100 5 study study NOUN dti-2622 100 6 , , PUNCT dti-2622 100 7 the the DET dti-2622 100 8 overall overall ADJ dti-2622 100 9 30 30 NUM dti-2622 100 10 - - PUNCT dti-2622 100 11 day day NOUN dti-2622 100 12 mortality mortality NOUN dti-2622 100 13 was be AUX dti-2622 100 14 38.7 38.7 NUM dti-2622 100 15 % % NOUN dti-2622 100 16 . . PUNCT dti-2622 101 1 the the DET dti-2622 101 2 optimal optimal ADJ dti-2622 101 3 antibiotic antibiotic ADJ dti-2622 101 4 regimen regiman NOUN dti-2622 101 5 that that PRON dti-2622 101 6 is be AUX dti-2622 101 7 the the DET dti-2622 101 8 most most ADV dti-2622 101 9 effective effective ADJ dti-2622 101 10 with with ADP dti-2622 101 11 lowest low ADJ dti-2622 101 12 side side NOUN dti-2622 101 13 effects effect NOUN dti-2622 101 14 is be AUX dti-2622 101 15 still still ADV dti-2622 101 16 unknown unknown ADJ dti-2622 101 17 , , PUNCT dti-2622 101 18 particularly particularly ADV dti-2622 101 19 for for ADP dti-2622 101 20 pneumonia pneumonia NOUN dti-2622 101 21 treatment treatment NOUN dti-2622 101 22 ( ( PUNCT dti-2622 101 23 2,8,19,23 2,8,19,23 PROPN dti-2622 101 24 ) ) PUNCT dti-2622 101 25 . . PUNCT dti-2622 102 1 the the DET dti-2622 102 2 recent recent ADJ dti-2622 102 3 guidelines guideline NOUN dti-2622 102 4 prefer prefer VERB dti-2622 102 5 new new ADJ dti-2622 102 6 blbis blbis NOUN dti-2622 102 7 and and CCONJ dti-2622 102 8 cefiderocol cefiderocol VERB dti-2622 102 9 for for ADP dti-2622 102 10 the the DET dti-2622 102 11 treatment treatment NOUN dti-2622 102 12 of of ADP dti-2622 102 13 cre cre PROPN dti-2622 102 14 infection infection NOUN dti-2622 102 15 ( ( PUNCT dti-2622 102 16 2,8 2,8 NUM dti-2622 102 17 ) ) PUNCT dti-2622 102 18 . . PUNCT dti-2622 103 1 furthermore furthermore ADV dti-2622 103 2 , , PUNCT dti-2622 103 3 a a DET dti-2622 103 4 growing grow VERB dti-2622 103 5 body body NOUN dti-2622 103 6 of of ADP dti-2622 103 7 evidence evidence NOUN dti-2622 103 8 demonstrated demonstrate VERB dti-2622 103 9 new new ADJ dti-2622 103 10 blbis blbis NOUN dti-2622 103 11 and and CCONJ dti-2622 103 12 cefiderocol cefiderocol NOUN dti-2622 103 13 has have VERB dti-2622 103 14 a a DET dti-2622 103 15 lower low ADJ dti-2622 103 16 mortality mortality NOUN dti-2622 103 17 in in ADP dti-2622 103 18 cre cre PROPN dti-2622 103 19 infection infection NOUN dti-2622 103 20 than than ADP dti-2622 103 21 treatment treatment NOUN dti-2622 103 22 regimen regiman NOUN dti-2622 103 23 used use VERB dti-2622 103 24 in in ADP dti-2622 103 25 this this DET dti-2622 103 26 study study NOUN dti-2622 103 27 ( ( PUNCT dti-2622 103 28 23 23 NUM dti-2622 103 29 - - SYM dti-2622 103 30 27 27 NUM dti-2622 103 31 ) ) PUNCT dti-2622 103 32 . . PUNCT dti-2622 104 1 these these DET dti-2622 104 2 antibiotics antibiotic NOUN dti-2622 104 3 were be AUX dti-2622 104 4 not not PART dti-2622 104 5 available available ADJ dti-2622 104 6 during during ADP dti-2622 104 7 the the DET dti-2622 104 8 period period NOUN dti-2622 104 9 of of ADP dti-2622 104 10 this this DET dti-2622 104 11 current current ADJ dti-2622 104 12 study study NOUN dti-2622 104 13 . . PUNCT dti-2622 105 1 the the DET dti-2622 105 2 best well ADV dti-2622 105 3 available available ADJ dti-2622 105 4 regimen regiman NOUN dti-2622 105 5 used use VERB dti-2622 105 6 in in ADP dti-2622 105 7 this this DET dti-2622 105 8 study study NOUN dti-2622 105 9 included include VERB dti-2622 105 10 monotherapy monotherapy NOUN dti-2622 105 11 and and CCONJ dti-2622 105 12 a a DET dti-2622 105 13 combination combination NOUN dti-2622 105 14 of of ADP dti-2622 105 15 carbapenem carbapenem PROPN dti-2622 105 16 , , PUNCT dti-2622 105 17 colistin colistin NOUN dti-2622 105 18 , , PUNCT dti-2622 105 19 amikacin amikacin PROPN dti-2622 105 20 , , PUNCT dti-2622 105 21 tigecycline tigecycline INTJ dti-2622 105 22 , , PUNCT dti-2622 105 23 and and CCONJ dti-2622 105 24 fosfomycin fosfomycin PROPN dti-2622 105 25 . . PUNCT dti-2622 106 1 this this PRON dti-2622 106 2 is be AUX dti-2622 106 3 the the DET dti-2622 106 4 one one NUM dti-2622 106 5 possible possible ADJ dti-2622 106 6 explanation explanation NOUN dti-2622 106 7 that that PRON dti-2622 106 8 might might AUX dti-2622 106 9 contribute contribute VERB dti-2622 106 10 to to ADP dti-2622 106 11 the the DET dti-2622 106 12 high high ADJ dti-2622 106 13 mortality mortality NOUN dti-2622 106 14 of of ADP dti-2622 106 15 this this DET dti-2622 106 16 study study NOUN dti-2622 106 17 . . PUNCT dti-2622 107 1 the the DET dti-2622 107 2 study study NOUN dti-2622 107 3 revealed reveal VERB dti-2622 107 4 that that SCONJ dti-2622 107 5 the the DET dti-2622 107 6 independent independent ADJ dti-2622 107 7 factors factor NOUN dti-2622 107 8 associated associate VERB dti-2622 107 9 with with ADP dti-2622 107 10 30 30 NUM dti-2622 107 11 - - PUNCT dti-2622 107 12 day day NOUN dti-2622 107 13 mortality mortality NOUN dti-2622 107 14 were be AUX dti-2622 107 15 sepsis sepsis NOUN dti-2622 107 16 at at ADP dti-2622 107 17 the the DET dti-2622 107 18 time time NOUN dti-2622 107 19 of of ADP dti-2622 107 20 cre cre PROPN dti-2622 107 21 infection infection NOUN dti-2622 107 22 diagnosis diagnosis NOUN dti-2622 107 23 , , PUNCT dti-2622 107 24 increasing increase VERB dti-2622 107 25 sap sap PROPN dti-2622 107 26 ii ii PROPN dti-2622 107 27 score score NOUN dti-2622 107 28 , , PUNCT dti-2622 107 29 pneumonia pneumonia NOUN dti-2622 107 30 , , PUNCT dti-2622 107 31 monotherapy monotherapy NOUN dti-2622 107 32 , , PUNCT dti-2622 107 33 and and CCONJ dti-2622 107 34 improper improper ADJ dti-2622 107 35 empiric empiric ADJ dti-2622 107 36 antibiotic antibiotic NOUN dti-2622 107 37 . . PUNCT dti-2622 108 1 similar similar ADJ dti-2622 108 2 to to ADP dti-2622 108 3 this this DET dti-2622 108 4 study study NOUN dti-2622 108 5 , , PUNCT dti-2622 108 6 de de PROPN dti-2622 108 7 maio maio PROPN dti-2622 108 8 carrilho carrilho PROPN dti-2622 108 9 et et PROPN dti-2622 108 10 al al PROPN dti-2622 108 11 reported report VERB dti-2622 108 12 pneumonia pneumonia NOUN dti-2622 108 13 and and CCONJ dti-2622 108 14 urinary urinary ADJ dti-2622 108 15 tract tract NOUN dti-2622 108 16 infection infection NOUN dti-2622 108 17 were be AUX dti-2622 108 18 the the DET dti-2622 108 19 most most ADV dti-2622 108 20 frequent frequent ADJ dti-2622 108 21 source source NOUN dti-2622 108 22 of of ADP dti-2622 108 23 cre cre PROPN dti-2622 108 24 infection infection NOUN dti-2622 108 25 . . PUNCT dti-2622 109 1 the the DET dti-2622 109 2 mortality mortality NOUN dti-2622 109 3 rate rate NOUN dti-2622 109 4 was be AUX dti-2622 109 5 34.6 34.6 NUM dti-2622 109 6 % % NOUN dti-2622 109 7 and and CCONJ dti-2622 109 8 higher high ADJ dti-2622 109 9 in in ADP dti-2622 109 10 pneumonia pneumonia NOUN dti-2622 109 11 patients patient NOUN dti-2622 109 12 . . PUNCT dti-2622 110 1 this this DET dti-2622 110 2 study study NOUN dti-2622 110 3 demonstrated demonstrate VERB dti-2622 110 4 shock shock NOUN dti-2622 110 5 was be AUX dti-2622 110 6 the the DET dti-2622 110 7 independent independent ADJ dti-2622 110 8 factor factor NOUN dti-2622 110 9 associated associate VERB dti-2622 110 10 with with ADP dti-2622 110 11 mortality mortality NOUN dti-2622 110 12 ( ( PUNCT dti-2622 110 13 12 12 NUM dti-2622 110 14 ) ) PUNCT dti-2622 110 15 . . PUNCT dti-2622 111 1 a a DET dti-2622 111 2 study study NOUN dti-2622 111 3 from from ADP dti-2622 111 4 china china PROPN dti-2622 111 5 by by ADP dti-2622 111 6 li li PROPN dti-2622 111 7 et et PROPN dti-2622 111 8 al al PROPN dti-2622 111 9 evaluated evaluate VERB dti-2622 111 10 the the DET dti-2622 111 11 mortality mortality NOUN dti-2622 111 12 rate rate NOUN dti-2622 111 13 in in ADP dti-2622 111 14 bloodstream bloodstream NOUN dti-2622 111 15 infections infection NOUN dti-2622 111 16 of of ADP dti-2622 111 17 cre cre PROPN dti-2622 111 18 . . PUNCT dti-2622 112 1 this this DET dti-2622 112 2 study study NOUN dti-2622 112 3 demonstrated demonstrate VERB dti-2622 112 4 mortality mortality NOUN dti-2622 112 5 rate rate NOUN dti-2622 112 6 was be AUX dti-2622 112 7 53.1 53.1 NUM dti-2622 112 8 % % NOUN dti-2622 112 9 and and CCONJ dti-2622 112 10 sepsis sepsis NOUN dti-2622 112 11 was be AUX dti-2622 112 12 the the DET dti-2622 112 13 independent independent ADJ dti-2622 112 14 factor factor NOUN dti-2622 112 15 for for ADP dti-2622 112 16 mortality mortality NOUN dti-2622 112 17 ( ( PUNCT dti-2622 112 18 13 13 NUM dti-2622 112 19 ) ) PUNCT dti-2622 112 20 . . PUNCT dti-2622 113 1 lim lim PROPN dti-2622 113 2 et et PROPN dti-2622 113 3 al al PROPN dti-2622 113 4 reported report VERB dti-2622 113 5 a a DET dti-2622 113 6 high high ADJ dti-2622 113 7 disease disease NOUN dti-2622 113 8 severity severity NOUN dti-2622 113 9 index index NOUN dti-2622 113 10 defined define VERB dti-2622 113 11 as as ADP dti-2622 113 12 an an DET dti-2622 113 13 apache apache NOUN dti-2622 113 14 score score NOUN dti-2622 113 15 ≥15 ≥15 NOUN dti-2622 113 16 had have VERB dti-2622 113 17 a a DET dti-2622 113 18 higher high ADJ dti-2622 113 19 mortality mortality NOUN dti-2622 113 20 risk risk NOUN dti-2622 113 21 ( ( PUNCT dti-2622 113 22 14 14 NUM dti-2622 113 23 ) ) PUNCT dti-2622 113 24 . . PUNCT dti-2622 114 1 seo seo NOUN dti-2622 114 2 et et PROPN dti-2622 114 3 al al PROPN dti-2622 114 4 also also ADV dti-2622 114 5 demonstrated demonstrate VERB dti-2622 114 6 higher high ADJ dti-2622 114 7 apache apache PROPN dti-2622 114 8 ii ii PROPN dti-2622 114 9 scores score NOUN dti-2622 114 10 were be AUX dti-2622 114 11 independent independent ADJ dti-2622 114 12 risk risk NOUN dti-2622 114 13 factors factor NOUN dti-2622 114 14 of of ADP dti-2622 114 15 mortality mortality NOUN dti-2622 114 16 of of ADP dti-2622 114 17 cre cre PROPN dti-2622 114 18 bacteremia bacteremia NOUN dti-2622 114 19 ( ( PUNCT dti-2622 114 20 15 15 NUM dti-2622 114 21 ) ) PUNCT dti-2622 114 22 . . PUNCT dti-2622 115 1 papadimitriou papadimitriou ADJ dti-2622 115 2 - - PUNCT dti-2622 115 3 olivgeris olivgeris NOUN dti-2622 115 4 et et PROPN dti-2622 115 5 al al PROPN dti-2622 115 6 reported report VERB dti-2622 115 7 that that SCONJ dti-2622 115 8 a a DET dti-2622 115 9 sap sap PROPN dti-2622 115 10 ii ii PROPN dti-2622 115 11 score score NOUN dti-2622 115 12 upon upon SCONJ dti-2622 115 13 infection infection NOUN dti-2622 115 14 onset onset NOUN dti-2622 115 15 was be AUX dti-2622 115 16 associated associate VERB dti-2622 115 17 with with ADP dti-2622 115 18 mortality mortality NOUN dti-2622 115 19 of of ADP dti-2622 115 20 carbapenemase carbapenemase NOUN dti-2622 115 21 - - PUNCT dti-2622 115 22 producing produce VERB dti-2622 115 23 k. k. NOUN dti-2622 115 24 pneumoniae pneumoniae ADJ dti-2622 115 25 bacteremia bacteremia NOUN dti-2622 115 26 ( ( PUNCT dti-2622 115 27 28 28 NUM dti-2622 115 28 ) ) PUNCT dti-2622 115 29 . . PUNCT dti-2622 116 1 these these DET dti-2622 116 2 reports report NOUN dti-2622 116 3 suggested suggest VERB dti-2622 116 4 that that SCONJ dti-2622 116 5 a a DET dti-2622 116 6 high high ADJ dti-2622 116 7 disease disease NOUN dti-2622 116 8 severity severity NOUN dti-2622 116 9 index index NOUN dti-2622 116 10 is be AUX dti-2622 116 11 associated associate VERB dti-2622 116 12 with with ADP dti-2622 116 13 mortality mortality NOUN dti-2622 116 14 of of ADP dti-2622 116 15 cre cre PROPN dti-2622 116 16 infection infection NOUN dti-2622 116 17 , , PUNCT dti-2622 116 18 like like ADP dti-2622 116 19 the the DET dti-2622 116 20 current current ADJ dti-2622 116 21 study study NOUN dti-2622 116 22 . . PUNCT dti-2622 117 1 daikos daikos ADV dti-2622 117 2 et et PROPN dti-2622 117 3 al al PROPN dti-2622 117 4 revealed reveal VERB dti-2622 117 5 that that SCONJ dti-2622 117 6 monotherapy monotherapy NOUN dti-2622 117 7 for for ADP dti-2622 117 8 cre cre PROPN dti-2622 117 9 infection infection NOUN dti-2622 117 10 was be AUX dti-2622 117 11 associated associate VERB dti-2622 117 12 with with ADP dti-2622 117 13 mortality mortality NOUN dti-2622 117 14 ( ( PUNCT dti-2622 117 15 16 16 NUM dti-2622 117 16 ) ) PUNCT dti-2622 117 17 . . PUNCT dti-2622 118 1 likewise likewise ADV dti-2622 118 2 , , PUNCT dti-2622 118 3 lim lim PROPN dti-2622 118 4 et et PROPN dti-2622 118 5 al al PROPN dti-2622 118 6 revealed reveal VERB dti-2622 118 7 that that SCONJ dti-2622 118 8 a a DET dti-2622 118 9 combination combination NOUN dti-2622 118 10 antibiotic antibiotic ADJ dti-2622 118 11 therapy therapy NOUN dti-2622 118 12 had have VERB dti-2622 118 13 lower low ADJ dti-2622 118 14 mortality mortality NOUN dti-2622 118 15 risk risk NOUN dti-2622 118 16 ( ( PUNCT dti-2622 118 17 14 14 NUM dti-2622 118 18 ) ) PUNCT dti-2622 118 19 . . PUNCT dti-2622 119 1 furthermore furthermore ADV dti-2622 119 2 , , PUNCT dti-2622 119 3 several several ADJ dti-2622 119 4 studies study NOUN dti-2622 119 5 demonstrated demonstrate VERB dti-2622 119 6 combination combination NOUN dti-2622 119 7 antibiotic antibiotic ADJ dti-2622 119 8 therapy therapy NOUN dti-2622 119 9 had have VERB dti-2622 119 10 a a DET dti-2622 119 11 good good ADJ dti-2622 119 12 outcome outcome NOUN dti-2622 119 13 for for ADP dti-2622 119 14 cre cre PROPN dti-2622 119 15 infection infection NOUN dti-2622 119 16 ( ( PUNCT dti-2622 119 17 17,28 17,28 NOUN dti-2622 119 18 - - SYM dti-2622 119 19 31 31 NUM dti-2622 119 20 ) ) PUNCT dti-2622 119 21 . . PUNCT dti-2622 120 1 similar similar ADJ dti-2622 120 2 to to ADP dti-2622 120 3 this this DET dti-2622 120 4 current current ADJ dti-2622 120 5 study study NOUN dti-2622 120 6 , , PUNCT dti-2622 120 7 a a DET dti-2622 120 8 combination combination NOUN dti-2622 120 9 antibiotic antibiotic ADJ dti-2622 120 10 therapy therapy NOUN dti-2622 120 11 was be AUX dti-2622 120 12 associated associate VERB dti-2622 120 13 with with ADP dti-2622 120 14 lower low ADJ dti-2622 120 15 mortality mortality NOUN dti-2622 120 16 . . PUNCT dti-2622 121 1 this this DET dti-2622 121 2 finding finding NOUN dti-2622 121 3 was be AUX dti-2622 121 4 unable unable ADJ dti-2622 121 5 to to PART dti-2622 121 6 be be AUX dti-2622 121 7 applied apply VERB dti-2622 121 8 to to ADP dti-2622 121 9 new new ADJ dti-2622 121 10 blbis blbis NOUN dti-2622 121 11 and and CCONJ dti-2622 121 12 cefiderocol cefiderocol VERB dti-2622 121 13 because because SCONJ dti-2622 121 14 the the DET dti-2622 121 15 aforementioned aforementioned ADJ dti-2622 121 16 studies study NOUN dti-2622 121 17 did do AUX dti-2622 121 18 not not PART dti-2622 121 19 include include VERB dti-2622 121 20 new new ADJ dti-2622 121 21 blbis blbis NOUN dti-2622 121 22 and and CCONJ dti-2622 121 23 cefiderocol cefiderocol VERB dti-2622 121 24 in in ADP dti-2622 121 25 the the DET dti-2622 121 26 studies study NOUN dti-2622 121 27 . . PUNCT dti-2622 122 1 this this DET dti-2622 122 2 current current ADJ dti-2622 122 3 study study NOUN dti-2622 122 4 endorsed endorse VERB dti-2622 122 5 the the DET dti-2622 122 6 esmid esmid NOUN dti-2622 122 7 guidelines guideline NOUN dti-2622 122 8 that that PRON dti-2622 122 9 are be AUX dti-2622 122 10 recommended recommend VERB dti-2622 122 11 for for ADP dti-2622 122 12 cre cre PROPN dti-2622 122 13 infection infection NOUN dti-2622 122 14 treatment treatment NOUN dti-2622 122 15 ; ; PUNCT dti-2622 122 16 in in ADP dti-2622 122 17 case case NOUN dti-2622 122 18 new new ADJ dti-2622 122 19 blbis blbis NOUN dti-2622 122 20 are be AUX dti-2622 122 21 not not PART dti-2622 122 22 available available ADJ dti-2622 122 23 , , PUNCT dti-2622 122 24 the the DET dti-2622 122 25 combination combination NOUN dti-2622 122 26 antibiotic antibiotic ADJ dti-2622 122 27 therapy therapy NOUN dti-2622 122 28 of of ADP dti-2622 122 29 drugs drug NOUN dti-2622 122 30 active active ADJ dti-2622 122 31 in in ADP dti-2622 122 32 vitro vitro X dti-2622 122 33 should should AUX dti-2622 122 34 be be AUX dti-2622 122 35 considered consider VERB dti-2622 122 36 ( ( PUNCT dti-2622 122 37 8) 8) NUM dti-2622 122 38 . . PUNCT dti-2622 123 1 tumbarello tumbarello PROPN dti-2622 123 2 et et PROPN dti-2622 123 3 al al PROPN dti-2622 123 4 revealed reveal VERB dti-2622 123 5 that that SCONJ dti-2622 123 6 inadequate inadequate ADJ dti-2622 123 7 empiric empiric ADJ dti-2622 123 8 antibiotic antibiotic ADJ dti-2622 123 9 therapy therapy NOUN dti-2622 123 10 was be AUX dti-2622 123 11 associated associate VERB dti-2622 123 12 with with ADP dti-2622 123 13 mortality mortality NOUN dti-2622 123 14 of of ADP dti-2622 123 15 carbapenemase carbapenemase NOUN dti-2622 123 16 - - PUNCT dti-2622 123 17 producing produce VERB dti-2622 123 18 klebsiella klebsiella NOUN dti-2622 123 19 pneumoniae pneumoniae ADJ dti-2622 123 20 bacteremia bacteremia NOUN dti-2622 123 21 ( ( PUNCT dti-2622 123 22 17 17 NUM dti-2622 123 23 ) ) PUNCT dti-2622 123 24 . . PUNCT dti-2622 124 1 another another DET dti-2622 124 2 study study NOUN dti-2622 124 3 by by ADP dti-2622 124 4 zilberberg zilberberg PROPN dti-2622 124 5 et et PROPN dti-2622 124 6 al al PROPN dti-2622 124 7 revealed reveal VERB dti-2622 124 8 that that SCONJ dti-2622 124 9 cre cre PROPN dti-2622 124 10 infection infection NOUN dti-2622 124 11 was be AUX dti-2622 124 12 threefold threefold ADV dti-2622 124 13 more more ADV dti-2622 124 14 likely likely ADJ dti-2622 124 15 of of ADP dti-2622 124 16 receiving receive VERB dti-2622 124 17 inappropriate inappropriate ADJ dti-2622 124 18 empiric empiric ADJ dti-2622 124 19 antibiotic antibiotic NOUN dti-2622 124 20 ( ( PUNCT dti-2622 124 21 46.5 46.5 NUM dti-2622 124 22 % % NOUN dti-2622 124 23 vs. vs. ADP dti-2622 124 24 11.8 11.8 NUM dti-2622 124 25 % % NOUN dti-2622 124 26 , , PUNCT dti-2622 124 27 p p X dti-2622 124 28 < < X dti-2622 124 29 0.001 0.001 NUM dti-2622 124 30 ) ) PUNCT dti-2622 124 31 , , PUNCT dti-2622 124 32 and and CCONJ dti-2622 124 33 receiving receive VERB dti-2622 124 34 inappropriate inappropriate ADJ dti-2622 124 35 empiric empiric ADJ dti-2622 124 36 antibiotic antibiotic NOUN dti-2622 124 37 was be AUX dti-2622 124 38 also also ADV dti-2622 124 39 associated associate VERB dti-2622 124 40 with with ADP dti-2622 124 41 rising rise VERB dti-2622 124 42 mortality mortality NOUN dti-2622 124 43 ( ( PUNCT dti-2622 124 44 32 32 NUM dti-2622 124 45 ) ) PUNCT dti-2622 124 46 . . PUNCT dti-2622 125 1 this this DET dti-2622 125 2 result result NOUN dti-2622 125 3 is be AUX dti-2622 125 4 similar similar ADJ dti-2622 125 5 to to ADP dti-2622 125 6 this this DET dti-2622 125 7 current current ADJ dti-2622 125 8 study study NOUN dti-2622 125 9 ; ; PUNCT dti-2622 125 10 improper improper ADJ dti-2622 125 11 empiric empiric ADJ dti-2622 125 12 antibiotic antibiotic ADJ dti-2622 125 13 therapy therapy NOUN dti-2622 125 14 had have VERB dti-2622 125 15 a a DET dti-2622 125 16 high high ADJ dti-2622 125 17 occurrence occurrence NOUN dti-2622 125 18 ( ( PUNCT dti-2622 125 19 55.2 55.2 NUM dti-2622 125 20 % % NOUN dti-2622 125 21 ) ) PUNCT dti-2622 125 22 and and CCONJ dti-2622 125 23 was be AUX dti-2622 125 24 associated associate VERB dti-2622 125 25 with with ADP dti-2622 125 26 mortality mortality NOUN dti-2622 125 27 . . PUNCT dti-2622 126 1 active active ADJ dti-2622 126 2 surveillance surveillance NOUN dti-2622 126 3 , , PUNCT dti-2622 126 4 local local ADJ dti-2622 126 5 data datum NOUN dti-2622 126 6 , , PUNCT dti-2622 126 7 and and CCONJ dti-2622 126 8 an an DET dti-2622 126 9 antibiogram antibiogram NOUN dti-2622 126 10 may may AUX dti-2622 126 11 guide guide VERB dti-2622 126 12 a a DET dti-2622 126 13 physician physician NOUN dti-2622 126 14 to to PART dti-2622 126 15 decide decide VERB dti-2622 126 16 on on ADP dti-2622 126 17 the the DET dti-2622 126 18 proper proper ADJ dti-2622 126 19 empiric empiric ADJ dti-2622 126 20 antibiotic antibiotic ADJ dti-2622 126 21 ( ( PUNCT dti-2622 126 22 33 33 NUM dti-2622 126 23 - - SYM dti-2622 126 24 35 35 NUM dti-2622 126 25 ) ) PUNCT dti-2622 126 26 . . PUNCT dti-2622 127 1 this this PRON dti-2622 127 2 might might AUX dti-2622 127 3 reduce reduce VERB dti-2622 127 4 the the DET dti-2622 127 5 mortality mortality NOUN dti-2622 127 6 of of ADP dti-2622 127 7 cre cre PROPN dti-2622 127 8 infection infection NOUN dti-2622 127 9 . . PUNCT dti-2622 128 1 this this DET dti-2622 128 2 study study NOUN dti-2622 128 3 emphasized emphasize VERB dti-2622 128 4 the the DET dti-2622 128 5 mortality mortality NOUN dti-2622 128 6 and and CCONJ dti-2622 128 7 factors factor NOUN dti-2622 128 8 associated associate VERB dti-2622 128 9 with with ADP dti-2622 128 10 mortality mortality NOUN dti-2622 128 11 of of ADP dti-2622 128 12 cre cre PROPN dti-2622 128 13 infection infection NOUN dti-2622 128 14 . . PUNCT dti-2622 129 1 the the DET dti-2622 129 2 study study NOUN dti-2622 129 3 had have VERB dti-2622 129 4 some some DET dti-2622 129 5 limitations limitation NOUN dti-2622 129 6 . . PUNCT dti-2622 130 1 first first ADV dti-2622 130 2 , , PUNCT dti-2622 130 3 this this PRON dti-2622 130 4 was be AUX dti-2622 130 5 a a DET dti-2622 130 6 retrospective retrospective ADJ dti-2622 130 7 study study NOUN dti-2622 130 8 , , PUNCT dti-2622 130 9 some some DET dti-2622 130 10 data datum NOUN dti-2622 130 11 were be AUX dti-2622 130 12 missing miss VERB dti-2622 130 13 , , PUNCT dti-2622 130 14 and and CCONJ dti-2622 130 15 the the DET dti-2622 130 16 selection selection NOUN dti-2622 130 17 bias bias NOUN dti-2622 130 18 was be AUX dti-2622 130 19 unable unable ADJ dti-2622 130 20 to to PART dti-2622 130 21 be be AUX dti-2622 130 22 avoided avoid VERB dti-2622 130 23 . . PUNCT dti-2622 131 1 second second ADJ dti-2622 131 2 , , PUNCT dti-2622 131 3 some some DET dti-2622 131 4 factors factor NOUN dti-2622 131 5 were be AUX dti-2622 131 6 found find VERB dti-2622 131 7 significantly significantly ADV dti-2622 131 8 associated associate VERB dti-2622 131 9 with with ADP dti-2622 131 10 mortality mortality NOUN dti-2622 131 11 of of ADP dti-2622 131 12 cre cre PROPN dti-2622 131 13 infection infection NOUN dti-2622 131 14 in in ADP dti-2622 131 15 previous previous ADJ dti-2622 131 16 studies study NOUN dti-2622 131 17 but but CCONJ dti-2622 131 18 could could AUX dti-2622 131 19 not not PART dti-2622 131 20 be be AUX dti-2622 131 21 identified identify VERB dti-2622 131 22 in in ADP dti-2622 131 23 this this DET dti-2622 131 24 study study NOUN dti-2622 131 25 , , PUNCT dti-2622 131 26 this this PRON dti-2622 131 27 might might AUX dti-2622 131 28 be be AUX dti-2622 131 29 because because SCONJ dti-2622 131 30 this this DET dti-2622 131 31 study study NOUN dti-2622 131 32 had have VERB dti-2622 131 33 a a DET dti-2622 131 34 relatively relatively ADV dti-2622 131 35 small small ADJ dti-2622 131 36 sample sample NOUN dti-2622 131 37 size size NOUN dti-2622 131 38 . . PUNCT dti-2622 132 1 third third ADJ dti-2622 132 2 , , PUNCT dti-2622 132 3 the the DET dti-2622 132 4 temporal temporal ADJ dti-2622 132 5 relationship relationship NOUN dti-2622 132 6 could could AUX dti-2622 132 7 not not PART dti-2622 132 8 be be AUX dti-2622 132 9 determined determine VERB dti-2622 132 10 according accord VERB dti-2622 132 11 to to ADP dti-2622 132 12 the the DET dti-2622 132 13 study study NOUN dti-2622 132 14 design design NOUN dti-2622 132 15 . . PUNCT dti-2622 133 1 conclusion conclusion NOUN dti-2622 133 2 the the DET dti-2622 133 3 overall overall ADJ dti-2622 133 4 30 30 NUM dti-2622 133 5 - - PUNCT dti-2622 133 6 day day NOUN dti-2622 133 7 mortality mortality NOUN dti-2622 133 8 of of ADP dti-2622 133 9 cre cre PROPN dti-2622 133 10 infection infection NOUN dti-2622 133 11 was be AUX dti-2622 133 12 high high ADJ dti-2622 133 13 . . PUNCT dti-2622 134 1 the the DET dti-2622 134 2 factors factor NOUN dti-2622 134 3 associated associate VERB dti-2622 134 4 with with ADP dti-2622 134 5 mortality mortality NOUN dti-2622 134 6 were be AUX dti-2622 134 7 an an DET dti-2622 134 8 increasing increase VERB dti-2622 134 9 sap sap PROPN dti-2622 134 10 ii ii PROPN dti-2622 134 11 score score NOUN dti-2622 134 12 , , PUNCT dti-2622 134 13 sepsis sepsis NOUN dti-2622 134 14 at at ADP dti-2622 134 15 time time NOUN dti-2622 134 16 of of ADP dti-2622 134 17 cre cre PROPN dti-2622 134 18 infection infection NOUN dti-2622 134 19 diagnosis diagnosis NOUN dti-2622 134 20 , , PUNCT dti-2622 134 21 pneumonia pneumonia NOUN dti-2622 134 22 , , PUNCT dti-2622 134 23 monotherapy monotherapy NOUN dti-2622 134 24 , , PUNCT dti-2622 134 25 and and CCONJ dti-2622 134 26 improper improper ADJ dti-2622 134 27 empiric empiric ADJ dti-2622 134 28 antibiotic antibiotic NOUN dti-2622 134 29 . . PUNCT dti-2622 135 1 the the DET dti-2622 135 2 study study NOUN dti-2622 135 3 suggested suggest VERB dti-2622 135 4 that that SCONJ dti-2622 135 5 proper proper ADJ dti-2622 135 6 empiric empiric ADJ dti-2622 135 7 antibiotic antibiotic ADJ dti-2622 135 8 and and CCONJ dti-2622 135 9 combination combination NOUN dti-2622 135 10 antibiotics antibiotic NOUN dti-2622 135 11 might might AUX dti-2622 135 12 reduce reduce VERB dti-2622 135 13 mortality mortality NOUN dti-2622 135 14 from from ADP dti-2622 135 15 cre cre PROPN dti-2622 135 16 infection infection NOUN dti-2622 135 17 . . PUNCT dti-2622 136 1 acknowledgments acknowledgment NOUN dti-2622 136 2 the the DET dti-2622 136 3 authors author NOUN dti-2622 136 4 would would AUX dti-2622 136 5 like like VERB dti-2622 136 6 to to PART dti-2622 136 7 thank thank VERB dti-2622 136 8 professor professor PROPN dti-2622 136 9 james james PROPN dti-2622 136 10 arthur arthur PROPN dti-2622 136 11 will will AUX dti-2622 136 12 for for ADP dti-2622 136 13 editing edit VERB dti-2622 136 14 this this DET dti-2622 136 15 manuscript manuscript NOUN dti-2622 136 16 via via ADP dti-2622 136 17 the the DET dti-2622 136 18 khon khon PROPN dti-2622 136 19 kaen kaen PROPN dti-2622 136 20 university university PROPN dti-2622 136 21 publication publication NOUN dti-2622 136 22 clinic clinic PROPN dti-2622 136 23 ( ( PUNCT dti-2622 136 24 thailand thailand PROPN dti-2622 136 25 ) ) PUNCT dti-2622 136 26 . . PUNCT dti-2622 137 1 table table NOUN dti-2622 137 2 iv iv NUM dti-2622 137 3 factors factor NOUN dti-2622 137 4 associated associate VERB dti-2622 137 5 with with ADP dti-2622 137 6 30 30 NUM dti-2622 137 7 - - PUNCT dti-2622 137 8 day day NOUN dti-2622 137 9 mortality mortality NOUN dti-2622 137 10 of of ADP dti-2622 137 11 cre cre PROPN dti-2622 137 12 infection infection NOUN dti-2622 137 13 parameters parameter NOUN dti-2622 137 14 cor cor PROPN dti-2622 137 15 ( ( PUNCT dti-2622 137 16 95 95 NUM dti-2622 137 17 % % NOUN dti-2622 137 18 ci ci NOUN dti-2622 137 19 ) ) PUNCT dti-2622 137 20 pvalue pvalue NOUN dti-2622 137 21 aor aor NOUN dti-2622 137 22 ( ( PUNCT dti-2622 137 23 95 95 NUM dti-2622 137 24 % % NOUN dti-2622 137 25 ci ci NOUN dti-2622 137 26 ) ) PUNCT dti-2622 137 27 pvalue pvalue NOUN dti-2622 137 28 age age NOUN dti-2622 137 29 > > NOUN dti-2622 137 30 60 60 NUM dti-2622 137 31 years year NOUN dti-2622 137 32 0.76 0.76 NUM dti-2622 137 33 ( ( PUNCT dti-2622 137 34 0.42 0.42 NUM dti-2622 137 35 - - SYM dti-2622 137 36 1.36 1.36 NUM dti-2622 137 37 ) ) PUNCT dti-2622 137 38 0.35 0.35 NUM dti-2622 137 39 sepsis sepsis NOUN dti-2622 137 40 * * SYM dti-2622 137 41 24.51 24.51 NUM dti-2622 137 42 ( ( PUNCT dti-2622 137 43 9.78 9.78 NUM dti-2622 137 44 - - SYM dti-2622 137 45 61.44 61.44 NUM dti-2622 137 46 ) ) PUNCT dti-2622 137 47 < < X dti-2622 137 48 0.001 0.001 NUM dti-2622 137 49 7.93 7.93 NUM dti-2622 137 50 ( ( PUNCT dti-2622 137 51 2.21 2.21 NUM dti-2622 137 52 - - SYM dti-2622 137 53 28.51 28.51 NUM dti-2622 137 54 ) ) PUNCT dti-2622 137 55 0.002 0.002 NUM dti-2622 137 56 increasing increase VERB dti-2622 137 57 sap sap PROPN dti-2622 137 58 ii ii PROPN dti-2622 137 59 score score NOUN dti-2622 137 60 * * PROPN dti-2622 137 61 1.13 1.13 NUM dti-2622 137 62 ( ( PUNCT dti-2622 137 63 1.09 1.09 NUM dti-2622 137 64 - - SYM dti-2622 137 65 1.17 1.17 NUM dti-2622 137 66 ) ) PUNCT dti-2622 137 67 < < X dti-2622 137 68 0.001 0.001 NUM dti-2622 137 69 1.11 1.11 NUM dti-2622 137 70 ( ( PUNCT dti-2622 137 71 1.05 1.05 NUM dti-2622 137 72 - - SYM dti-2622 137 73 1.16 1.16 NUM dti-2622 137 74 ) ) PUNCT dti-2622 137 75 < < X dti-2622 137 76 0.001 0.001 NUM dti-2622 137 77 pneumonia pneumonia NOUN dti-2622 137 78 9.28 9.28 NUM dti-2622 137 79 ( ( PUNCT dti-2622 137 80 4.72 4.72 NUM dti-2622 137 81 - - SYM dti-2622 137 82 18.22 18.22 NUM dti-2622 137 83 ) ) PUNCT dti-2622 137 84 < < X dti-2622 137 85 0.001 0.001 NUM dti-2622 137 86 4.48 4.48 NUM dti-2622 137 87 ( ( PUNCT dti-2622 137 88 1.61 1.61 NUM dti-2622 137 89 - - SYM dti-2622 137 90 12.44 12.44 NUM dti-2622 137 91 ) ) PUNCT dti-2622 137 92 0.004 0.004 NUM dti-2622 137 93 urinary urinary ADJ dti-2622 137 94 tract tract NOUN dti-2622 137 95 infection infection NOUN dti-2622 137 96 0.16 0.16 NUM dti-2622 137 97 ( ( PUNCT dti-2622 137 98 0.61 0.61 NUM dti-2622 137 99 - - SYM dti-2622 137 100 0.44 0.44 NUM dti-2622 137 101 ) ) PUNCT dti-2622 137 102 < < X dti-2622 137 103 0.001 0.001 NUM dti-2622 137 104 monotherapy monotherapy NOUN dti-2622 137 105 3.01 3.01 NUM dti-2622 137 106 ( ( PUNCT dti-2622 137 107 1.59 1.59 NUM dti-2622 137 108 - - SYM dti-2622 137 109 5.71 5.71 NUM dti-2622 137 110 ) ) PUNCT dti-2622 137 111 0.001 0.001 NUM dti-2622 137 112 4.69 4.69 NUM dti-2622 137 113 ( ( PUNCT dti-2622 137 114 1.71 1.71 NUM dti-2622 137 115 - - SYM dti-2622 137 116 12.85 12.85 NUM dti-2622 137 117 ) ) PUNCT dti-2622 137 118 0.003 0.003 NUM dti-2622 137 119 improper improper ADJ dti-2622 137 120 empiric empiric ADJ dti-2622 137 121 antibiotic antibiotic ADJ dti-2622 137 122 1.65 1.65 NUM dti-2622 137 123 ( ( PUNCT dti-2622 137 124 0.91 0.91 NUM dti-2622 137 125 - - SYM dti-2622 137 126 2.98 2.98 NUM dti-2622 137 127 ) ) PUNCT dti-2622 137 128 0.09 0.09 NUM dti-2622 137 129 5.13 5.13 NUM dti-2622 137 130 ( ( PUNCT dti-2622 137 131 1.83 1.83 NUM dti-2622 137 132 - - SYM dti-2622 137 133 14.40 14.40 NUM dti-2622 137 134 ) ) PUNCT dti-2622 137 135 0.002 0.002 NUM dti-2622 137 136 aor aor NOUN dti-2622 137 137 = = NOUN dti-2622 137 138 adjusted adjust VERB dti-2622 137 139 odds odd NOUN dti-2622 137 140 ratio ratio NOUN dti-2622 137 141 ; ; PUNCT dti-2622 137 142 cor cor PROPN dti-2622 137 143 = = SYM dti-2622 137 144 crude crude ADJ dti-2622 137 145 odds odd NOUN dti-2622 137 146 ratio ratio NOUN dti-2622 137 147 ; ; PUNCT dti-2622 137 148 ci ci NOUN dti-2622 137 149 = = NOUN dti-2622 137 150 confidence confidence NOUN dti-2622 137 151 interval interval NOUN dti-2622 137 152 ; ; PUNCT dti-2622 137 153 cre cre PROPN dti-2622 137 154 = = SYM dti-2622 137 155 carbapenem carbapenem PROPN dti-2622 137 156 - - PUNCT dti-2622 137 157 resistant resistant ADJ dti-2622 137 158 enterobacteriaceae enterobacteriaceae NOUN dti-2622 137 159 ; ; PUNCT dti-2622 138 1 sap sap PROPN dti-2622 138 2 = = SYM dti-2622 138 3 simplified simplify VERB dti-2622 138 4 acute acute NOUN dti-2622 138 5 physiology physiology NOUN dti-2622 138 6 . . PUNCT dti-2622 139 1 * * PUNCT dti-2622 139 2 status status NOUN dti-2622 139 3 at at ADP dti-2622 139 4 time time NOUN dti-2622 139 5 of of ADP dti-2622 139 6 cre cre PROPN dti-2622 139 7 infection infection NOUN dti-2622 139 8 diagnosis diagnosis NOUN dti-2622 139 9 . . PUNCT dti-2622 140 1 mortality mortality NOUN dti-2622 140 2 and and CCONJ dti-2622 140 3 factors factor NOUN dti-2622 140 4 associated associate VERB dti-2622 140 5 with with ADP dti-2622 140 6 mortality mortality NOUN dti-2622 140 7 of of ADP dti-2622 140 8 cre cre PROPN dti-2622 140 9 infection124 infection124 PROPN dti-2622 140 10 © © PROPN dti-2622 140 11 2023 2023 NUM dti-2622 140 12 the the DET dti-2622 140 13 authors author NOUN dti-2622 140 14 . . PUNCT dti-2622 141 1 drug drug NOUN dti-2622 141 2 target target NOUN dti-2622 141 3 insights insight NOUN dti-2622 141 4 issn issn VERB dti-2622 141 5 1177 1177 NUM dti-2622 141 6 - - SYM dti-2622 141 7 3928 3928 NUM dti-2622 141 8 www.aboutscience.eu/dti www.aboutscience.eu/dti NOUN dti-2622 141 9 disclosures disclosure NOUN dti-2622 141 10 conflict conflict NOUN dti-2622 141 11 of of ADP dti-2622 141 12 interest interest NOUN dti-2622 141 13 : : PUNCT dti-2622 141 14 the the DET dti-2622 141 15 authors author NOUN dti-2622 141 16 declare declare VERB dti-2622 141 17 no no DET dti-2622 141 18 conflict conflict NOUN dti-2622 141 19 of of ADP dti-2622 141 20 interest interest NOUN dti-2622 141 21 . . PUNCT dti-2622 142 1 financial financial ADJ dti-2622 142 2 support support NOUN dti-2622 142 3 : : PUNCT dti-2622 142 4 this this DET dti-2622 142 5 research research NOUN dti-2622 142 6 received receive VERB dti-2622 142 7 no no DET dti-2622 142 8 specific specific ADJ dti-2622 142 9 grant grant NOUN dti-2622 142 10 from from ADP dti-2622 142 11 any any DET dti-2622 142 12 funding funding NOUN dti-2622 142 13 agency agency NOUN dti-2622 142 14 in in ADP dti-2622 142 15 the the DET dti-2622 142 16 public public ADJ dti-2622 142 17 , , PUNCT dti-2622 142 18 commercial commercial ADJ dti-2622 142 19 , , PUNCT dti-2622 142 20 or or CCONJ dti-2622 142 21 not not PART dti-2622 142 22 - - PUNCT dti-2622 142 23 for for ADP dti-2622 142 24 - - PUNCT dti-2622 142 25 profit profit NOUN dti-2622 142 26 sectors sector NOUN dti-2622 142 27 . . PUNCT dti-2622 143 1 authors author NOUN dti-2622 143 2 contribution contribution VERB dti-2622 143 3 : : PUNCT dti-2622 143 4 all all DET dti-2622 143 5 authors author NOUN dti-2622 143 6 contributed contribute VERB dti-2622 143 7 to to ADP dti-2622 143 8 the the DET dti-2622 143 9 study study NOUN dti-2622 143 10 design design NOUN dti-2622 143 11 , , PUNCT dti-2622 143 12 data datum NOUN dti-2622 143 13 interpretation interpretation NOUN dti-2622 143 14 , , PUNCT dti-2622 143 15 manuscript manuscript NOUN dti-2622 143 16 preparation preparation NOUN dti-2622 143 17 , , PUNCT dti-2622 143 18 and and CCONJ dti-2622 143 19 reviewed review VERB dti-2622 143 20 the the DET dti-2622 143 21 manuscript manuscript NOUN dti-2622 143 22 . . PUNCT dti-2622 144 1 a.s a.s PROPN dti-2622 144 2 . . PROPN dti-2622 144 3 and and CCONJ dti-2622 144 4 n.o n.o PROPN dti-2622 144 5 . . PROPN dti-2622 144 6 contributed contribute VERB dti-2622 144 7 to to ADP dti-2622 144 8 data datum NOUN dti-2622 144 9 acquisition acquisition NOUN dti-2622 144 10 . . PUNCT dti-2622 145 1 a.s a.s PROPN dti-2622 145 2 . . PROPN dti-2622 145 3 and and CCONJ dti-2622 145 4 a.m. a.m. PROPN dti-2622 145 5 contributed contribute VERB dti-2622 145 6 to to ADP dti-2622 145 7 data data NOUN dti-2622 145 8 analysis analysis NOUN dti-2622 145 9 and and CCONJ dti-2622 145 10 interpretation interpretation NOUN dti-2622 145 11 . . PUNCT dti-2622 146 1 all all DET dti-2622 146 2 authors author NOUN dti-2622 146 3 have have AUX dti-2622 146 4 read read VERB dti-2622 146 5 and and CCONJ dti-2622 146 6 agree agree VERB dti-2622 146 7 to to ADP dti-2622 146 8 the the DET dti-2622 146 9 published publish VERB dti-2622 146 10 version version NOUN dti-2622 146 11 of of ADP dti-2622 146 12 the the DET dti-2622 146 13 manuscript manuscript NOUN dti-2622 146 14 . . PUNCT dti-2622 147 1 references reference NOUN dti-2622 147 2 1 1 NUM dti-2622 147 3 . . PUNCT dti-2622 148 1 david david PROPN dti-2622 148 2 s s PROPN dti-2622 148 3 , , PUNCT dti-2622 148 4 reuter reuter PROPN dti-2622 148 5 s s PROPN dti-2622 148 6 , , PUNCT dti-2622 148 7 harris harris PROPN dti-2622 148 8 sr sr PROPN dti-2622 148 9 , , PUNCT dti-2622 148 10 et et PROPN dti-2622 148 11 al al PROPN dti-2622 148 12 ; ; PUNCT dti-2622 148 13 euscape euscape NOUN dti-2622 148 14 working working NOUN dti-2622 148 15 group group NOUN dti-2622 148 16 ; ; PUNCT dti-2622 148 17 esgem esgem PROPN dti-2622 148 18 study study NOUN dti-2622 148 19 group group NOUN dti-2622 148 20 . . PUNCT dti-2622 149 1 epidemic epidemic NOUN dti-2622 149 2 of of ADP dti-2622 149 3 carbapenem carbapenem NOUN dti-2622 149 4 - - PUNCT dti-2622 149 5 resistant resistant ADJ dti-2622 149 6 klebsiella klebsiella NOUN dti-2622 149 7 pneumoniae pneumoniae ADJ dti-2622 149 8 in in ADP dti-2622 149 9 europe europe PROPN dti-2622 149 10 is be AUX dti-2622 149 11 driven drive VERB dti-2622 149 12 by by ADP dti-2622 149 13 nosocomial nosocomial ADJ dti-2622 149 14 spread spread NOUN dti-2622 149 15 . . PUNCT dti-2622 150 1 nat nat PROPN dti-2622 150 2 microbiol microbiol PROPN dti-2622 150 3 . . PUNCT dti-2622 151 1 2019;4(11):1919 2019;4(11):1919 NUM dti-2622 151 2 - - SYM dti-2622 151 3 1929 1929 NUM dti-2622 151 4 . . PUNCT dti-2622 152 1 crossref crossref PROPN dti-2622 152 2 pubmed pubmed PROPN dti-2622 152 3 2 2 PROPN dti-2622 152 4 . . PUNCT dti-2622 153 1 tamma tamma PROPN dti-2622 153 2 pd pd PROPN dti-2622 153 3 , , PUNCT dti-2622 153 4 aitken aitken PROPN dti-2622 153 5 sl sl PROPN dti-2622 153 6 , , PUNCT dti-2622 153 7 bonomo bonomo PROPN dti-2622 153 8 ra ra PROPN dti-2622 153 9 , , PUNCT dti-2622 153 10 mathers mathers PROPN dti-2622 153 11 aj aj PROPN dti-2622 153 12 , , PUNCT dti-2622 153 13 van van PROPN dti-2622 153 14 duin duin PROPN dti-2622 153 15 d d PROPN dti-2622 153 16 , , PUNCT dti-2622 153 17 clancy clancy PROPN dti-2622 153 18 cj cj PROPN dti-2622 153 19 . . PUNCT dti-2622 154 1 infectious infectious ADJ dti-2622 154 2 diseases disease NOUN dti-2622 154 3 society society PROPN dti-2622 154 4 of of ADP dti-2622 154 5 america america PROPN dti-2622 154 6 guidance guidance NOUN dti-2622 154 7 on on ADP dti-2622 154 8 the the DET dti-2622 154 9 treatment treatment NOUN dti-2622 154 10 of of ADP dti-2622 154 11 extended extend VERB dti-2622 154 12 - - PUNCT dti-2622 154 13 spectrum spectrum NOUN dti-2622 154 14 β β NOUN dti-2622 154 15 - - PUNCT dti-2622 154 16 lactamase lactamase ADJ dti-2622 154 17 producing produce VERB dti-2622 154 18 enterobacterales enterobacterale NOUN dti-2622 154 19 ( ( PUNCT dti-2622 154 20 esbl esbl NOUN dti-2622 154 21 - - PUNCT dti-2622 154 22 e e NOUN dti-2622 154 23 ) ) PUNCT dti-2622 154 24 , , PUNCT dti-2622 154 25 carbapenem carbapenem NOUN dti-2622 154 26 - - PUNCT dti-2622 154 27 resistant resistant ADJ dti-2622 154 28 enterobacterales enterobacterale NOUN dti-2622 154 29 ( ( PUNCT dti-2622 154 30 cre cre PROPN dti-2622 154 31 ) ) PUNCT dti-2622 154 32 , , PUNCT dti-2622 154 33 and and CCONJ dti-2622 154 34 pseudomonas pseudomona VERB dti-2622 154 35 aeruginosa aeruginosa NOUN dti-2622 154 36 with with ADP dti-2622 154 37 difficult difficult ADJ dti-2622 154 38 - - PUNCT dti-2622 154 39 to to ADP dti-2622 154 40 - - PUNCT dti-2622 154 41 treat treat VERB dti-2622 154 42 resistance resistance NOUN dti-2622 154 43 ( ( PUNCT dti-2622 154 44 dtr dtr NOUN dti-2622 154 45 - - PUNCT dti-2622 154 46 p. p. NOUN dti-2622 154 47 aeruginosa aeruginosa NOUN dti-2622 154 48 ) ) PUNCT dti-2622 154 49 . . PUNCT dti-2622 155 1 clin clin PROPN dti-2622 155 2 infect infect PROPN dti-2622 155 3 dis dis PROPN dti-2622 155 4 . . PUNCT dti-2622 156 1 2021;72(7):e169 2021;72(7):e169 PROPN dti-2622 156 2 - - PUNCT dti-2622 156 3 e183 e183 PROPN dti-2622 156 4 . . PUNCT dti-2622 156 5 crossref crossref PROPN dti-2622 156 6 pubmed pubmed PROPN dti-2622 156 7 3 3 PROPN dti-2622 156 8 . . PUNCT dti-2622 157 1 van van PROPN dti-2622 157 2 duin duin PROPN dti-2622 157 3 d d PROPN dti-2622 157 4 , , PUNCT dti-2622 157 5 doi doi PROPN dti-2622 157 6 y. y. NOUN dti-2622 157 7 the the DET dti-2622 157 8 global global ADJ dti-2622 157 9 epidemiology epidemiology NOUN dti-2622 157 10 of of ADP dti-2622 157 11 carbapenemaseproducing carbapenemaseproduce VERB dti-2622 157 12 enterobacteriaceae enterobacteriaceae PROPN dti-2622 157 13 . . PUNCT dti-2622 158 1 virulence virulence NOUN dti-2622 158 2 . . PUNCT dti-2622 159 1 2017;8(4):460 2017;8(4):460 NUM dti-2622 159 2 - - SYM dti-2622 159 3 469 469 NUM dti-2622 159 4 . . PUNCT dti-2622 160 1 crossref crossref PROPN dti-2622 160 2 pubmed pubmed PROPN dti-2622 160 3 4 4 PROPN dti-2622 160 4 . . PUNCT dti-2622 160 5 tängdén tängdén PROPN dti-2622 160 6 t t PROPN dti-2622 160 7 , , PUNCT dti-2622 160 8 giske giske PROPN dti-2622 160 9 cg cg PROPN dti-2622 160 10 . . PUNCT dti-2622 161 1 global global ADJ dti-2622 161 2 dissemination dissemination NOUN dti-2622 161 3 of of ADP dti-2622 161 4 extensively extensively ADV dti-2622 161 5 drugresistant drugresistant ADJ dti-2622 161 6 carbapenemase carbapenemase NOUN dti-2622 161 7 - - PUNCT dti-2622 161 8 producing produce VERB dti-2622 161 9 enterobacteriaceae enterobacteriaceae NOUN dti-2622 161 10 : : PUNCT dti-2622 161 11 clinical clinical ADJ dti-2622 161 12 perspectives perspective NOUN dti-2622 161 13 on on ADP dti-2622 161 14 detection detection NOUN dti-2622 161 15 , , PUNCT dti-2622 161 16 treatment treatment NOUN dti-2622 161 17 and and CCONJ dti-2622 161 18 infection infection NOUN dti-2622 161 19 control control NOUN dti-2622 161 20 . . PUNCT dti-2622 162 1 j j PROPN dti-2622 162 2 intern intern PROPN dti-2622 162 3 med me VERB dti-2622 162 4 . . PUNCT dti-2622 163 1 2015;277(5):501 2015;277(5):501 NUM dti-2622 163 2 - - PUNCT dti-2622 163 3 512 512 NUM dti-2622 163 4 . . PUNCT dti-2622 164 1 crossref crossref PROPN dti-2622 164 2 pubmed pubmed PROPN dti-2622 164 3 5 5 PROPN dti-2622 164 4 . . PUNCT dti-2622 165 1 tzouvelekis tzouvelekis PROPN dti-2622 165 2 ls ls PROPN dti-2622 165 3 , , PUNCT dti-2622 165 4 markogiannakis markogiannakis PROPN dti-2622 165 5 a a PRON dti-2622 165 6 , , PUNCT dti-2622 165 7 psichogiou psichogiou NOUN dti-2622 165 8 m m PROPN dti-2622 165 9 , , PUNCT dti-2622 165 10 tassios tassio VERB dti-2622 165 11 pt pt PROPN dti-2622 165 12 , , PUNCT dti-2622 165 13 daikos daikos PROPN dti-2622 165 14 gl gl PROPN dti-2622 165 15 . . PROPN dti-2622 165 16 carbapenemases carbapenemase NOUN dti-2622 165 17 in in ADP dti-2622 165 18 klebsiella klebsiella NOUN dti-2622 165 19 pneumoniae pneumoniae NOUN dti-2622 165 20 and and CCONJ dti-2622 165 21 other other ADJ dti-2622 165 22 enterobacteriaceae enterobacteriaceae PROPN dti-2622 165 23 : : PUNCT dti-2622 165 24 an an DET dti-2622 165 25 evolving evolve VERB dti-2622 165 26 crisis crisis NOUN dti-2622 165 27 of of ADP dti-2622 165 28 global global ADJ dti-2622 165 29 dimensions dimension NOUN dti-2622 165 30 . . PUNCT dti-2622 166 1 clin clin PROPN dti-2622 166 2 microbiol microbiol PROPN dti-2622 166 3 rev rev VERB dti-2622 166 4 . . PUNCT dti-2622 167 1 2012;25(4):682 2012;25(4):682 NUM dti-2622 167 2 - - PUNCT dti-2622 167 3 707 707 NUM dti-2622 167 4 . . PUNCT dti-2622 168 1 crossref crossref PROPN dti-2622 168 2 pubmed pubmed PROPN dti-2622 168 3 6 6 NUM dti-2622 168 4 . . PUNCT dti-2622 169 1 cantón cantón PROPN dti-2622 169 2 r r PROPN dti-2622 169 3 , , PUNCT dti-2622 169 4 akóva akóva PROPN dti-2622 169 5 m m PROPN dti-2622 169 6 , , PUNCT dti-2622 169 7 carmeli carmeli PROPN dti-2622 169 8 y y PROPN dti-2622 169 9 , , PUNCT dti-2622 169 10 et et PROPN dti-2622 169 11 al al PROPN dti-2622 169 12 ; ; PUNCT dti-2622 169 13 european european ADJ dti-2622 169 14 network network NOUN dti-2622 169 15 on on ADP dti-2622 169 16 carbapenemases carbapenemase NOUN dti-2622 169 17 . . PUNCT dti-2622 170 1 rapid rapid ADJ dti-2622 170 2 evolution evolution NOUN dti-2622 170 3 and and CCONJ dti-2622 170 4 spread spread VERB dti-2622 170 5 of of ADP dti-2622 170 6 carbapenemases carbapenemase NOUN dti-2622 170 7 among among ADP dti-2622 170 8 enterobacteriaceae enterobacteriaceae PROPN dti-2622 170 9 in in ADP dti-2622 170 10 europe europe PROPN dti-2622 170 11 . . PUNCT dti-2622 171 1 clin clin PROPN dti-2622 171 2 microbiol microbiol PROPN dti-2622 171 3 infect infect VERB dti-2622 171 4 . . PUNCT dti-2622 172 1 2012;18(5):413 2012;18(5):413 NUM dti-2622 172 2 - - PUNCT dti-2622 172 3 431 431 NUM dti-2622 172 4 . . PUNCT dti-2622 173 1 crossref crossref PROPN dti-2622 173 2 pubmed pubmed PROPN dti-2622 173 3 7 7 PROPN dti-2622 173 4 . . PUNCT dti-2622 174 1 tamma tamma PROPN dti-2622 174 2 pd pd PROPN dti-2622 174 3 , , PUNCT dti-2622 174 4 hsu hsu PROPN dti-2622 174 5 aj aj PROPN dti-2622 174 6 . . PUNCT dti-2622 174 7 defining define VERB dti-2622 174 8 the the DET dti-2622 174 9 role role NOUN dti-2622 174 10 of of ADP dti-2622 174 11 novel novel ADJ dti-2622 174 12 β β NOUN dti-2622 174 13 - - NOUN dti-2622 174 14 lactam lactam ADJ dti-2622 174 15 agents agent NOUN dti-2622 174 16 that that PRON dti-2622 174 17 target target VERB dti-2622 174 18 carbapenem carbapenem NOUN dti-2622 174 19 - - PUNCT dti-2622 174 20 resistant resistant ADJ dti-2622 174 21 gram gram NOUN dti-2622 174 22 - - PUNCT dti-2622 174 23 negative negative ADJ dti-2622 174 24 organisms organism NOUN dti-2622 174 25 . . PUNCT dti-2622 175 1 j j PROPN dti-2622 175 2 pediatric pediatric ADJ dti-2622 175 3 infect infect PROPN dti-2622 175 4 dis dis PROPN dti-2622 175 5 soc soc PROPN dti-2622 175 6 . . PUNCT dti-2622 176 1 2019;8(3):251 2019;8(3):251 X dti-2622 176 2 - - SYM dti-2622 176 3 260 260 NUM dti-2622 176 4 . . PUNCT dti-2622 177 1 crossref crossref PROPN dti-2622 177 2 pubmed pubmed PROPN dti-2622 177 3 8 8 PROPN dti-2622 177 4 . . PUNCT dti-2622 178 1 paul paul PROPN dti-2622 178 2 m m PROPN dti-2622 178 3 , , PUNCT dti-2622 178 4 carrara carrara ADJ dti-2622 178 5 e e NOUN dti-2622 178 6 , , PUNCT dti-2622 178 7 retamar retamar PROPN dti-2622 178 8 p p X dti-2622 178 9 , , PUNCT dti-2622 178 10 et et PROPN dti-2622 178 11 al al PROPN dti-2622 178 12 . . PUNCT dti-2622 179 1 european european PROPN dti-2622 179 2 society society PROPN dti-2622 179 3 of of ADP dti-2622 179 4 clinical clinical ADJ dti-2622 179 5 microbiology microbiology NOUN dti-2622 179 6 and and CCONJ dti-2622 179 7 infectious infectious ADJ dti-2622 179 8 diseases disease NOUN dti-2622 179 9 ( ( PUNCT dti-2622 179 10 escmid escmid NOUN dti-2622 179 11 ) ) PUNCT dti-2622 179 12 guidelines guideline NOUN dti-2622 179 13 for for ADP dti-2622 179 14 the the DET dti-2622 179 15 treatment treatment NOUN dti-2622 179 16 of of ADP dti-2622 179 17 infections infection NOUN dti-2622 179 18 caused cause VERB dti-2622 179 19 by by ADP dti-2622 179 20 multidrug multidrug NOUN dti-2622 179 21 - - PUNCT dti-2622 179 22 resistant resistant ADJ dti-2622 179 23 gram gram NOUN dti-2622 179 24 - - PUNCT dti-2622 179 25 negative negative ADJ dti-2622 179 26 bacilli bacilli NOUN dti-2622 179 27 ( ( PUNCT dti-2622 179 28 endorsed endorse VERB dti-2622 179 29 by by ADP dti-2622 179 30 european european ADJ dti-2622 179 31 society society NOUN dti-2622 179 32 of of ADP dti-2622 179 33 intensive intensive ADJ dti-2622 179 34 care care NOUN dti-2622 179 35 medicine medicine NOUN dti-2622 179 36 ) ) PUNCT dti-2622 179 37 . . PUNCT dti-2622 180 1 clin clin PROPN dti-2622 180 2 microbiol microbiol PROPN dti-2622 180 3 infect infect VERB dti-2622 180 4 . . PUNCT dti-2622 181 1 2022;28(4):521547 2022;28(4):521547 NUM dti-2622 181 2 . . PUNCT dti-2622 182 1 crossref crossref PROPN dti-2622 182 2 pubmed pubmed PROPN dti-2622 182 3 9 9 PROPN dti-2622 182 4 . . PUNCT dti-2622 183 1 sheu sheu PROPN dti-2622 183 2 cc cc PROPN dti-2622 183 3 , , PUNCT dti-2622 183 4 chang chang PROPN dti-2622 183 5 yt yt PROPN dti-2622 183 6 , , PUNCT dti-2622 183 7 lin lin PROPN dti-2622 183 8 sy sy PROPN dti-2622 183 9 , , PUNCT dti-2622 183 10 chen chen PROPN dti-2622 183 11 yh yh PROPN dti-2622 183 12 , , PUNCT dti-2622 183 13 hsueh hsueh PROPN dti-2622 183 14 pr pr PROPN dti-2622 183 15 . . PUNCT dti-2622 184 1 infections infection NOUN dti-2622 184 2 caused cause VERB dti-2622 184 3 by by ADP dti-2622 184 4 carbapenem carbapenem NOUN dti-2622 184 5 - - PUNCT dti-2622 184 6 resistant resistant ADJ dti-2622 184 7 enterobacteriaceae enterobacteriaceae NOUN dti-2622 184 8 : : PUNCT dti-2622 184 9 an an DET dti-2622 184 10 update update NOUN dti-2622 184 11 on on ADP dti-2622 184 12 therapeutic therapeutic ADJ dti-2622 184 13 options option NOUN dti-2622 184 14 . . PUNCT dti-2622 185 1 front front ADJ dti-2622 185 2 microbiol microbiol NOUN dti-2622 185 3 . . PUNCT dti-2622 186 1 2019;10:80 2019;10:80 NUM dti-2622 186 2 . . PUNCT dti-2622 187 1 crossref crossref PROPN dti-2622 187 2 pubmed pubmed PROPN dti-2622 187 3 10 10 PROPN dti-2622 187 4 . . PUNCT dti-2622 188 1 doi doi PROPN dti-2622 188 2 y. y. PROPN dti-2622 188 3 treatment treatment NOUN dti-2622 188 4 options option NOUN dti-2622 188 5 for for ADP dti-2622 188 6 carbapenem carbapenem NOUN dti-2622 188 7 - - PUNCT dti-2622 188 8 resistant resistant ADJ dti-2622 188 9 gramnegative gramnegative ADJ dti-2622 188 10 bacterial bacterial ADJ dti-2622 188 11 infections infection NOUN dti-2622 188 12 . . PUNCT dti-2622 189 1 clin clin PROPN dti-2622 189 2 infect infect PROPN dti-2622 189 3 dis dis PROPN dti-2622 189 4 . . PUNCT dti-2622 190 1 2019;69(suppl 2019;69(suppl PROPN dti-2622 190 2 7 7 NUM dti-2622 190 3 ): ): PUNCT dti-2622 190 4 s565 s565 PROPN dti-2622 190 5 - - PUNCT dti-2622 190 6 s575 s575 PROPN dti-2622 190 7 . . PUNCT dti-2622 191 1 crossref crossref PROPN dti-2622 191 2 pubmed pubmed PROPN dti-2622 191 3 11 11 NUM dti-2622 191 4 . . PUNCT dti-2622 192 1 garbati garbati PROPN dti-2622 192 2 ma ma PROPN dti-2622 192 3 , , PUNCT dti-2622 192 4 sakkijha sakkijha PROPN dti-2622 192 5 h h PROPN dti-2622 192 6 , , PUNCT dti-2622 192 7 abushaheen abushaheen ADJ dti-2622 192 8 a. a. NOUN dti-2622 192 9 infections infection NOUN dti-2622 192 10 due due ADJ dti-2622 192 11 to to ADP dti-2622 192 12 carbapenem carbapenem PROPN dti-2622 192 13 resistant resistant ADJ dti-2622 192 14 enterobacteriaceae enterobacteriaceae NOUN dti-2622 192 15 among among ADP dti-2622 192 16 saudi saudi ADJ dti-2622 192 17 arabian arabian ADJ dti-2622 192 18 hospitalized hospitalize VERB dti-2622 192 19 patients patient NOUN dti-2622 192 20 : : PUNCT dti-2622 192 21 a a DET dti-2622 192 22 matched match VERB dti-2622 192 23 case case NOUN dti-2622 192 24 - - PUNCT dti-2622 192 25 control control NOUN dti-2622 192 26 study study NOUN dti-2622 192 27 . . PUNCT dti-2622 193 1 biomed biome VERB dti-2622 193 2 res re NOUN dti-2622 193 3 int int NOUN dti-2622 193 4 . . PUNCT dti-2622 194 1 2016;2016:3961684 2016;2016:3961684 NUM dti-2622 194 2 . . PUNCT dti-2622 195 1 crossref crossref PROPN dti-2622 195 2 pubmed pubmed PROPN dti-2622 195 3 12 12 NUM dti-2622 195 4 . . PUNCT dti-2622 196 1 de de PROPN dti-2622 196 2 maio maio PROPN dti-2622 196 3 carrilho carrilho PROPN dti-2622 196 4 cm cm PROPN dti-2622 196 5 , , PUNCT dti-2622 196 6 de de PROPN dti-2622 196 7 oliveira oliveira PROPN dti-2622 196 8 lm lm PROPN dti-2622 196 9 , , PUNCT dti-2622 196 10 gaudereto gaudereto PROPN dti-2622 196 11 j j PROPN dti-2622 196 12 , , PUNCT dti-2622 196 13 et et PROPN dti-2622 196 14 al al PROPN dti-2622 196 15 . . PUNCT dti-2622 197 1 a a DET dti-2622 197 2 prospective prospective ADJ dti-2622 197 3 study study NOUN dti-2622 197 4 of of ADP dti-2622 197 5 treatment treatment NOUN dti-2622 197 6 of of ADP dti-2622 197 7 carbapenem carbapenem NOUN dti-2622 197 8 - - PUNCT dti-2622 197 9 resistant resistant ADJ dti-2622 197 10 enterobacteriaceae enterobacteriaceae NOUN dti-2622 197 11 infections infection NOUN dti-2622 197 12 and and CCONJ dti-2622 197 13 risk risk NOUN dti-2622 197 14 factors factor NOUN dti-2622 197 15 associated associate VERB dti-2622 197 16 with with ADP dti-2622 197 17 outcome outcome NOUN dti-2622 197 18 . . PUNCT dti-2622 198 1 bmc bmc PROPN dti-2622 198 2 infect infect PROPN dti-2622 198 3 dis dis PROPN dti-2622 198 4 . . PUNCT dti-2622 199 1 2016;16(1):629 2016;16(1):629 PROPN dti-2622 199 2 . . PUNCT dti-2622 200 1 crossref crossref PROPN dti-2622 200 2 pubmed pubmed PROPN dti-2622 200 3 13 13 NUM dti-2622 200 4 . . PUNCT dti-2622 201 1 li li PROPN dti-2622 201 2 c c PROPN dti-2622 201 3 , , PUNCT dti-2622 201 4 li li PROPN dti-2622 201 5 y y PROPN dti-2622 201 6 , , PUNCT dti-2622 201 7 zhao zhao PROPN dti-2622 201 8 z z PROPN dti-2622 201 9 , , PUNCT dti-2622 201 10 liu liu PROPN dti-2622 201 11 q q PROPN dti-2622 201 12 , , PUNCT dti-2622 201 13 li li PROPN dti-2622 201 14 b. b. PROPN dti-2622 201 15 treatment treatment PROPN dti-2622 201 16 options option NOUN dti-2622 201 17 and and CCONJ dti-2622 201 18 clinical clinical ADJ dti-2622 201 19 outcomes outcome NOUN dti-2622 201 20 for for ADP dti-2622 201 21 carbapenem carbapenem NOUN dti-2622 201 22 - - PUNCT dti-2622 201 23 resistant resistant ADJ dti-2622 201 24 enterobacteriaceae enterobacteriaceae NOUN dti-2622 201 25 bloodstream bloodstream NOUN dti-2622 201 26 infection infection NOUN dti-2622 201 27 in in ADP dti-2622 201 28 a a DET dti-2622 201 29 chinese chinese ADJ dti-2622 201 30 university university NOUN dti-2622 201 31 hospital hospital NOUN dti-2622 201 32 . . PUNCT dti-2622 202 1 j j PROPN dti-2622 202 2 infect infect VERB dti-2622 202 3 public public ADJ dti-2622 202 4 health health NOUN dti-2622 202 5 . . PUNCT dti-2622 203 1 2019;12(1):26 2019;12(1):26 X dti-2622 203 2 - - SYM dti-2622 203 3 31 31 NUM dti-2622 203 4 . . PUNCT dti-2622 204 1 crossref crossref PROPN dti-2622 204 2 pubmed pubmed PROPN dti-2622 204 3 14 14 PROPN dti-2622 204 4 . . PUNCT dti-2622 205 1 lim lim PROPN dti-2622 205 2 fk fk PROPN dti-2622 205 3 , , PUNCT dti-2622 205 4 liew liew PROPN dti-2622 205 5 yx yx PROPN dti-2622 205 6 , , PUNCT dti-2622 205 7 cai cai PROPN dti-2622 205 8 y y PROPN dti-2622 205 9 , , PUNCT dti-2622 205 10 et et PROPN dti-2622 205 11 al al PROPN dti-2622 205 12 . . PUNCT dti-2622 205 13 treatment treatment NOUN dti-2622 205 14 and and CCONJ dti-2622 205 15 outcomes outcome NOUN dti-2622 205 16 of of ADP dti-2622 205 17 infections infection NOUN dti-2622 205 18 caused cause VERB dti-2622 205 19 by by ADP dti-2622 205 20 diverse diverse ADJ dti-2622 205 21 carbapenemase carbapenemase NOUN dti-2622 205 22 - - PUNCT dti-2622 205 23 producing produce VERB dti-2622 205 24 carbapenem carbapenem NOUN dti-2622 205 25 - - PUNCT dti-2622 205 26 resistant resistant ADJ dti-2622 205 27 enterobacterales enterobacterale NOUN dti-2622 205 28 . . PUNCT dti-2622 206 1 front front ADJ dti-2622 206 2 cell cell NOUN dti-2622 206 3 infect infect VERB dti-2622 206 4 microbiol microbiol NOUN dti-2622 206 5 . . PUNCT dti-2622 207 1 2020;10:579462 2020;10:579462 X dti-2622 207 2 . . PUNCT dti-2622 208 1 crossref crossref PROPN dti-2622 208 2 pubmed pubmed PROPN dti-2622 208 3 15 15 NUM dti-2622 208 4 . . PUNCT dti-2622 209 1 seo seo NOUN dti-2622 209 2 h h PROPN dti-2622 209 3 , , PUNCT dti-2622 209 4 lee lee PROPN dti-2622 209 5 sc sc PROPN dti-2622 209 6 , , PUNCT dti-2622 209 7 chung chung PROPN dti-2622 209 8 h h PROPN dti-2622 209 9 , , PUNCT dti-2622 209 10 et et PROPN dti-2622 209 11 al al PROPN dti-2622 209 12 . . PROPN dti-2622 210 1 clinical clinical ADJ dti-2622 210 2 and and CCONJ dti-2622 210 3 microbiological microbiological ADJ dti-2622 210 4 analysis analysis NOUN dti-2622 210 5 of of ADP dti-2622 210 6 risk risk NOUN dti-2622 210 7 factors factor NOUN dti-2622 210 8 for for ADP dti-2622 210 9 mortality mortality NOUN dti-2622 210 10 in in ADP dti-2622 210 11 patients patient NOUN dti-2622 210 12 with with ADP dti-2622 210 13 carbapenem carbapenem NOUN dti-2622 210 14 - - PUNCT dti-2622 210 15 resistant resistant ADJ dti-2622 210 16 enterobacteriaceae enterobacteriaceae NOUN dti-2622 210 17 bacteremia bacteremia NOUN dti-2622 210 18 . . PUNCT dti-2622 211 1 int int NOUN dti-2622 211 2 j j PROPN dti-2622 211 3 antimicrob antimicrob PROPN dti-2622 211 4 agents agent NOUN dti-2622 211 5 . . PUNCT dti-2622 212 1 2020;56(4):106126 2020;56(4):106126 X dti-2622 212 2 . . PUNCT dti-2622 213 1 crossref crossref PROPN dti-2622 213 2 pubmed pubmed PROPN dti-2622 213 3 16 16 NUM dti-2622 213 4 . . PUNCT dti-2622 214 1 daikos daikos PROPN dti-2622 214 2 gl gl PROPN dti-2622 214 3 , , PUNCT dti-2622 214 4 tsaousi tsaousi PROPN dti-2622 214 5 s s PROPN dti-2622 214 6 , , PUNCT dti-2622 214 7 tzouvelekis tzouvelekis PROPN dti-2622 214 8 ls ls PROPN dti-2622 214 9 , , PUNCT dti-2622 214 10 et et PROPN dti-2622 214 11 al al PROPN dti-2622 214 12 . . PUNCT dti-2622 215 1 carbapenemaseproducing carbapenemaseproduce VERB dti-2622 215 2 klebsiella klebsiella NOUN dti-2622 215 3 pneumoniae pneumoniae ADJ dti-2622 215 4 bloodstream bloodstream NOUN dti-2622 215 5 infections infection NOUN dti-2622 215 6 : : PUNCT dti-2622 215 7 lowering lower VERB dti-2622 215 8 mortality mortality NOUN dti-2622 215 9 by by ADP dti-2622 215 10 antibiotic antibiotic ADJ dti-2622 215 11 combination combination NOUN dti-2622 215 12 schemes scheme NOUN dti-2622 215 13 and and CCONJ dti-2622 215 14 the the DET dti-2622 215 15 role role NOUN dti-2622 215 16 of of ADP dti-2622 215 17 carbapenems carbapenem NOUN dti-2622 215 18 . . PUNCT dti-2622 216 1 antimicrob antimicrob PROPN dti-2622 216 2 agents agents PROPN dti-2622 216 3 chemother chemother PROPN dti-2622 216 4 . . PUNCT dti-2622 217 1 2014;58(4):2322 2014;58(4):2322 PROPN dti-2622 217 2 - - PUNCT dti-2622 217 3 2328 2328 NUM dti-2622 217 4 . . PUNCT dti-2622 218 1 crossref crossref PROPN dti-2622 218 2 pubmed pubmed PROPN dti-2622 218 3 17 17 NUM dti-2622 218 4 . . PUNCT dti-2622 219 1 tumbarello tumbarello PROPN dti-2622 219 2 m m PROPN dti-2622 219 3 , , PUNCT dti-2622 219 4 trecarichi trecarichi VERB dti-2622 219 5 em em PRON dti-2622 219 6 , , PUNCT dti-2622 219 7 de de PROPN dti-2622 219 8 rosa rosa PROPN dti-2622 219 9 fg fg PROPN dti-2622 219 10 , , PUNCT dti-2622 219 11 et et PROPN dti-2622 219 12 al al PROPN dti-2622 219 13 ; ; PUNCT dti-2622 219 14 isgri isgri NOUN dti-2622 219 15 - - PUNCT dti-2622 219 16 sita sita NOUN dti-2622 219 17 ( ( PUNCT dti-2622 219 18 italian italian ADJ dti-2622 219 19 study study NOUN dti-2622 219 20 group group NOUN dti-2622 219 21 on on ADP dti-2622 219 22 resistant resistant ADJ dti-2622 219 23 infections infection NOUN dti-2622 219 24 of of ADP dti-2622 219 25 the the DET dti-2622 219 26 società società ADJ dti-2622 219 27 italiana italiana PROPN dti-2622 219 28 terapia terapia PROPN dti-2622 219 29 antinfettiva antinfettiva PROPN dti-2622 219 30 ) ) PUNCT dti-2622 219 31 . . PUNCT dti-2622 220 1 infections infection NOUN dti-2622 220 2 caused cause VERB dti-2622 220 3 by by ADP dti-2622 220 4 kpcproducing kpcproduce VERB dti-2622 220 5 klebsiella klebsiella NOUN dti-2622 220 6 pneumoniae pneumoniae NOUN dti-2622 220 7 : : PUNCT dti-2622 220 8 differences difference NOUN dti-2622 220 9 in in ADP dti-2622 220 10 therapy therapy NOUN dti-2622 220 11 and and CCONJ dti-2622 220 12 mortality mortality NOUN dti-2622 220 13 in in ADP dti-2622 220 14 a a DET dti-2622 220 15 multicentre multicentre NOUN dti-2622 220 16 study study NOUN dti-2622 220 17 . . PUNCT dti-2622 221 1 j j PROPN dti-2622 221 2 antimicrob antimicrob PROPN dti-2622 221 3 chemother chemother PROPN dti-2622 221 4 . . PUNCT dti-2622 222 1 2015;70(7):2133 2015;70(7):2133 NUM dti-2622 222 2 - - SYM dti-2622 222 3 2143 2143 NUM dti-2622 222 4 . . PUNCT dti-2622 223 1 crossref crossref PROPN dti-2622 223 2 pubmed pubmed PROPN dti-2622 223 3 18 18 NUM dti-2622 223 4 . . PUNCT dti-2622 224 1 clinical clinical ADJ dti-2622 224 2 and and CCONJ dti-2622 224 3 laboratory laboratory NOUN dti-2622 224 4 standards standards PROPN dti-2622 224 5 institute institute PROPN dti-2622 224 6 . . PUNCT dti-2622 225 1 methods method NOUN dti-2622 225 2 for for ADP dti-2622 225 3 dilution dilution NOUN dti-2622 225 4 of of ADP dti-2622 225 5 antimicrobial antimicrobial ADJ dti-2622 225 6 susceptibility susceptibility NOUN dti-2622 225 7 tests test NOUN dti-2622 225 8 for for ADP dti-2622 225 9 bacteria bacteria NOUN dti-2622 225 10 that that PRON dti-2622 225 11 grow grow VERB dti-2622 225 12 aerobically aerobically ADV dti-2622 225 13 ; ; PUNCT dti-2622 225 14 approved approve VERB dti-2622 225 15 standard—10th standard—10th PROPN dti-2622 225 16 edition edition PROPN dti-2622 225 17 . . PUNCT dti-2622 226 1 clsi clsi PROPN dti-2622 226 2 document document NOUN dti-2622 226 3 m07 m07 NOUN dti-2622 226 4 - - PUNCT dti-2622 226 5 a10 a10 NOUN dti-2622 226 6 . . PUNCT dti-2622 227 1 clinical clinical ADJ dti-2622 227 2 and and CCONJ dti-2622 227 3 laboratory laboratory NOUN dti-2622 227 4 standards standards PROPN dti-2622 227 5 institute institute PROPN dti-2622 227 6 , , PUNCT dti-2622 227 7 wayne wayne PROPN dti-2622 227 8 , , PUNCT dti-2622 227 9 pa pa PROPN dti-2622 227 10 ; ; PUNCT dti-2622 227 11 2015 2015 NUM dti-2622 227 12 . . PUNCT dti-2622 228 1 19 19 NUM dti-2622 228 2 . . X dti-2622 228 3 trecarichi trecarichi PROPN dti-2622 228 4 em em PRON dti-2622 228 5 , , PUNCT dti-2622 228 6 tumbarello tumbarello PROPN dti-2622 228 7 m. m. NOUN dti-2622 228 8 therapeutic therapeutic ADJ dti-2622 228 9 options option NOUN dti-2622 228 10 for for ADP dti-2622 228 11 carbapenem carbapenem NOUN dti-2622 228 12 - - PUNCT dti-2622 228 13 resistant resistant ADJ dti-2622 228 14 enterobacteriaceae enterobacteriaceae NOUN dti-2622 228 15 infections infection NOUN dti-2622 228 16 . . PUNCT dti-2622 229 1 virulence virulence NOUN dti-2622 229 2 . . PUNCT dti-2622 230 1 2017;8(4):470 2017;8(4):470 X dti-2622 230 2 - - SYM dti-2622 230 3 484 484 NUM dti-2622 230 4 . . PUNCT dti-2622 231 1 crossref crossref PROPN dti-2622 231 2 pubmed pubmed PROPN dti-2622 231 3 20 20 NUM dti-2622 231 4 . . PUNCT dti-2622 232 1 marchaim marchaim PROPN dti-2622 232 2 d d PROPN dti-2622 232 3 , , PUNCT dti-2622 232 4 chopra chopra PROPN dti-2622 232 5 t t PROPN dti-2622 232 6 , , PUNCT dti-2622 232 7 perez perez PROPN dti-2622 232 8 f f PROPN dti-2622 232 9 , , PUNCT dti-2622 232 10 et et PROPN dti-2622 232 11 al al PROPN dti-2622 232 12 . . PUNCT dti-2622 233 1 outcomes outcome NOUN dti-2622 233 2 and and CCONJ dti-2622 233 3 genetic genetic ADJ dti-2622 233 4 relatedness relatedness NOUN dti-2622 233 5 of of ADP dti-2622 233 6 carbapenem carbapenem NOUN dti-2622 233 7 - - PUNCT dti-2622 233 8 resistant resistant ADJ dti-2622 233 9 enterobacteriaceae enterobacteriaceae PROPN dti-2622 233 10 at at ADP dti-2622 233 11 detroit detroit PROPN dti-2622 233 12 medical medical PROPN dti-2622 233 13 center center PROPN dti-2622 233 14 . . PUNCT dti-2622 234 1 infect infect VERB dti-2622 234 2 control control PROPN dti-2622 234 3 hosp hosp PROPN dti-2622 234 4 epidemiol epidemiol PROPN dti-2622 234 5 . . PUNCT dti-2622 235 1 2011;32(9 2011;32(9 NUM dti-2622 235 2 ): ): PUNCT dti-2622 235 3 861 861 NUM dti-2622 235 4 - - SYM dti-2622 235 5 871 871 NUM dti-2622 235 6 . . PUNCT dti-2622 236 1 crossref crossref PROPN dti-2622 236 2 pubmed pubmed PROPN dti-2622 236 3 21 21 NUM dti-2622 236 4 . . PUNCT dti-2622 237 1 correa correa PROPN dti-2622 237 2 l l PROPN dti-2622 237 3 , , PUNCT dti-2622 237 4 martino martino PROPN dti-2622 237 5 md md PROPN dti-2622 237 6 , , PUNCT dti-2622 237 7 siqueira siqueira PROPN dti-2622 237 8 i i PRON dti-2622 237 9 , , PUNCT dti-2622 237 10 et et PROPN dti-2622 237 11 al al PROPN dti-2622 237 12 . . PUNCT dti-2622 238 1 a a DET dti-2622 238 2 hospital hospital NOUN dti-2622 238 3 - - PUNCT dti-2622 238 4 based base VERB dti-2622 238 5 matched match VERB dti-2622 238 6 case case NOUN dti-2622 238 7 - - PUNCT dti-2622 238 8 control control NOUN dti-2622 238 9 study study NOUN dti-2622 238 10 to to PART dti-2622 238 11 identify identify VERB dti-2622 238 12 clinical clinical ADJ dti-2622 238 13 outcome outcome NOUN dti-2622 238 14 and and CCONJ dti-2622 238 15 risk risk NOUN dti-2622 238 16 factors factor NOUN dti-2622 238 17 associated associate VERB dti-2622 238 18 with with ADP dti-2622 238 19 carbapenem carbapenem NOUN dti-2622 238 20 - - PUNCT dti-2622 238 21 resistant resistant ADJ dti-2622 238 22 klebsiella klebsiella NOUN dti-2622 238 23 pneumoniae pneumoniae ADJ dti-2622 238 24 infection infection NOUN dti-2622 238 25 . . PUNCT dti-2622 239 1 bmc bmc PROPN dti-2622 239 2 infect infect PROPN dti-2622 239 3 dis dis PROPN dti-2622 239 4 . . PUNCT dti-2622 240 1 2013;13(1):80 2013;13(1):80 X dti-2622 240 2 . . PUNCT dti-2622 241 1 crossref crossref PROPN dti-2622 241 2 pubmed pubmed PROPN dti-2622 241 3 22 22 PROPN dti-2622 241 4 . . PUNCT dti-2622 242 1 kontopidou kontopidou PROPN dti-2622 243 1 f f X dti-2622 243 2 , , PUNCT dti-2622 243 3 giamarellou giamarellou ADJ dti-2622 243 4 h h NOUN dti-2622 243 5 , , PUNCT dti-2622 243 6 katerelos katerelos PROPN dti-2622 243 7 p p PROPN dti-2622 243 8 , , PUNCT dti-2622 243 9 et et PROPN dti-2622 243 10 al al PROPN dti-2622 243 11 ; ; PUNCT dti-2622 243 12 group group NOUN dti-2622 243 13 for for ADP dti-2622 243 14 the the DET dti-2622 243 15 study study NOUN dti-2622 243 16 of of ADP dti-2622 243 17 kpc kpc NOUN dti-2622 243 18 - - PUNCT dti-2622 243 19 producing produce VERB dti-2622 243 20 klebsiella klebsiella NOUN dti-2622 243 21 pneumoniae pneumoniae ADJ dti-2622 243 22 infections infection NOUN dti-2622 243 23 in in ADP dti-2622 243 24 intensive intensive ADJ dti-2622 243 25 care care NOUN dti-2622 243 26 units unit NOUN dti-2622 243 27 . . PUNCT dti-2622 244 1 infections infection NOUN dti-2622 244 2 caused cause VERB dti-2622 244 3 by by ADP dti-2622 244 4 carbapenem carbapenem NOUN dti-2622 244 5 - - PUNCT dti-2622 244 6 resistant resistant ADJ dti-2622 244 7 klebsiella klebsiella NOUN dti-2622 244 8 pneumoniae pneumoniae ADJ dti-2622 244 9 among among ADP dti-2622 244 10 patients patient NOUN dti-2622 244 11 in in ADP dti-2622 244 12 intensive intensive ADJ dti-2622 244 13 care care NOUN dti-2622 244 14 units unit NOUN dti-2622 244 15 in in ADP dti-2622 244 16 greece greece PROPN dti-2622 244 17 : : PUNCT dti-2622 244 18 a a DET dti-2622 244 19 multi multi ADJ dti-2622 244 20 - - ADJ dti-2622 244 21 centre centre ADJ dti-2622 244 22 study study NOUN dti-2622 244 23 on on ADP dti-2622 244 24 clinical clinical ADJ dti-2622 244 25 outcome outcome NOUN dti-2622 244 26 and and CCONJ dti-2622 244 27 therapeutic therapeutic ADJ dti-2622 244 28 options option NOUN dti-2622 244 29 . . PUNCT dti-2622 245 1 clin clin PROPN dti-2622 245 2 microbiol microbiol PROPN dti-2622 245 3 infect infect PROPN dti-2622 245 4 . . PUNCT dti-2622 246 1 2014;20(2):o117 2014;20(2):o117 NUM dti-2622 246 2 - - PUNCT dti-2622 246 3 o123 o123 PROPN dti-2622 246 4 . . PUNCT dti-2622 247 1 crossref crossref PROPN dti-2622 247 2 pubmed pubmed PROPN dti-2622 247 3 23 23 NUM dti-2622 247 4 . . PUNCT dti-2622 247 5 hu hu PROPN dti-2622 248 1 q q PROPN dti-2622 248 2 , , PUNCT dti-2622 248 3 chen chen PROPN dti-2622 248 4 j j PROPN dti-2622 248 5 , , PUNCT dti-2622 248 6 sun sun PROPN dti-2622 248 7 s s PROPN dti-2622 248 8 , , PUNCT dti-2622 248 9 deng deng PROPN dti-2622 248 10 s. s. PROPN dti-2622 248 11 mortality mortality PROPN dti-2622 248 12 - - PUNCT dti-2622 248 13 related relate VERB dti-2622 248 14 risk risk NOUN dti-2622 248 15 factors factor NOUN dti-2622 248 16 and and CCONJ dti-2622 248 17 novel novel ADJ dti-2622 248 18 antimicrobial antimicrobial ADJ dti-2622 248 19 regimens regimen NOUN dti-2622 248 20 for for ADP dti-2622 248 21 carbapenem carbapenem NOUN dti-2622 248 22 - - PUNCT dti-2622 248 23 resistant resistant ADJ dti-2622 248 24 enterobacteriaceae enterobacteriaceae NOUN dti-2622 248 25 infections infection NOUN dti-2622 248 26 : : PUNCT dti-2622 248 27 a a DET dti-2622 248 28 systematic systematic ADJ dti-2622 248 29 review review NOUN dti-2622 248 30 . . PUNCT dti-2622 249 1 infect infect VERB dti-2622 249 2 drug drug NOUN dti-2622 249 3 resist resist NOUN dti-2622 249 4 . . PUNCT dti-2622 250 1 2022;15:6907 2022;15:6907 X dti-2622 250 2 - - SYM dti-2622 250 3 6926 6926 NUM dti-2622 250 4 . . PUNCT dti-2622 251 1 crossref crossref PROPN dti-2622 251 2 pubmed pubmed PROPN dti-2622 251 3 24 24 NUM dti-2622 251 4 . . PUNCT dti-2622 252 1 hakeam hakeam PROPN dti-2622 252 2 ha ha PROPN dti-2622 252 3 , , PUNCT dti-2622 252 4 alsahli alsahli NOUN dti-2622 252 5 h h NOUN dti-2622 252 6 , , PUNCT dti-2622 252 7 albabtain albabtain NOUN dti-2622 252 8 l l NOUN dti-2622 252 9 , , PUNCT dti-2622 252 10 alassaf alassaf PROPN dti-2622 252 11 s s PROPN dti-2622 252 12 , , PUNCT dti-2622 253 1 al al PROPN dti-2622 253 2 duhailib duhailib PROPN dti-2622 253 3 z z PROPN dti-2622 253 4 , , PUNCT dti-2622 253 5 althawadi althawadi PROPN dti-2622 253 6 s. s. PROPN dti-2622 253 7 effectiveness effectiveness NOUN dti-2622 253 8 of of ADP dti-2622 253 9 ceftazidime ceftazidime NOUN dti-2622 253 10 - - PUNCT dti-2622 253 11 avibactam avibactam NOUN dti-2622 253 12 versus versus ADP dti-2622 253 13 colistin colistin NOUN dti-2622 253 14 in in ADP dti-2622 253 15 treating treat VERB dti-2622 253 16 carbapenem carbapenem NOUN dti-2622 253 17 - - PUNCT dti-2622 253 18 resistant resistant ADJ dti-2622 253 19 enterobacteriaceae enterobacteriaceae NOUN dti-2622 253 20 bacteremia bacteremia NOUN dti-2622 253 21 . . PUNCT dti-2622 254 1 int int NOUN dti-2622 254 2 j j PROPN dti-2622 254 3 infect infect VERB dti-2622 254 4 dis dis PROPN dti-2622 254 5 . . PUNCT dti-2622 255 1 2021;109:1 2021;109:1 X dti-2622 255 2 - - SYM dti-2622 255 3 7 7 NUM dti-2622 255 4 . . PUNCT dti-2622 255 5 crossref crossref PROPN dti-2622 255 6 pubmed pubmed PROPN dti-2622 255 7 25 25 NUM dti-2622 255 8 . . PUNCT dti-2622 256 1 wunderink wunderink PROPN dti-2622 256 2 rg rg PROPN dti-2622 256 3 , , PUNCT dti-2622 256 4 giamarellos giamarellos PROPN dti-2622 256 5 - - PUNCT dti-2622 256 6 bourboulis bourboulis PROPN dti-2622 256 7 ej ej PROPN dti-2622 256 8 , , PUNCT dti-2622 256 9 rahav rahav ADP dti-2622 256 10 g g PROPN dti-2622 256 11 , , PUNCT dti-2622 256 12 et et PROPN dti-2622 256 13 al al PROPN dti-2622 256 14 . . PROPN dti-2622 256 15 effect effect NOUN dti-2622 256 16 and and CCONJ dti-2622 256 17 safety safety NOUN dti-2622 256 18 of of ADP dti-2622 256 19 meropenem meropenem PROPN dti-2622 256 20 - - PUNCT dti-2622 256 21 vaborbactam vaborbactam NOUN dti-2622 256 22 versus versus ADP dti-2622 256 23 best well ADV dti-2622 256 24 - - PUNCT dti-2622 256 25 available available ADJ dti-2622 256 26 therapy therapy NOUN dti-2622 256 27 in in ADP dti-2622 256 28 patients patient NOUN dti-2622 256 29 with with ADP dti-2622 256 30 carbapenem carbapenem NOUN dti-2622 256 31 - - PUNCT dti-2622 256 32 resistant resistant ADJ dti-2622 256 33 enterobacteriaceae enterobacteriaceae NOUN dti-2622 256 34 infections infection NOUN dti-2622 256 35 : : PUNCT dti-2622 256 36 the the DET dti-2622 256 37 tango tango PROPN dti-2622 256 38 ii ii PROPN dti-2622 256 39 randomized randomize VERB dti-2622 256 40 clinical clinical ADJ dti-2622 256 41 trial trial NOUN dti-2622 256 42 . . PUNCT dti-2622 257 1 infect infect VERB dti-2622 257 2 dis dis PROPN dti-2622 257 3 ther ther ADV dti-2622 257 4 . . PUNCT dti-2622 258 1 2018;7(4):439 2018;7(4):439 NUM dti-2622 258 2 - - SYM dti-2622 258 3 455 455 NUM dti-2622 258 4 . . PUNCT dti-2622 259 1 crossref crossref PROPN dti-2622 259 2 pubmed pubmed PROPN dti-2622 259 3 26 26 NUM dti-2622 259 4 . . PUNCT dti-2622 260 1 yang yang PROPN dti-2622 260 2 j j PROPN dti-2622 260 3 , , PUNCT dti-2622 260 4 naik naik PROPN dti-2622 260 5 j j PROPN dti-2622 260 6 , , PUNCT dti-2622 260 7 massello massello PROPN dti-2622 260 8 m m PROPN dti-2622 260 9 , , PUNCT dti-2622 260 10 ralph ralph PROPN dti-2622 260 11 l l PROPN dti-2622 260 12 , , PUNCT dti-2622 260 13 dillon dillon PROPN dti-2622 260 14 rj rj PROPN dti-2622 260 15 . . PUNCT dti-2622 260 16 cost cost NOUN dti-2622 260 17 - - PUNCT dti-2622 260 18 effectiveness effectiveness NOUN dti-2622 260 19 of of ADP dti-2622 260 20 imipenem imipenem PROPN dti-2622 260 21 / / SYM dti-2622 260 22 cilastatin cilastatin NOUN dti-2622 260 23 / / SYM dti-2622 260 24 relebactam relebactam NOUN dti-2622 260 25 compared compare VERB dti-2622 260 26 with with ADP dti-2622 260 27 colistin colistin NOUN dti-2622 260 28 in in ADP dti-2622 260 29 treatment treatment NOUN dti-2622 260 30 of of ADP dti-2622 260 31 gram gram NOUN dti-2622 260 32 - - PUNCT dti-2622 260 33 negative negative ADJ dti-2622 260 34 infections infection NOUN dti-2622 260 35 caused cause VERB dti-2622 260 36 by by ADP dti-2622 260 37 carbapenemnon carbapenemnon NOUN dti-2622 260 38 - - PUNCT dti-2622 260 39 susceptible susceptible ADJ dti-2622 260 40 organisms organism NOUN dti-2622 260 41 . . PUNCT dti-2622 261 1 infect infect VERB dti-2622 261 2 dis dis PROPN dti-2622 261 3 ther ther ADJ dti-2622 261 4 . . PUNCT dti-2622 262 1 2022;11(4):14431457 2022;11(4):14431457 NUM dti-2622 262 2 . . PUNCT dti-2622 263 1 crossref crossref PROPN dti-2622 263 2 pubmed pubmed PROPN dti-2622 263 3 27 27 NUM dti-2622 263 4 . . PUNCT dti-2622 264 1 bassetti bassetti PROPN dti-2622 264 2 m m PROPN dti-2622 264 3 , , PUNCT dti-2622 264 4 echols echols PROPN dti-2622 264 5 r r PROPN dti-2622 264 6 , , PUNCT dti-2622 264 7 matsunaga matsunaga NOUN dti-2622 264 8 y y PROPN dti-2622 264 9 , , PUNCT dti-2622 264 10 et et PROPN dti-2622 264 11 al al PROPN dti-2622 264 12 . . PROPN dti-2622 264 13 efficacy efficacy NOUN dti-2622 264 14 and and CCONJ dti-2622 264 15 safety safety NOUN dti-2622 264 16 of of ADP dti-2622 264 17 cefiderocol cefiderocol NOUN dti-2622 264 18 or or CCONJ dti-2622 264 19 best good ADJ dti-2622 264 20 available available ADJ dti-2622 264 21 therapy therapy NOUN dti-2622 264 22 for for ADP dti-2622 264 23 the the DET dti-2622 264 24 treatment treatment NOUN dti-2622 264 25 of of ADP dti-2622 264 26 https://doi.org/10.1038/s41564-019-0492-8 https://doi.org/10.1038/s41564-019-0492-8 PROPN dti-2622 264 27 https://www.ncbi.nlm.nih.gov/pubmed/31358985 https://www.ncbi.nlm.nih.gov/pubmed/31358985 X dti-2622 264 28 https://doi.org/10.1093/cid/ciaa1478 https://doi.org/10.1093/cid/ciaa1478 VERB dti-2622 264 29 https://www.ncbi.nlm.nih.gov/pubmed/33106864 https://www.ncbi.nlm.nih.gov/pubmed/33106864 NUM dti-2622 264 30 https://doi.org/10.1080/21505594.2016.1222343 https://doi.org/10.1080/21505594.2016.1222343 NOUN dti-2622 264 31 https://www.ncbi.nlm.nih.gov/pubmed/27593176 https://www.ncbi.nlm.nih.gov/pubmed/27593176 PROPN dti-2622 264 32 https://doi.org/10.1111/joim.12342 https://doi.org/10.1111/joim.12342 NOUN dti-2622 264 33 https://www.ncbi.nlm.nih.gov/pubmed/25556628 https://www.ncbi.nlm.nih.gov/pubmed/25556628 X dti-2622 264 34 https://doi.org/10.1128/cmr.05035-11 https://doi.org/10.1128/cmr.05035-11 PROPN dti-2622 264 35 https://www.ncbi.nlm.nih.gov/pubmed/23034326 https://www.ncbi.nlm.nih.gov/pubmed/23034326 NUM dti-2622 264 36 https://doi.org/10.1111/j.1469-0691.2012.03821.x https://doi.org/10.1111/j.1469-0691.2012.03821.x NOUN dti-2622 264 37 https://www.ncbi.nlm.nih.gov/pubmed/22507109 https://www.ncbi.nlm.nih.gov/pubmed/22507109 NUM dti-2622 264 38 https://doi.org/10.1093/jpids/piz002 https://doi.org/10.1093/jpids/piz002 NOUN dti-2622 264 39 https://www.ncbi.nlm.nih.gov/pubmed/30793757 https://www.ncbi.nlm.nih.gov/pubmed/30793757 NOUN dti-2622 264 40 https://doi.org/10.1016/j.cmi.2021.11.025 https://doi.org/10.1016/j.cmi.2021.11.025 NOUN dti-2622 264 41 https://www.ncbi.nlm.nih.gov/pubmed/34923128 https://www.ncbi.nlm.nih.gov/pubmed/34923128 ADP dti-2622 264 42 https://doi.org/10.3389/fmicb.2019.00080 https://doi.org/10.3389/fmicb.2019.00080 PROPN dti-2622 264 43 https://www.ncbi.nlm.nih.gov/pubmed/30761114 https://www.ncbi.nlm.nih.gov/pubmed/30761114 X dti-2622 264 44 https://doi.org/10.1093/cid/ciz830 https://doi.org/10.1093/cid/ciz830 PROPN dti-2622 264 45 https://www.ncbi.nlm.nih.gov/pubmed/31724043 https://www.ncbi.nlm.nih.gov/pubmed/31724043 PUNCT dti-2622 264 46 https://doi.org/10.1155/2016/3961684 https://doi.org/10.1155/2016/3961684 PROPN dti-2622 264 47 https://www.ncbi.nlm.nih.gov/pubmed/27144165 https://www.ncbi.nlm.nih.gov/pubmed/27144165 NUM dti-2622 264 48 https://doi.org/10.1186/s12879-016-1979-z https://doi.org/10.1186/s12879-016-1979-z PROPN dti-2622 264 49 https://www.ncbi.nlm.nih.gov/pubmed/27809803 https://www.ncbi.nlm.nih.gov/pubmed/27809803 NUM dti-2622 264 50 https://doi.org/10.1016/j.jiph.2018.08.002 https://doi.org/10.1016/j.jiph.2018.08.002 NOUN dti-2622 264 51 https://www.ncbi.nlm.nih.gov/pubmed/30145151 https://www.ncbi.nlm.nih.gov/pubmed/30145151 NUM dti-2622 264 52 https://doi.org/10.3389/fcimb.2020.579462 https://doi.org/10.3389/fcimb.2020.579462 PROPN dti-2622 264 53 https://www.ncbi.nlm.nih.gov/pubmed/33178629 https://www.ncbi.nlm.nih.gov/pubmed/33178629 NUM dti-2622 264 54 https://doi.org/10.1016/j.ijantimicag.2020.106126 https://doi.org/10.1016/j.ijantimicag.2020.106126 PROPN dti-2622 264 55 https://www.ncbi.nlm.nih.gov/pubmed/32755654 https://www.ncbi.nlm.nih.gov/pubmed/32755654 PROPN dti-2622 264 56 https://doi.org/10.1128/aac.02166-13 https://doi.org/10.1128/aac.02166-13 PROPN dti-2622 264 57 https://www.ncbi.nlm.nih.gov/pubmed/24514083 https://www.ncbi.nlm.nih.gov/pubmed/24514083 X dti-2622 265 1 https://doi.org/10.1093/jac/dkv086 https://doi.org/10.1093/jac/dkv086 PROPN dti-2622 265 2 https://www.ncbi.nlm.nih.gov/pubmed/25900159 https://www.ncbi.nlm.nih.gov/pubmed/25900159 X dti-2622 265 3 https://doi.org/10.1080/21505594.2017.1292196 https://doi.org/10.1080/21505594.2017.1292196 PROPN dti-2622 265 4 https://www.ncbi.nlm.nih.gov/pubmed/28276996 https://www.ncbi.nlm.nih.gov/pubmed/28276996 X dti-2622 265 5 https://doi.org/10.1086/661597 https://doi.org/10.1086/661597 NOUN dti-2622 265 6 https://www.ncbi.nlm.nih.gov/pubmed/21828966 https://www.ncbi.nlm.nih.gov/pubmed/21828966 NUM dti-2622 266 1 https://doi.org/10.1186/1471-2334-13-80 https://doi.org/10.1186/1471-2334-13-80 ADV dti-2622 266 2 https://www.ncbi.nlm.nih.gov/pubmed/23398691 https://www.ncbi.nlm.nih.gov/pubmed/23398691 NUM dti-2622 266 3 https://doi.org/10.1111/1469-0691.12341 https://doi.org/10.1111/1469-0691.12341 ADV dti-2622 266 4 https://www.ncbi.nlm.nih.gov/pubmed/23992130 https://www.ncbi.nlm.nih.gov/pubmed/23992130 PRON dti-2622 266 5 https://doi.org/10.2147/idr.s390635 https://doi.org/10.2147/idr.s390635 NOUN dti-2622 266 6 https://www.ncbi.nlm.nih.gov/pubmed/36465807 https://www.ncbi.nlm.nih.gov/pubmed/36465807 ADP dti-2622 266 7 https://doi.org/10.1016/j.ijid.2021.05.079 https://doi.org/10.1016/j.ijid.2021.05.079 PROPN dti-2622 266 8 https://www.ncbi.nlm.nih.gov/pubmed/34091006 https://www.ncbi.nlm.nih.gov/pubmed/34091006 NUM dti-2622 266 9 https://doi.org/10.1007/s40121-018-0214-1 https://doi.org/10.1007/s40121-018-0214-1 PROPN dti-2622 266 10 https://www.ncbi.nlm.nih.gov/pubmed/30270406 https://www.ncbi.nlm.nih.gov/pubmed/30270406 NUM dti-2622 266 11 https://doi.org/10.1007/s40121-022-00607-x https://doi.org/10.1007/s40121-022-00607-x VERB dti-2622 266 12 https://www.ncbi.nlm.nih.gov/pubmed/35334080 https://www.ncbi.nlm.nih.gov/pubmed/35334080 ADJ dti-2622 266 13 so so ADV dti-2622 266 14 - - PUNCT dti-2622 266 15 ngern ngern ADJ dti-2622 266 16 et et PROPN dti-2622 266 17 al al PROPN dti-2622 266 18 drug drug PROPN dti-2622 266 19 target target NOUN dti-2622 266 20 insights insight NOUN dti-2622 266 21 2023 2023 NUM dti-2622 266 22 ; ; PUNCT dti-2622 266 23 17 17 NUM dti-2622 266 24 : : SYM dti-2622 266 25 125 125 NUM dti-2622 266 26 © © PROPN dti-2622 266 27 2023 2023 NUM dti-2622 266 28 the the DET dti-2622 266 29 authors author NOUN dti-2622 266 30 . . PUNCT dti-2622 267 1 published publish VERB dti-2622 267 2 by by ADP dti-2622 267 3 aboutscience aboutscience NOUN dti-2622 267 4 www.aboutscience.eu www.aboutscience.eu NOUN dti-2622 267 5 serious serious ADJ dti-2622 267 6 infections infection NOUN dti-2622 267 7 caused cause VERB dti-2622 267 8 by by ADP dti-2622 267 9 carbapenem carbapenem NOUN dti-2622 267 10 - - PUNCT dti-2622 267 11 resistant resistant ADJ dti-2622 267 12 gramnegative gramnegative ADJ dti-2622 267 13 bacteria bacteria NOUN dti-2622 267 14 ( ( PUNCT dti-2622 267 15 credible credible ADJ dti-2622 267 16 - - PUNCT dti-2622 267 17 cr cr NOUN dti-2622 267 18 ): ): PUNCT dti-2622 267 19 a a DET dti-2622 267 20 randomised randomised ADJ dti-2622 267 21 , , PUNCT dti-2622 267 22 open open ADJ dti-2622 267 23 - - PUNCT dti-2622 267 24 label label NOUN dti-2622 267 25 , , PUNCT dti-2622 267 26 multicentre multicentre NOUN dti-2622 267 27 , , PUNCT dti-2622 267 28 pathogen pathogen NOUN dti-2622 267 29 - - PUNCT dti-2622 267 30 focused focused ADJ dti-2622 267 31 , , PUNCT dti-2622 267 32 descriptive descriptive ADJ dti-2622 267 33 , , PUNCT dti-2622 267 34 phase phase NOUN dti-2622 267 35 3 3 NUM dti-2622 267 36 trial trial NOUN dti-2622 267 37 . . PUNCT dti-2622 268 1 lancet lancet PROPN dti-2622 268 2 infect infect PROPN dti-2622 268 3 dis dis PROPN dti-2622 268 4 . . PUNCT dti-2622 269 1 2021;21(2):226 2021;21(2):226 NUM dti-2622 269 2 - - PUNCT dti-2622 269 3 240 240 NUM dti-2622 269 4 . . PUNCT dti-2622 270 1 crossref crossref PROPN dti-2622 270 2 pubmed pubmed PROPN dti-2622 270 3 28 28 PROPN dti-2622 270 4 . . PUNCT dti-2622 271 1 papadimitriou papadimitriou ADJ dti-2622 271 2 - - PUNCT dti-2622 271 3 olivgeris olivgeris NOUN dti-2622 271 4 m m PROPN dti-2622 271 5 , , PUNCT dti-2622 271 6 fligou fligou PROPN dti-2622 271 7 f f PROPN dti-2622 271 8 , , PUNCT dti-2622 271 9 bartzavali bartzavali PROPN dti-2622 271 10 c c NOUN dti-2622 271 11 , , PUNCT dti-2622 271 12 et et PROPN dti-2622 271 13 al al PROPN dti-2622 271 14 . . PUNCT dti-2622 271 15 carbapenemase carbapenemase NOUN dti-2622 271 16 - - PUNCT dti-2622 271 17 producing produce VERB dti-2622 271 18 klebsiella klebsiella NOUN dti-2622 271 19 pneumoniae pneumoniae ADJ dti-2622 271 20 bloodstream bloodstream NOUN dti-2622 271 21 infection infection NOUN dti-2622 271 22 in in ADP dti-2622 271 23 critically critically ADV dti-2622 271 24 ill ill ADJ dti-2622 271 25 patients patient NOUN dti-2622 271 26 : : PUNCT dti-2622 271 27 risk risk NOUN dti-2622 271 28 factors factor NOUN dti-2622 271 29 and and CCONJ dti-2622 271 30 predictors predictor NOUN dti-2622 271 31 of of ADP dti-2622 271 32 mortality mortality NOUN dti-2622 271 33 . . PUNCT dti-2622 272 1 eur eur PROPN dti-2622 272 2 j j PROPN dti-2622 272 3 clin clin PROPN dti-2622 272 4 microbiol microbiol PROPN dti-2622 272 5 infect infect VERB dti-2622 272 6 dis dis PROPN dti-2622 272 7 . . PUNCT dti-2622 273 1 2017;36(7 2017;36(7 NUM dti-2622 273 2 ): ): PUNCT dti-2622 273 3 1125 1125 NUM dti-2622 273 4 - - SYM dti-2622 273 5 1131 1131 NUM dti-2622 273 6 . . PUNCT dti-2622 274 1 crossref crossref PROPN dti-2622 274 2 pubmed pubmed PROPN dti-2622 274 3 29 29 NUM dti-2622 274 4 . . PUNCT dti-2622 275 1 gutiérrez gutiérrez NOUN dti-2622 275 2 - - PUNCT dti-2622 275 3 gutiérrez gutiérrez PROPN dti-2622 275 4 b b PROPN dti-2622 275 5 , , PUNCT dti-2622 275 6 salamanca salamanca PROPN dti-2622 275 7 e e PROPN dti-2622 275 8 , , PUNCT dti-2622 275 9 de de PROPN dti-2622 275 10 cueto cueto PROPN dti-2622 275 11 m m PROPN dti-2622 275 12 , , PUNCT dti-2622 275 13 et et PROPN dti-2622 275 14 al al PROPN dti-2622 275 15 ; ; PUNCT dti-2622 275 16 reipi/ reipi/ NUM dti-2622 275 17 esgbis esgbis NOUN dti-2622 275 18 / / SYM dti-2622 275 19 increment increment NOUN dti-2622 275 20 investigators investigator NOUN dti-2622 275 21 . . PUNCT dti-2622 276 1 effect effect NOUN dti-2622 276 2 of of ADP dti-2622 276 3 appropriate appropriate ADJ dti-2622 276 4 combination combination NOUN dti-2622 276 5 therapy therapy NOUN dti-2622 276 6 on on ADP dti-2622 276 7 mortality mortality NOUN dti-2622 276 8 of of ADP dti-2622 276 9 patients patient NOUN dti-2622 276 10 with with ADP dti-2622 276 11 bloodstream bloodstream NOUN dti-2622 276 12 infections infection NOUN dti-2622 276 13 due due ADJ dti-2622 276 14 to to ADP dti-2622 276 15 carbapenemase carbapenemase NOUN dti-2622 276 16 - - PUNCT dti-2622 276 17 producing produce VERB dti-2622 276 18 enterobacteriaceae enterobacteriaceae NOUN dti-2622 276 19 ( ( PUNCT dti-2622 276 20 increment increment NOUN dti-2622 276 21 ): ): PUNCT dti-2622 276 22 a a DET dti-2622 276 23 retrospective retrospective ADJ dti-2622 276 24 cohort cohort NOUN dti-2622 276 25 study study NOUN dti-2622 276 26 . . PUNCT dti-2622 277 1 lancet lancet PROPN dti-2622 277 2 infect infect PROPN dti-2622 277 3 dis dis PROPN dti-2622 277 4 . . PUNCT dti-2622 278 1 2017;17(7):726 2017;17(7):726 NUM dti-2622 278 2 - - SYM dti-2622 278 3 734 734 NUM dti-2622 278 4 . . PUNCT dti-2622 279 1 crossref crossref PROPN dti-2622 279 2 pubmed pubmed PROPN dti-2622 279 3 30 30 NUM dti-2622 279 4 . . PUNCT dti-2622 280 1 tofas tofas PROPN dti-2622 280 2 p p NOUN dti-2622 280 3 , , PUNCT dti-2622 280 4 skiada skiada PROPN dti-2622 280 5 a a X dti-2622 280 6 , , PUNCT dti-2622 280 7 angelopoulou angelopoulou PROPN dti-2622 280 8 m m PROPN dti-2622 280 9 , , PUNCT dti-2622 280 10 et et PROPN dti-2622 280 11 al al PROPN dti-2622 280 12 . . PUNCT dti-2622 281 1 carbapenemaseproducing carbapenemaseproduce VERB dti-2622 281 2 klebsiella klebsiella NOUN dti-2622 281 3 pneumoniae pneumoniae ADJ dti-2622 281 4 bloodstream bloodstream NOUN dti-2622 281 5 infections infection NOUN dti-2622 281 6 in in ADP dti-2622 281 7 neutropenic neutropenic ADJ dti-2622 281 8 patients patient NOUN dti-2622 281 9 with with ADP dti-2622 281 10 haematological haematological ADJ dti-2622 281 11 malignancies malignancy NOUN dti-2622 281 12 or or CCONJ dti-2622 281 13 aplastic aplastic ADJ dti-2622 281 14 anaemia anaemia NOUN dti-2622 281 15 : : PUNCT dti-2622 281 16 analysis analysis NOUN dti-2622 281 17 of of ADP dti-2622 281 18 50 50 NUM dti-2622 281 19 cases case NOUN dti-2622 281 20 . . PUNCT dti-2622 282 1 int int NOUN dti-2622 282 2 j j PROPN dti-2622 282 3 antimicrob antimicrob PROPN dti-2622 282 4 agents agent NOUN dti-2622 282 5 . . PUNCT dti-2622 283 1 2016;47(4):335 2016;47(4):335 NUM dti-2622 283 2 - - SYM dti-2622 283 3 339 339 NUM dti-2622 283 4 . . PUNCT dti-2622 284 1 crossref crossref PROPN dti-2622 284 2 pubmed pubmed PROPN dti-2622 284 3 31 31 NUM dti-2622 284 4 . . PUNCT dti-2622 285 1 schmid schmid PROPN dti-2622 285 2 a a PROPN dti-2622 285 3 , , PUNCT dti-2622 285 4 wolfensberger wolfensberger VERB dti-2622 285 5 a a PRON dti-2622 285 6 , , PUNCT dti-2622 285 7 nemeth nemeth PROPN dti-2622 285 8 j j PROPN dti-2622 285 9 , , PUNCT dti-2622 285 10 schreiber schreiber PROPN dti-2622 285 11 pw pw PROPN dti-2622 285 12 , , PUNCT dti-2622 285 13 sax sax PROPN dti-2622 285 14 h h NOUN dti-2622 285 15 , , PUNCT dti-2622 285 16 kuster kuster PROPN dti-2622 285 17 sp sp NOUN dti-2622 285 18 . . NOUN dti-2622 285 19 monotherapy monotherapy NOUN dti-2622 285 20 versus versus ADP dti-2622 285 21 combination combination NOUN dti-2622 285 22 therapy therapy NOUN dti-2622 285 23 for for ADP dti-2622 285 24 multidrug multidrug NOUN dti-2622 285 25 - - PUNCT dti-2622 285 26 resistant resistant ADJ dti-2622 285 27 gram gram NOUN dti-2622 285 28 - - PUNCT dti-2622 285 29 negative negative ADJ dti-2622 285 30 infections infection NOUN dti-2622 285 31 : : PUNCT dti-2622 285 32 systematic systematic ADJ dti-2622 285 33 review review NOUN dti-2622 285 34 and and CCONJ dti-2622 285 35 meta meta ADJ dti-2622 285 36 - - PUNCT dti-2622 285 37 analysis analysis NOUN dti-2622 285 38 . . PUNCT dti-2622 286 1 sci sci PROPN dti-2622 286 2 rep rep PROPN dti-2622 286 3 . . PROPN dti-2622 286 4 2019;9(1):15290 2019;9(1):15290 NUM dti-2622 286 5 . . PUNCT dti-2622 287 1 crossref crossref PROPN dti-2622 287 2 pubmed pubmed PROPN dti-2622 287 3 32 32 NUM dti-2622 287 4 . . PUNCT dti-2622 288 1 zilberberg zilberberg PROPN dti-2622 288 2 md md PROPN dti-2622 288 3 , , PUNCT dti-2622 288 4 nathanson nathanson PROPN dti-2622 288 5 bh bh PROPN dti-2622 288 6 , , PUNCT dti-2622 288 7 sulham sulham PROPN dti-2622 288 8 k k PROPN dti-2622 288 9 , , PUNCT dti-2622 288 10 fan fan PROPN dti-2622 288 11 w w PROPN dti-2622 288 12 , , PUNCT dti-2622 288 13 shorr shorr ADJ dti-2622 288 14 af af PROPN dti-2622 288 15 . . PROPN dti-2622 288 16 carbapenem carbapenem PROPN dti-2622 288 17 resistance resistance PROPN dti-2622 288 18 , , PUNCT dti-2622 288 19 inappropriate inappropriate ADJ dti-2622 288 20 empiric empiric ADJ dti-2622 288 21 treatment treatment NOUN dti-2622 288 22 and and CCONJ dti-2622 288 23 outcomes outcome NOUN dti-2622 288 24 among among ADP dti-2622 288 25 patients patient NOUN dti-2622 288 26 hospitalized hospitalize VERB dti-2622 288 27 with with ADP dti-2622 288 28 enterobacteriaceae enterobacteriaceae PROPN dti-2622 288 29 urinary urinary ADJ dti-2622 288 30 tract tract NOUN dti-2622 288 31 infection infection NOUN dti-2622 288 32 , , PUNCT dti-2622 288 33 pneumonia pneumonia NOUN dti-2622 288 34 and and CCONJ dti-2622 288 35 sepsis sepsis NOUN dti-2622 288 36 . . PUNCT dti-2622 289 1 bmc bmc PROPN dti-2622 289 2 infect infect PROPN dti-2622 289 3 dis dis PROPN dti-2622 289 4 . . PUNCT dti-2622 290 1 2017;17(1):279 2017;17(1):279 PROPN dti-2622 290 2 . . PUNCT dti-2622 291 1 crossref crossref PROPN dti-2622 291 2 pubmed pubmed PROPN dti-2622 291 3 33 33 NUM dti-2622 291 4 . . PUNCT dti-2622 292 1 liang liang PROPN dti-2622 292 2 q q PROPN dti-2622 292 3 , , PUNCT dti-2622 292 4 chen chen PROPN dti-2622 292 5 j j PROPN dti-2622 292 6 , , PUNCT dti-2622 292 7 xu xu PROPN dti-2622 292 8 y y PROPN dti-2622 292 9 , , PUNCT dti-2622 292 10 chen chen PROPN dti-2622 292 11 y y PROPN dti-2622 292 12 , , PUNCT dti-2622 292 13 huang huang PROPN dti-2622 292 14 m. m. PROPN dti-2622 292 15 active active ADJ dti-2622 292 16 surveillance surveillance NOUN dti-2622 292 17 of of ADP dti-2622 292 18 carbapenem carbapenem NOUN dti-2622 292 19 - - PUNCT dti-2622 292 20 resistant resistant ADJ dti-2622 292 21 gram gram NOUN dti-2622 292 22 - - PUNCT dti-2622 292 23 negative negative ADJ dti-2622 292 24 bacteria bacteria NOUN dti-2622 292 25 to to PART dti-2622 292 26 guide guide VERB dti-2622 292 27 antibiotic antibiotic ADJ dti-2622 292 28 therapy therapy NOUN dti-2622 292 29 : : PUNCT dti-2622 292 30 a a DET dti-2622 292 31 single single ADJ dti-2622 292 32 - - PUNCT dti-2622 292 33 center center NOUN dti-2622 292 34 prospective prospective ADJ dti-2622 292 35 observational observational ADJ dti-2622 292 36 study study NOUN dti-2622 292 37 . . PUNCT dti-2622 293 1 antimicrob antimicrob PROPN dti-2622 293 2 resist resist VERB dti-2622 293 3 infect infect NOUN dti-2622 293 4 control control NOUN dti-2622 293 5 . . PUNCT dti-2622 294 1 2022;11(1):89 2022;11(1):89 X dti-2622 294 2 . . PUNCT dti-2622 295 1 crossref crossref PROPN dti-2622 295 2 pubmed pubmed PROPN dti-2622 295 3 34 34 NUM dti-2622 295 4 . . PUNCT dti-2622 296 1 klinker klinker PROPN dti-2622 296 2 kp kp PROPN dti-2622 296 3 , , PUNCT dti-2622 296 4 hidayat hidayat PROPN dti-2622 296 5 lk lk PROPN dti-2622 296 6 , , PUNCT dti-2622 296 7 deryke deryke PROPN dti-2622 296 8 ca can AUX dti-2622 296 9 , , PUNCT dti-2622 296 10 depestel depestel PROPN dti-2622 296 11 dd dd PROPN dti-2622 296 12 , , PUNCT dti-2622 296 13 motyl motyl NOUN dti-2622 296 14 m m PROPN dti-2622 296 15 , , PUNCT dti-2622 296 16 bauer bauer PROPN dti-2622 296 17 ka ka PROPN dti-2622 296 18 . . PROPN dti-2622 296 19 antimicrobial antimicrobial ADJ dti-2622 296 20 stewardship stewardship NOUN dti-2622 296 21 and and CCONJ dti-2622 296 22 antibiograms antibiogram NOUN dti-2622 296 23 : : PUNCT dti-2622 296 24 importance importance NOUN dti-2622 296 25 of of ADP dti-2622 296 26 moving move VERB dti-2622 296 27 beyond beyond ADP dti-2622 296 28 traditional traditional ADJ dti-2622 296 29 antibiograms antibiogram NOUN dti-2622 296 30 . . PUNCT dti-2622 297 1 ther ther VERB dti-2622 297 2 adv adv PROPN dti-2622 297 3 infect infect VERB dti-2622 297 4 dis dis PROPN dti-2622 297 5 . . PUNCT dti-2622 298 1 2021;8:20499361211011373 2021;8:20499361211011373 PROPN dti-2622 298 2 . . PUNCT dti-2622 299 1 crossref crossref PROPN dti-2622 299 2 pubmed pubmed PROPN dti-2622 299 3 35 35 NUM dti-2622 299 4 . . PUNCT dti-2622 300 1 chang chang PROPN dti-2622 300 2 cm cm PROPN dti-2622 300 3 , , PUNCT dti-2622 300 4 hsieh hsieh PROPN dti-2622 300 5 ms ms PROPN dti-2622 300 6 , , PUNCT dti-2622 300 7 yang yang PROPN dti-2622 300 8 cj cj PROPN dti-2622 300 9 , , PUNCT dti-2622 300 10 how how SCONJ dti-2622 300 11 ck ck ADJ dti-2622 300 12 , , PUNCT dti-2622 300 13 chen chen PROPN dti-2622 300 14 pc pc PROPN dti-2622 300 15 , , PUNCT dti-2622 300 16 meng meng PROPN dti-2622 300 17 yh yh PROPN dti-2622 300 18 . . PUNCT dti-2622 300 19 effects effect NOUN dti-2622 300 20 of of ADP dti-2622 300 21 empiric empiric ADJ dti-2622 300 22 antibiotic antibiotic ADJ dti-2622 300 23 treatment treatment NOUN dti-2622 300 24 based base VERB dti-2622 300 25 on on ADP dti-2622 300 26 hospital hospital NOUN dti-2622 300 27 cumulative cumulative ADJ dti-2622 300 28 antibiograms antibiogram NOUN dti-2622 300 29 in in ADP dti-2622 300 30 patients patient NOUN dti-2622 300 31 with with ADP dti-2622 300 32 bacteraemic bacteraemic ADJ dti-2622 300 33 sepsis sepsis NOUN dti-2622 300 34 : : PUNCT dti-2622 300 35 a a DET dti-2622 300 36 retrospective retrospective ADJ dti-2622 300 37 cohort cohort NOUN dti-2622 300 38 study study NOUN dti-2622 300 39 . . PUNCT dti-2622 301 1 clin clin PROPN dti-2622 301 2 microbiol microbiol PROPN dti-2622 301 3 infect infect VERB dti-2622 301 4 . . PUNCT dti-2622 302 1 2023;29(6 2023;29(6 NUM dti-2622 302 2 ): ): PUNCT dti-2622 302 3 765 765 NUM dti-2622 302 4 - - SYM dti-2622 302 5 771 771 NUM dti-2622 302 6 . . PUNCT dti-2622 303 1 crossref crossref PROPN dti-2622 303 2 pubmed pubmed PROPN dti-2622 303 3 https://doi.org/10.1016/s1473-3099(20)30796-9 https://doi.org/10.1016/s1473-3099(20)30796-9 PROPN dti-2622 303 4 https://www.ncbi.nlm.nih.gov/pubmed/33058795 https://www.ncbi.nlm.nih.gov/pubmed/33058795 PROPN dti-2622 303 5 https://doi.org/10.1007/s10096-017-2899-6 https://doi.org/10.1007/s10096-017-2899-6 PROPN dti-2622 303 6 https://www.ncbi.nlm.nih.gov/pubmed/28102514 https://www.ncbi.nlm.nih.gov/pubmed/28102514 NUM dti-2622 303 7 https://doi.org/10.1016/s1473-3099(17)30228-1 https://doi.org/10.1016/s1473-3099(17)30228-1 NOUN dti-2622 303 8 https://www.ncbi.nlm.nih.gov/pubmed/28442293 https://www.ncbi.nlm.nih.gov/pubmed/28442293 NUM dti-2622 303 9 https://doi.org/10.1016/j.ijantimicag.2016.01.011 https://doi.org/10.1016/j.ijantimicag.2016.01.011 NOUN dti-2622 303 10 https://www.ncbi.nlm.nih.gov/pubmed/27005460 https://www.ncbi.nlm.nih.gov/pubmed/27005460 NUM dti-2622 303 11 https://doi.org/10.1038/s41598-019-51711-x https://doi.org/10.1038/s41598-019-51711-x PROPN dti-2622 303 12 https://www.ncbi.nlm.nih.gov/pubmed/31664064 https://www.ncbi.nlm.nih.gov/pubmed/31664064 PROPN dti-2622 303 13 https://doi.org/10.1186/s12879-017-2383-z https://doi.org/10.1186/s12879-017-2383-z PROPN dti-2622 303 14 https://www.ncbi.nlm.nih.gov/pubmed/28415969 https://www.ncbi.nlm.nih.gov/pubmed/28415969 PROPN dti-2622 303 15 https://doi.org/10.1186/s13756-022-01103-0 https://doi.org/10.1186/s13756-022-01103-0 NOUN dti-2622 303 16 https://www.ncbi.nlm.nih.gov/pubmed/35733230 https://www.ncbi.nlm.nih.gov/pubmed/35733230 NUM dti-2622 303 17 https://doi.org/10.1177/20499361211011373 https://doi.org/10.1177/20499361211011373 NOUN dti-2622 303 18 https://www.ncbi.nlm.nih.gov/pubmed/33996074 https://www.ncbi.nlm.nih.gov/pubmed/33996074 X dti-2622 303 19 https://doi.org/10.1016/j.cmi.2023.01.004 https://doi.org/10.1016/j.cmi.2023.01.004 VERB dti-2622 303 20 https://www.ncbi.nlm.nih.gov/pubmed/36641052 https://www.ncbi.nlm.nih.gov/pubmed/36641052 PRON